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ABSTRACT	  	  
	  
Placenta	  is	  critical	  during	  pregnancy,	  forming	  the	  interface	  between	  mother	  and	  fetus.	  A	  
key	  process	  in	  placental	  development	  is	  the	  differentiation	  and	  invasion	  of	  extravillous	  
trophoblast	   cells	   (EVT).	  While	   some	  EVT	   invade	   the	  uterine	   interstitial	   space,	  a	   subset	  
upregulates	   endovascular	   genes	   forming	   the	   endovascular	   EVT	   (enEVT)	   that	   invade	  
decidual	  vessels.	  EnEVT	  are	  critical	  mediators	  in	  spiral	  artery	  remodeling	  (SAR),	  which	  is	  
essential	   for	  proper	  placentation.	  Preeclampsia	   (PE)	   is	   a	   serious	  hypertensive	  disorder	  
that	   can	  manifest	  during	  pregnancy.	  The	  cause	  of	  PE	   is	  unclear;	  however	   shallow	  EVT	  
invasion,	  inadequate	  enEVT	  differentiation	  and	  SAR	  play	  crucial	  roles.	  The	  transforming	  
growth	   factor-­‐β	   (TGF-­‐β)	   family	   is	   known	   to	   regulate	   placentation	   and	   has	   been	  
implicated	  in	  the	  pathogenesis	  of	  PE.	  Specifically,	  TGF-­‐βs	  and	  Nodal	  are	  upregulated	  in	  
PE	   placenta	   and	   they	   exert	   potent	   inhibitory	   effects	   on	   EVT	   invasion.	   MicroRNAs	  
(miRNA)	  are	  small	  non-­‐coding	  RNAs	  that	  regulate	  most	  physiological	  processes	  and	  are	  
dysregulated	  in	  PE.	  In	  this	  study,	  we	  investigated	  the	  role	  of	  miR-­‐218-­‐5p	  in	  modulating	  
TGF-­‐β	  signaling	  and	  placental	  development	  and	  their	  contribution	  to	  the	  pathogenesis	  
of	   PE.	   The	   models	   used	   in	   our	   study	   included	   a	   human	   trophoblast	   cell	   line	  
(HTR8/SVneo),	   first	   trimester	   placenta	   and	   decidua	   tissues,	   and	   clinical	   samples.	   Our	  
findings	   indicate	   that	   the	   expression	   of	   miR-­‐218-­‐5p	   was	   downregulated	   in	   PE	   and	  
upregulated	  during	   second	   trimester	   in	  healthy	   tissues.	  Overexpression	  of	  miR-­‐218-­‐5p	  
promoted	   trophoblast	   migration	   and	   invasion.	   Furthermore,	   miR-­‐218-­‐5p	   upregulated	  
key	  genes	  involved	  in	  enEVT	  differentiation	  and	  accelerated	  SAR	  in	  vitro.	  Using	  a	  TGF-­‐β	  
signaling	  reporter,	  we	  found	  that	  basal	  and	  TGF-­‐β-­‐induced	  transcriptional	  activities	  were	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strongly	   inhibited	  by	  mir-­‐218-­‐1.	  TGF-­‐β2,	  Smad2,	  and	  Smad3	  are	  predicted	  miR-­‐218-­‐5p	  
targets,	   and	   their	   expression	   was	   inhibited	   by	   miR-­‐218-­‐5p.	   Both	   TGF-­‐β2	   and	   Smad2	  
were	   able	   to	   partly	   rescue	   the	   miR-­‐218-­‐5p	   phenotype.	   Interestingly,	   knockdown	   of	  
Smad2	   promoted,	   while	   knockdown	   of	   Smad3	   inhibited,	   invasion	   and	   enEVT	  
differentiation,	   suggesting	   they	  play	  differential	   roles	   in	  placentation.	  Additionally,	   the	  
level	   of	   pSmad3	   is	   strikingly	   downregulated	   in	   PE	   placentas.	   In	   conclusion,	   our	   study	  
demonstrates	  that	  TGF-­‐β	  signaling	  in	  the	  maternal-­‐fetal	  interface	  is	  modulated	  by	  miR-­‐
218-­‐5p	  and	  disruption	  of	  the	  balance	  between	  miR-­‐218-­‐5p	  and	  TGF-­‐β	  signaling	  may	  lead	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NLS	   nuclear	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  binding	  elements	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  stem	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Smurf2	   Smad	  ubiquitination	  regulatory	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  2	  	  
HUVEC	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  Umbilical	  Vein	  Endothelial	  Cells	  	  
SNP	   single	  nucleotide	  polymorphism	  	  
FBS	   Fetal	  Bovine	  Serum	  	  
GFP	   green	  fluorescent	  protein	  	  
Cyc1	   Cytochrome	  c1	  
NC	   non-­‐targeting	  control	  	  
PBS	   Phosphate	  Buffered	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RIPA	   radioimmunoprecipitation	  assay	  	  
BSA	   Bovine	  Serum	  Albumin	  
PBS-­‐T	   Phosphate	  Buffered	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  with	  Tween	  20	  
ITGA1	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  Alpha	  1	  
ECSCR	   Endothelial	  Cell-­‐Specific	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  Regulator	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IL-­‐8	   Interleukin-­‐8	  	  
IL1b	   Interleukin-­‐1b	  	  
CXCL1	   Chemokine	  C-­‐X-­‐C	  motif	  ligand	  1	  	  
IL6	   interleukin-­‐6	  	  
CCL2	   chemokine	  C-­‐C	  motif	  ligand	  2	  	  
CXCL16	   chemokine	  C-­‐X-­‐C	  motif	  ligand	  16	  
CX3CL1	   C-­‐X3-­‐C	  motif	  chemokine	  ligand	  1	  	  
MIF	   macrophage	  migration	  inhibitory	  factor	  	  
CK-­‐7	   cytokeratin-­‐7	  
SMA	   smooth	  muscle	  actin	  
CD45	   cluster	  of	  differentiation	  45	  
ICAM1	   Intercellular	  Adhesion	  Molecule-­‐1	  	  
QRT-­‐PCR	  	   quantitative	  real	  time	  polymerase	  chain	  reaction	  
GAPDH	   Glyceraldehyde	  3-­‐phosphate	  dehydrogenase	  
cPML	   Cytoplasmic promyelocytic leukaemia  
DAB-­‐2	   disabled-­‐2	  	  
ERK	   Extracellular signal–regulated kinases 
Akt	   RAC-­‐alpha	  serine/threonine-­‐protein	  kinase	  
pSmad2	   phosphorylated	  Smad2	  
pSmad3	   phosphorylated	  Smad3	  
NF-­‐κB	  
nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  
cells	  
p50	   Also	  known	  as	  NFkB1	  
p65	   Also	  known	  as	  Rel1	  
ACHP	   2-­‐Amino-­‐6-­‐[2-­‐(cyclopropylmethoxy)-­‐6-­‐hydroxyphenyl]-­‐4-­‐(4-­‐
piperidinyl)-­‐3-­‐pyridinecarbonitrile	  
WT	   Wild	  Type	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CHAPTER	  1:	  LITERATURE	  REVIEW	  
	  
I.	  THE	  HUMAN	  PLACENTA	  
	  
The	   placenta	   is	   a	   transient	   organ	   that	   has	   a	   multitude	   of	   critical	   roles	   in	   maintaining	   and	  
protecting	   the	  developing	   fetus	   throughout	   the	   entire	   pregnancy.	  Animal	  models	   and	  human	  
pregnancies	  alike	  have	  shown	  that	  the	  multifaceted	  nature	  of	  the	  placenta	   is	  vital	   for	  embryo	  
survival	   and	  health	   1.	   Serving	   as	   the	   interface	  between	   fetal	   and	  maternal	   environments,	   the	  
placenta	   is	   involved	   in	   the	   exchange	   of	   gases,	   nutrients,	   and	   waste	   products	   between	   the	  
mother	  and	  the	  growing	  fetus	  2.	  The	  human	  placenta,	  along	  with	  some	  rodents	  and	  higher	  apes,	  
is	  characterized	  as	  “hemochorial”,	  since	  maternal	  blood	  is	  in	  direct	  contact	  with	  the	  chorion.	  In	  
fact,	   the	   human	   placenta	   has	   the	   greatest	   degree	   of	   maternal-­‐fetal	   contact,	   reducing	   the	  
thickness	  of	  the	  maternal-­‐fetal	  barrier	  to	  a	  single	  cell	   layer	  by	  the	  third	  trimester	  3.	  Moreover,	  
the	   placenta	   serves	   as	   an	   endocrine	   organ	   producing	   a	   number	   of	   pregnancy-­‐associated	  
hormones	   and	   growth	   factors,	   as	   well	   as	   ensuring	   protection	   of	   the	   fetus	   from	   maternal	  
immune	  attack	  4.	  	  	  
1.	  IMPLANTATION	  AND	  THE	  TROPHECTODERM	  
	  
Implantation	   is	   a	   complex	   process	   that	   requires	   coordinated	   communication	   between	   the	  
maturing	  blastocyst	  and	  the	  transiently	  receptive	  uterus	  5,6.	  In	  preparation	  for	  implantation,	  the	  
endometrium	  undergoes	  a	  progesterone-­‐induced	  decidualization	  process,	  whereby	   it	   thickens	  
and	  further	  matures	  the	  decidual	  blood	  vessels	  in	  order	  to	  become	  receptive	  to	  the	  blastocyst	  7.	  
The	  blastocyst	  is	  comprised	  of	  two	  cell	  lineages:	  the	  outer	  cell	  layer,	  the	  trophectoderm,	  and	  an	  
inner	  cell	  mass.	  The	  trophectoderm	  gives	  rise	  to	  the	  chorion,	  while	  the	  inner	  cell	  mass	  develops	  
	   2	  
into	   the	   embryo	   and	   other	   extra-­‐embryonic	   tissues	   8.	   Upon	   blastocyst	  maturation,	   the	   outer	  
covering	  known	  as	   the	  zona	  pellucida	   is	  shed,	  exposing	  the	  trophectoderm	   layer	  and	  allowing	  
for	  implantation	  to	  begin	  6.	  	  
	  
The	  implantation	  process	  can	  be	  divided	  into	  three	  stages:	  apposition,	  attachment,	  and	  invasion	  
9	  (Figure	  1.1).	  Apposition	  describes	  the	  initial	  adhesion	  of	  the	  blastocyst	  to	  the	  decidua,	  which	  is	  
very	   unstable,	   resembling	   rolling	   adhesion	   in	   leukocytes	   6.	   It	   involves	   the	   interaction	   of	   the	  
trophoblasts	  and	  decidua	  through	  a	  variety	  of	  secretory	  molecules,	  receptors,	  and	  endometrial	  
epithelial	  protrusions	  (pinopodes)	  3.	  These	  interactions	  accumulate	  into	  a	  more	  stable	  adhesion,	  
leading	   to	   the	   invasion	   of	   the	   extra	   cellular	   matrix	   of	   the	   decidua	   by	   the	   proliferating	  
trophectoderm	  layer,	  thus	  embedding	  the	  blastocyst	  deep	  into	  the	  uterine	  wall.	  Soon	  after,	  the	  
uterine	   epithelial	   cells	   grow	   over	   the	   blastocyst	   to	   cover	   the	   implantation	   site.	   Once	   the	  
blastocyst	  is	  in	  intimate	  contact	  with	  the	  decidua,	  the	  process	  of	  placentation	  can	  begin.	  Cells	  of	  
the	   trophectoderm	   continue	   to	   invade	   until	   they	   reach	   the	   inner-­‐third	   of	   the	   myometrium,	  
remodeling	  the	  maternal	  vasculature	  along	  the	  way	  9.	  
	  
2.	  ANATOMY	  OF	  THE	  HUMAN	  PLACENTA	  
	  
The	  placenta	  begins	  to	  develop	  at	   implantation	  and	  continues	  to	  grow	  throughout	  pregnancy.	  
Starting	  from	  a	  single	  layer	  of	  cells	  on	  the	  blastocyst,	  the	  placenta	  expands	  into	  a	  complex	  organ	  
encompassing	  extra-­‐embryonic	  membranes	  as	  well	  as	  maternal	  tissues.	  The	  full-­‐term	  placenta	  is	  
discoid	  in	  shape,	  averaging	  22	  cm	  in	  diameter	  with	  a	  central	  thickness	  of	  2.5	  cm,	  and	  weighing	  
approximately	  470	  g	  11.	  	  

















Figure	  1.1	  Proposed	  Schematic	  of	  Blastocyst	  Implantation	  
(1)	   Free	   floating	   blastocyst	   (BL)	   composed	   of	   trophectoderm	   layer	   and	   inner	   cell	   mass,	  
surrounded	  by	  zona	  pellucida	   (ZP).	   (2)	  Hatching	  of	   the	  blastocyst	   through	  the	  shedding	  of	   the	  
ZP.	   (3)	   Apposition	   stage	   of	   implantation	   showing	   secretory	   molecules,	   receptors	   along	   with	  
transient	   interactions	  with	  pinopods	   (P)	  on	  the	  surface	  of	   the	  uterine	   luminal	  epithelium	  (LE).	  
(4)	   Adhesion	   of	   the	   blastocyst	   to	   the	   decidualized	   endometrium.	   (5)	   Invasion	   stage	   of	  
implantation	  characterized	  by	   the	   infiltration	  of	   syncytiotrophoblast	   (ST)	  cells	   formed	  through	  
the	   proliferation	   of	   the	   underling	   cytotrophoblast	   (CT)	   progenitor	   cells.	   (6)	   Blastocyst	   fully	  
embedded	   and	   covered	   by	   uterine	   epithelium,	   closing	   the	   implantation	   window.	   Used	   with	  
permission	  from	  Fitzgerald	  JS.,	  et	  al.	  (2008)	  10.	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Throughout	   the	   entire	   process	   of	   development,	   the	   placenta	   remains	   functionally	   active,	  
keeping	  up	  with	  the	  demands	  of	  a	  growing	  fetus.	  	  
	  
There	  are	  three	  distinct	  layers	  of	  extra-­‐embryonic	  membranes	  (Figure	  1.2).	  The	  amnion,	  which	  
begins	   at	   the	   base	   of	   the	   umbilical	   cord,	   is	   the	   inner	   layer	   that	   forms	   the	   amniotic	   sac	   that	  
encapsulates	   the	   fetus.	   At	   the	   fetal-­‐facing	   side	   of	   the	   placenta,	   the	   amnion	   lies	   over	   the	  
chorionic	  membrane	   that	   gives	   rise	   to	   the	   chorionic	   villi.	   Lastly,	   the	   decidua	   capsularis	   is	   the	  
maternal	   component	   of	   the	   membranes	   composed	   of	   the	   decidualized	   endometrium,	   which	  
covers	  the	  membranes	  on	  the	  luminal	  side	  of	  the	  uterus	  12.	  
	  
The	  chorionic	  villi	  make	  up	  the	  main	  structure	  of	  the	  maternal-­‐facing	  side	  of	  the	  placenta.	  The	  
villus	   “trees”	   are	   composed	   of	   a	   cytotrophoblast	   (CTB)	   layer	   covering	   the	   villus	   core,	   and	   a	  
syncytiotrophoblast	   (STB)	   layer	  on	  the	  villus	  surface	   in	  direct	  contact	  with	  the	  maternal	  blood	  
(Figure	  1.3).	  Like	  the	  rest	  of	  the	  tissue,	  these	  villi	  go	  through	  several	  stages	  of	  development	  until	  
term.	   In	   the	   first	   seven	   weeks,	   the	   placenta	   is	   composed	   of	   primitive	   villi	   that	   lack	   proper	  
vascularization.	   Through	   trophoblast	   sprouting	   and	   proliferation,	   they	   elongate	   and	   mature	  
forming	  stem	  villi	  that	  are	  anchored	  to	  the	  chorionic	  plate.	  From	  stem	  villi,	  peripheral	  branching	  
gives	  rise	  to	  intermediate	  and	  tertiary	  villi	  that	  are	  the	  primary	  site	  of	  fetal-­‐maternal	  exchange	  
in	   the	   intervillous	   space.	   This	   stage	   of	   development	   is	   accompanied	   with	   rapid	   formation	   of	  
villus	   core	   fetal	   capillaries	   2.	   The	   stem	   villi	   are	   organized	   into	   15-­‐28	   cotyledons	   that	   give	   the	  
maternal	   side	  of	   the	  placenta	   its	   lobular	  appearance.	   	  A	  subset	  of	  chorionic	  villi	  attach	   to	   the	  
maternal	  decidua	  forming	  the	  basal	  plate.	  	   	  




Figure	  1.2	  Extra-­‐embryonic	  Membranes	  and	  Placenta	  Formation	  
In	  the	   innermost	   layer,	  the	  amnion	  stretches	  from	  the	  base	  of	  the	  umbilical	  cord,	  forming	  the	  
fluid-­‐filled	   amniotic	   cavity	   that	   encapsulates	   the	   fetus.	   The	   umbilical	   cord	   stretches	   from	   the	  
fetus	  and	  then	  inserts	  itself	  into	  the	  chorionic	  plate.	  The	  chorion	  arises	  from	  the	  trophectoderm	  
layer	  and	  develops	  into	  the	  chorionic	  villi	  of	  the	  placenta.	  The	  maternal	  decidua	  can	  be	  divided	  
into	  three	  parts.	  The	  decidua	  capsularis	  forms	  the	  third	  membrane	  around	  the	  fetus	  and	  ends	  at	  
the	  placenta	  margin.	  The	  decidua	  basalis	  is	  in	  intimate	  contact	  with	  the	  chorionic	  villi,	  while	  the	  
remaining,	  non-­‐interacting,	  decidua	  makes	  up	  the	  decidua	  parietalis.	  Used	  with	  permission	  from	  
Martini	  FH.,	  et	  al.	  (2014)	  13.	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Consisting	  of	  cytotrophoblasts,	  decidua	  basalis,	  maternal	  immune	  cells,	  and	  remodeled	  vessels,	  
the	   basal	   plate	   forms	   the	   extravillous	   tissue	   of	   the	   placenta.	   At	   the	   basal	   plate,	   the	  
establishment	  of	  proper	  placental	  perfusion	  is	  key	  to	  a	  healthy	  pregnancy.	  	  
	  
The	  placenta	   is	   a	  highly	   vascularized	  organ	   composed	  of	  both	  maternal	   and	  embryonic	  blood	  
vessels.	  The	  utero-­‐placental	  blood	  flow	  consists	  of	  maternal	  spiral	  arteries	  bringing	  oxygen-­‐rich	  
blood	  to	  the	  intervillous	  space,	  while	  waste	  products	  are	  drained	  through	  the	  uterine	  veins.	  The	  
feto-­‐placental	  blood	   flow	   is	   comprised	  of	  umbilical	   vessels	   that	   feed	   through	   the	   fetal	   side	  of	  
the	   placenta	   and	   branch	   into	   capillary	   loops	   of	   the	   chorionic	   villi.	  Within	   the	   umbilical	   cord,	  
there	  is	  one	  vein	  that	  leads	  oxygen-­‐rich	  blood	  from	  the	  intervillous	  space	  to	  the	  fetus,	  and	  two	  
arteries	   that	   lead	  blood	   from	  the	   fetus	   to	   the	   intervillous	  space	   2.	  The	  vascular	  density	  of	   the	  
cotyledons,	  as	  well	  as	  the	  uterine	  and	  umbilical	  blood	  flow,	  greatly	  increase	  in	  the	  later	  part	  of	  
gestation,	   coinciding	   with	   an	   exponential	   increase	   in	   fetal	   growth	   16.	   Adequate	   placental	  
vascularization	   is	   essential	   in	   order	   to	   keep	   pace	   with	   the	   growing	   fetus.	   Reduced	   vascular	  
development	   can	   lead	   to	   increases	   in	   vascular	   resistance,	   which	   can	   result	   in	   compromised	  
pregnancies.	   	  








Figure	  1.3	  The	  Placenta	  Unit	  
(A)	  Anatomy	  of	  placenta	  and	  fetal	  membranes	  at	  term.	  Bottom	  panel	  shows	  the	  fetal	  side	  of	  the	  
placenta	  where	   the	   umbilical	   cord	   is	   inserted.	   The	   smooth	  membranes	   are	   composed	   of	   the	  
amnion	  and	  chorion.	  The	  chorion	  gives	  rise	  to	  the	  chorionic	  villi	  (top	  panel)	  on	  the	  maternal	  side	  
that	  are	  organized	   into	   lobules	  or	  cotyledons.	   (B)	  Arrangement	  of	   the	  placenta	   from	  the	   fetal	  
side	   (chorionic	   plate)	   to	   the	  maternal	   side	   (basal	   plate).	   At	   the	   chorionic	   plate	   the	   stem	   villi	  
branch	   into	   intermediate	   and	   terminal	   villus	   that	   are	   extensively	   vascularized	   with	   the	   fetal	  
blood	  vessels.	  The	  villus	  core	   is	  covered	  with	  a	   layer	  of	  cytotrophoblast	   (CTB)	  progenitor	  cells	  
that	  fuse	  to	  form	  the	  multinucleated	  syncytiotrophoblast	  cells	  (STB).	  While	  some	  villi	  float	  in	  the	  
intervillous	  space,	  bathing	  in	  maternal	  blood,	  a	  subset	  become	  anchoring	  villi,	  attaching	  to	  the	  
maternal	   decidua	   forming	   the	  basal	   plate.	   From	   the	   anchoring	   cites,	   trophoblasts	   invade	   and	  
remodel	   the	   maternal	   blood	   vessels	   up	   to	   the	   inner	   third	   of	   the	   myometrium.	   Used	   with	  
permission	  from	  Barcena	  A.,	  et	  al.	  (2011)	  and	  Standring	  S.	  (2015)	  14,15	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3.	  PATHWAYS	  OF	  HUMAN	  PLACENTAL	  TROPHOBLAST	  CELL	  DIFFERENTIATION	  
	  
Human	   cytotrophoblast	   progenitor	   cells	   differentiate	   toward	   two	   general	   pathways:	   villous	  
trophoblasts	  and	  invasive	  extravillous	  trophoblasts	  (EVT)	  (Figure	  1.4).	  While	  the	  villous	  pathway	  
is	   active	   throughout	   gestation,	   the	   invasive	   differentiation	   pathway	   is	   indispensible	   in	   early	  
placenta	  development	  and	  decreases	  to	  term.	  
	  	  
3.1.	  Trophoblast	  cell	  fusion:	  differentiation	  toward	  syncytiotrophoblasts	  (STBs)	  	  
In	   the	   villous	   pathway,	   mononucleated	   CTBs	   fuse	   into	   multinucleated	   STBs,	   forming	   the	  
syncytial	   layer	   that	  covers	   the	  placental	  villous	   tree.	  These	  cells	  are	   intimately	   involved	   in	   the	  
exchange	   of	   gases,	   nutrients	   and	   waste	   across	   the	   maternal–fetal	   interface.	   The	   absorptive	  
capabilities	  of	  this	  layer	  are	  maximized	  by	  the	  presence	  of	  microvilli	  that	  considerably	  increase	  
the	  surface	  area	  17.	  The	  syncytial	  layer	  also	  plays	  a	  major	  role	  in	  the	  maintenance	  of	  pregnancy	  
via	   the	   production	   of	   pregnancy-­‐related	   hormones,	   such	   as	   human	   chorionic	   gonadotropin	  
(hCG)	  and	  human	  placental	   lactogen	   (hPL)	   4.	   	  Additionally,	  STBs	  are	   in	  direct	  contact	  with	   the	  
maternal	   blood	   and	   are	   therefore	   required	   to	   exhibit	   a	   degree	   of	   immune	   tolerance.	   This	  
tolerance	  is	  achieved	  in	  large	  part	  through	  the	  lack	  of	  classical	  class	  I	  human	  leucocyte	  antigens	  
(HLA)	  expression	  18.	  	  
	  
Syncytiotrophoblasts	   are	   non-­‐proliferative	   and	   are	   therefore	   continually	   replenished	  
throughout	  pregnancy	  via	  the	  fusion	  of	  the	  underlying	  CTB	  cell	  layer	  and	  shedding	  of	  the	  aged	  
portions	   of	   the	   STBs	   	   (i.e.	   syncytial	   knots)	   19.	   Interestingly,	   this	   cell	   fusion	   occurs	   exclusively	  
between	  the	  CTB	  and	  the	  overlaying	  syncytium;	  not	  between	  neighboring	  CTBs.	  
	  






Figure	  1.4	  Pathways	  of	  Human	  Placenta	  Trophoblast	  Differentiation	  
(A)	   A	   single	   layer	   of	   progenitor	   cytotrophoblast	   (CTB)	   cells	   lines	   the	   villus	  mesenchyme	   core.	  
CTB	  fuse	  down	  the	  villus	  pathway	  to	  form	  multinucleated	  syncytiotrophoblast	  (STB)	  cells.	  These	  
floating	  villi	  are	  the	  primary	  site	  of	  exchange	  with	  maternal	  blood	  and	  hormone	  production.	  In	  
the	  invasive	  pathway,	  proliferative	  CTB	  form	  the	  anchoring	  villus	  that	  attaches	  to	  the	  decidua.	  
As	   cells	   leave	   the	   column,	   they	   form	   the	   interstitial	   extravillous	   trophoblasts	   (iEVT)	   and	  
endovascular	  EVT	  (enEVT).	  While	  iEVT	  form	  giant	  cells,	  the	  enEVT	  will	  actively	  remodel	  maternal	  
arterioles.	   (B)	   Flowchart	   of	   trophoblast	   differentiation	   from	   progenitor	   cytotrophoblast	   cells	  
(CTB).	  Used	  with	  permission	  from	  Hannan	  NJ.,	  et	  al.	  (2006)	  20.	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Although	   the	   process	   of	   trophoblast	   cell	   fusion	   is	   poorly	   understood,	   it	   is	   generally	   accepted	  
that	   trophoblast	   differentiation	   into	   endocrine	   STBs	   is	   downstream	   of	   the	   fusogenic	   event.	  
Specifically,	   the	   cascade	   is	   believed	   to	   begin	   with	   increased	   cAMP	   (cyclic	   adenosine	  
monophosphate)	  level,	  which	  occurs	  via	  the	  activation	  of	  adenylyl	  cyclase	  and	  the	  consequent	  
activation	  of	  protein	  kinase	  A	  (PKA).	  The	  downstream	  activation	  of	  transcription	  factors,	  such	  as	  
glial	   cells	   missing-­‐1	   (GCM-­‐1)	   and	   its	   target	   genes	   (for	   instance,	   the	   well-­‐characterized	   fusion	  
peptide	   synctytin-­‐1)	   induces	   syncytialization	   and	   a	   subsequent	   increase	   in	   hCG	  production	   21.	  
Syncytin-­‐1	   is	   localized	   to	   the	   syncytiotrophoblast	   cells	   and	   its	   expression	   is	   maintained	  
throughout	   gestation	   22,23.	   Evidence	   from	   studies	   in	   BeWo	   cells,	   a	   well-­‐established	   human	  
choriocarcinoma	  cell	  line	  and	  an	  in	  vitro	  model	  of	  trophoblast	  fusion,	  conclusively	  demonstrates	  
the	  role	  of	  syncytin-­‐1	  in	  triggering	  cell	  fusion	  24.	  
	  
Alternatively,	  there	  is	  growing	  evidence	  for	  the	  hypothesis	  that	  the	  mechanisms	  that	  govern	  the	  
fusogenic	   and	  endocrine	  properties	  of	   STBs,	   although	   linked,	   are	   independently	   regulated.	  As	  
demonstrated	  by	  Orendi	  et	  al.,	  H-­‐89,	  a	  selective	   inhibitor	  of	  cAMP-­‐dependent	  PKA,	  prevented	  
the	  cell	  fusion	  event	  in	  BeWo	  cells	  without	  affecting	  the	  production	  of	  hCG.	  This	  result	  suggests	  
a	  second,	  PKA-­‐independent,	  pathway	  in	  hCG	  synthesis	  25.	  	  
	  
The	   continual	   fusion	   of	   CTBs	   into	   a	   growing	   syncytial	   layer	   raises	   questions	   regarding	   the	  
balance	   between	   tissue	   renewal	   and	   tissue	   loss.	   Whether	   the	   syncytium	   continues	   to	  
accumulate	   nuclei	   throughout	   pregnancy	   or	   if	   aging	   nuclei	   are	   selectively	   shed	   via	   apoptosis	  
into	  the	  maternal	  circulation	  is	  widely	  debated,	  and	  there	  is	  a	  great	  deal	  of	  evidence	  to	  support	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both	  claims.	  On	  one	  side	  of	   the	  argument,	   there	   is	  evidence	   to	  support	  a	  model	  where	  aging	  
nuclei	  must	  be	  shed	  to	  maintain	  the	  balance	  between	  renewal	  and	  loss	  as	  new	  CTBs	  join	  the	  STB	  
layer.	   Studies	   that	   have	   examined	   the	   STB	   layer	   have	   indicated	   that	   these	   nuclei	   become	  
packaged	   into	  membrane	  bound	   vesicles,	   termed	   syncytial	   knots,	   and	   released	   into	  maternal	  
circulation	  26,27.	  It	  has	  been	  suggested	  that	  it	  takes	  approximately	  3–4	  weeks	  following	  syncytial	  
fusion	   for	   one	   aging	   nucleus	   to	   be	   removed	   from	   the	   growing	   cell	   28.	   Alternatively,	   another	  
argument	  states	  that	  the	  nuclei	   in	  the	  STB	   layer	  continue	  to	  accumulate	  throughout	  gestation	  
and	  that	  their	  heterogeneous	  appearance	  is	  primarily	  a	  result	  of	  their	  differential	  ages	  29.	  
	  
3.2.	  Trophoblast	  cell	  invasion:	  differentiation	  toward	  extravillous	  trophoblasts	  (EVTs)	  
The	  invasive	  pathway	  depends	  on	  the	  establishment	  of	  anchoring	  villi	  that	  serve	  to	  attach	  the	  
placenta	  to	  the	  uterine	  wall.	  	  The	  anchoring	  sites	  are	  established	  as	  early	  as	  the	  second	  week	  of	  
gestation	  and	  are	  composed	  of	  a	  heterogeneous	  population	  of	  CTBs	   30.	  Trophoblasts	   invading	  
the	  decidua	  from	  anchoring	  columns	  are	  essential	  in	  establishing	  an	  adequate	  perfusion	  of	  the	  
placenta	  to	  sustain	  the	  growing	  fetus.	  	  
	  
A	   subpopulation	   of	   rapidly	   proliferating	   CTBs,	   which	   participate	   in	   the	   creation	   of	   the	   cell	  
column	  bridge	  between	  the	  placental	  villous	  tip	  and	  the	  maternal	  decidualized	  stroma,	  can	  be	  
found	   at	   the	   proximal	   ends	   of	   the	   anchoring	   sites.	   Studies	   of	   human	   placental	   and	   decidual	  
explant	   cultures	   suggest	   that	  decidual	   contact	   signals	   the	  proliferative	  burst	  of	  CTBs	   to	  break	  
through	  the	  STB	  layer	  30.	  The	  stability	  of	  this	  interaction	  is	  in	  part	  mediated	  by	  the	  upregulation	  
of	  integrin	  α5β1	  and	  a	  fibronectin-­‐rich	  matrix	  on	  the	  CTBs	  that	  are	  located	  in	  the	  distal	  portions	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of	  the	  trophoblast	  cell	  columns	  31,32.	  There	  is	  also	  evidence	  that	  the	  L-­‐Selectin	  adhesion	  system	  
may	  participate	  in	  the	  formation	  and	  maintenance	  of	  the	  anchoring	  villi	  early	  in	  pregnancy	  33.	  At	  
the	  distal	  ends	  of	  the	  columns,	  CTBs	  exit	  the	  cell	  cycle	  and	  begin	  to	  lose	  their	  cell–cell	  contacts.	  
These	  CTBs	  detach	  from	  columns	  and,	  as	  they	  come	  into	  contact	  with	  the	  decidual	  extracellular	  
matrix,	   they	  differentiate	   into	   interstitial	   EVTs	   (iEVTs)	   and	  endovascular	   EVTs	   (enEVTs),	  which	  
have	  distinct	  roles	  in	  maternal	  decidua	  34.	  
	  
The	  differentiation	  process	  within	  the	  heterogeneous	  trophoblast	  column	  population	  is	  unclear,	  
however,	   in	   vitro	   studies	   suggest	   that	   this	   process	   may	   be	   intrinsic	   35.	   A	   large	   part	   of	   this	  
differentiation	   process	   is	   composed	   of	   a	   switch	   in	   adhesion	  molecule	   profiles	   as	   well	   as	   the	  
production	  and	  regulation	  of	  several	  proteases.	  
3.2.1.	  Interstitial	  trophoblast	  cells:	  invasion	  into	  uterine	  stroma	  
Interstitial	   EVTs	   are	   described	   as	   having	   two	   distinct	   phenotypes:	   large	   polygonal	   iEVTs	   (or	   X	  
cells)	   and	   small	   spindle-­‐shaped	   iEVTs.	   The	   large	   iEVTs	   are	   believed	   to	   remain	   around	   the	  
placental–decidua	   transition,	   securing	   the	   placenta	   to	   the	   uterus	   throughout	   gestation	   by	  
producing	   a	   “trophoblast	   glue”	   that	   is	  made	   of	   a	  matrix-­‐type	   firbrinoid	   36.	   In	   contrast,	   it	   has	  
been	  demonstrated	  that	  the	  small	  iEVTs	  invade	  deep	  into	  the	  decidua,	  as	  far	  as	  the	  inner	  third	  
of	  the	  myometrium	  36.	  
	  
Interstitial	  EVTs	  have	  a	  distinct	  adhesion	  molecule	  and	  histocompatibility	  antigen	  profile.	  There	  
is	   a	  marked	  downregulation	  of	   integrin	  α6β4	   and	   an	  upregulation	  of	   the	   fibronectin	   integrin,	  
α5β1,	   within	   the	   distal	   part	   of	   the	   cell	   column.	   The	   collagen	   integrin,	   α1β1,	   is	   expressed	   at	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higher	   levels	   in	   the	   iEVTs	   that	   invade	   deeply	   in	   the	   decidua	   32,37.	   The	   downregulation	   of	   E-­‐
cadherin	   is	  observed	   in	  the	  distal	  portion	  of	  cell	  column	  and	   is	  believed	  to	  contribute	  both	  to	  
the	  loss	  of	  cell–cell	  contact	  and	  to	  the	  increase	  in	  invasiveness	  in	  iEVTs	  38.	  Consistent	  with	  their	  
invasive	  phenotype,	   iEVTs	  have	  been	  demonstrated	  to	  secrete	  several	  proteases	  that	  facilitate	  
the	   breakdown	   of	   the	   decidual	   extracellular	   matrix.	   Specifically,	   the	   immunolocalization	   of	  
urokinase-­‐type	   plasminogen	   activator	   (uPA)	   and	   several	   matrix	   metalloproteinases	   (MMPs),	  
most	   notably	   the	   gelatinases	   MMP-­‐2	   and	   MMP-­‐9,	   have	   been	   reported.	   Interestingly,	   the	  
inhibitors	  of	  these	  enzymes,	  plasminogen	  activator	  inhibitor	  1/2	  (PAI-­‐1/2)	  and	  tissue	  inhibitor	  of	  
metalloproteinase-­‐1	   (TIMP-­‐1),	   are	   observed	   to	   be	   co-­‐localized	   to	   iEVTs,	   indicating	   a	   certain	  
degree	  of	  “fine-­‐tuning”	  with	  respect	  to	  limiting	  the	  invasiveness	  of	  these	  cells	  39,40.	  Furthermore,	  
unlike	   the	   villous	   CTBs,	   iEVTs	   express	   HLA	   class	   I	   major	   histocompatibility	   complex	   (MHC)	  
antigens.	  Specifically,	  these	  cells	  express	  HLA-­‐E,	  trophoblast	  specific	  HLA-­‐G	  and	  the	  polymorphic	  
HLA-­‐C	  41-­‐43.	  
	  
How	  this	  movement	  of	  iEVTs	  through	  the	  immune	  cell-­‐dense	  decidua	  during	  the	  first	  trimester	  
does	  not	  elicit	  a	  maternal	  immune	  response	  remains	  a	  great	  topic	  of	  discussion	  44.	  Most	  notable	  
in	   this	   regard	   is	   the	   interaction	  of	   iEVTs	  with	  decidua-­‐specific	  natural	   killer	   (dNK)	   cells,	  which	  
differ	  from	  the	  NK	  cells	  that	  are	  found	  in	  the	  peripheral	  blood,	  and	  which	  make	  up	  the	  largest	  
proportion	  of	  leukocytes	  at	  the	  implantation	  site.	  The	  receptor	  profiles	  on	  dNK	  cells	  allow	  them	  
to	  interact	  with	  all	  three	  of	  the	  HLA	  antigens	  that	  are	  expressed	  on	  iEVTs.	  Likewise,	  all	  of	  these	  
HLA	   antigens	   contribute	   to	   the	   immune	   tolerance	   that	   is	   observed	   at	   the	   maternal-­‐fetal	  
interface.	   HLA-­‐E	   binds	   with	   higher	   affinity	   to	   the	   more	   abundant	   inhibitor	   dNK	   receptor,	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suggesting	   a	   role	   in	   inhibiting	   cytotoxicity	   of	   dNKs	   45.	  Work	   by	   Apps	   et	   al.	   indicates	   that	   the	  
inhibitory	   leukocyte	   immunoglobulin-­‐like	   receptor	   (LILR),	   LILRB1,	   has	   highest	   affinity	   for	  
dimerized	   HLA-­‐G	   on	   iEVTs,	   suggesting	   that	   this	   placenta-­‐specific	   process	   modulates	   the	  
maternal	   immune	   response	   46.	   Lastly,	   studies	   of	   the	   interaction	   between	   HLA-­‐C	   and	  
corresponding	   dNK	   killer	   cell	   immunoglobulin-­‐like	   receptors	   (KIRs)	   provides	   evidence	   for	   the	  
importance	   of	   this	   interaction	   in	   fetal	   growth	   and	   blood	   supply	   42.	   The	   invading	   iEVTs	   finally	  
differentiate	   into	   placental	   bed	   giant	   cells.	   Similar	   to	   STBs,	   these	   cells	   have	   the	   capacity	   to	  
produce	   both	   hCG	   and	   hPL,	   suggesting	   their	   role	   in	   the	   maintenance	   of	   normal	   pregnancy.	  
Furthermore,	  these	  giant	  cells	  produce	  protease	  inhibitors	  that	  may	  be	  involved	  in	  limiting	  EVT	  
invasion	  past	  the	  myometrium	  47.	  
3.2.2.	  Endovascular	  trophoblast	  cells:	  remodeling	  of	  uterine	  spiral	  arteries	  
Placental	  circulation	  is	  established	  between	  8	  and	  12	  weeks	  of	  gestation,	  with	  the	  spiral	  arteries	  
being	  fully	  remodeled	  by	  approximately	  20	  weeks.	  Endovascular	  EVTs	  are	  believed	  to	  play	  key	  
roles	   in	   this	   remodeling	   process	   48.	   Decidual	   biopsies	   indicate	   that	   enEVTs	   invade	   maternal	  
vasculature	  in	  the	  decidua	  and	  the	  inner-­‐third	  portion	  of	  the	  myometrium	  49.	  The	  remodeling	  of	  
the	   spiral	   arteries	   from	   high-­‐resistance	   and	   low-­‐flow	  muscular	   vessels	   to	   low-­‐resistance	   and	  
high-­‐flow	  sac-­‐like	  vessels	  involves	  cross	  talk	  between	  different	  cell	  types,	  with	  enEVTs	  being	  the	  
key	   players	   (Figure	   1.5).	   These	   events	   can	   be	   divided	   into	   five	   stages:	   (1)	   decidua-­‐associated	  
early	  vascular	  remodeling,	  (2)	  iEVT-­‐associated	  early	  vascular	  remodeling	  (3)	  enEVT	  migration,	  (4)	  
the	   incorporation	  of	  enEVTs	   into	  the	  vessel	  wall	  and	  (5)	  the	  re-­‐endothelization	  and	  subintimal	  
thickening	  7,50.	  During	  the	  decidualization	  process,	  the	  maternal	  vessels	  are	  modified	  to	  prepare	  
them	  for	  EVT	  invasion.	  This	  “priming”	  process	  appears	  to	  be	  trophoblast-­‐independent	  based	  on	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studies	   of	   ectopic	   pregnancies	   51.	   These	   alterations	   include	   smooth	   muscle	   swelling	   and	  
endothelial	   cell	   vacuolation	   50.	   Leukocytes,	   specifically	   dNKs	   and	   macrophages,	   have	   been	  
implicated	  in	  this	  process.	  MMP-­‐dependent	  matrix	  degradation	  and	  apoptosis	  are	  the	  suggested	  
mechanisms	  by	  which	  trophoblast-­‐independent	  early	  vascular	  remodeling	  occurs	  52.	  
	  
Two	  possible	  origins	  of	   the	  enEVTs	  have	  been	  suggested:	   iEVTs	  and	  enEVT	  plugs.	  During	  early	  
pregnancy,	   spiral	   arteries	   in	   the	   superficial	   decidua	   are	   surrounded	   by	   iEVTs	   54.	   These	   iEVTs	  
position	  themselves	  along	  the	  arteries	  and	  begin	  to	  disrupt	  and	  disorganize	  the	  vascular	  smooth	  
muscle	  cell	  layer.	  As	  these	  iEVTs	  invade	  the	  lumen	  of	  the	  arteries,	  they	  are	  believed	  to	  switch	  to	  
the	   endovascular	   phenotype.	   However,	   it	   has	   been	   suggested	   that	   the	   switch	   from	   iEVTs	   to	  
enEVTs	  occurs	  only	   in	  regions	  of	   the	  spiral	  arteries	   in	   the	  superficial	  zone	  of	   the	  decidua,	  and	  
that	  deeper	  regions	  of	  the	  arteries	  are	  remodeled	  by	  enEVTs	  from	  a	  second	  origin,	  the	  enEVT	  
plugs	  50.	  	  
	  
EnEVTs	   from	   the	   initial	   plugs	   are	   believed	   to	   travel	   down	   the	   vessel	   lumen	   in	   a	   retrograde	  
manner	  7.	  This	  infiltration	  by	  the	  EVTs	  results	  in	  maternal	  vascular	  apoptosis,	  the	  detachment	  of	  
these	  cells	  from	  the	  surrounding	  extracellular	  matrix	  and	  their	  migration	  away	  from	  the	  vessels.	  
EnEVTs	  go	  on	  to	  replace	  the	  endothelial	  cells	  of	  the	  maternal	  vessels	  through	  a	  process	  that	  is	  
referred	  to	  as	  pseudovasculogenesis	  or	  vascular	  mimicry	  37,38,55.	  	  Endovascular	  EVTs	  are	  able	  to	  
exist	  within	  the	  maternal	  vasculature	   in	  a	  manner	  that	   is	  similar	  to	  endothelial	  cells,	  primarily	  
due	   to	   their	   ability	   to	   switch	   from	   an	   epithelial	   to	   an	   endothelial	   adhesion	   molecule	  
phenotype56.	  
	   16	  
	  
	  
Figure	  1.5	  Cellular	  Interactions	  in	  Spiral	  Artery	  Remodeling	  
Unremodeled	   decidua	   spiral	   arteries	   are	   low-­‐flow,	   high-­‐resistance	   vessels.	   They	   have	   tight,	  
circular	  cross	  sections,	  and	  are	  made	  up	  of	  a	  thick	  vascular	  smooth	  muscle	  cell	  (VSMC)	  layer	  and	  
an	   endothelial	   cell	   (EC)	   layer	   embedded	   in	   an	   extra	   cellular	   matrix	   (ECM).	   The	   remodeling	  
process	   begins	   prior	   to	   EVT	   infiltration.	   Decidual	   immune	   cells	   (mainly	   decidual	   natural	   killer	  
cells	  and	  macrophages)	  begin	  priming	  the	  vessels	  starting	  with	  the	  VSMC.	  EVT	  are	   involved	   in	  
the	  spiral	  arteries	  through	  their	  interstitial	  pool	  or	  down	  the	  lumen	  as	  endovascular	  EVT.	  Once	  
the	   endothelial	   cells	   have	   been	   removed,	   the	   enEVT	   reline	   the	   vessel,	   completing	   the	  
remodeling	  process.	  As	  seen	  in	  the	  diagram,	  the	  VSMC	  and	  EC	  are	  removed	  and	  replaced	  with	  
enEVT	   once	   remodeled,	   which	   consequently	   produce	   high-­‐flow,	   low-­‐resistance	   vessels	  
supplying	  blood	  to	  to	  the	  feto-­‐maternal	  interface.	  	  Used	  with	  permission	  from	  Whitley	  G.St.J.,	  et	  
al	  (2008)	  53.	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These	  cells	  downregulate	  the	  epithelial-­‐type	  markers	  E-­‐cadherin	  and	  α6β4,	  and	  upregulate	  the	  
expression	   of	   the	   adhesion	   molecules	   vascular	   endothelial	   (VE)-­‐Cadherin,	   Platelet	   And	  
Endothelial	  Cell	  Adhesion	  Molecule	  1	  (PECAM1),	  and	  Neural	  Cell	  Adhesion	  Molecule	  (NCAM),	  as	  
well	  as	  integrins	  α5β1,	  α1β1,	  and	  αVβ3	  37,38.	  Lastly,	  studies	  in	  mice	  have	  provided	  evidence	  for	  
maternal	  vascular	   repair.	  This	  process	  encompasses	  re-­‐endothelization	  and	  the	  appearance	  of	  
subintimal	  thickening	  between	  the	  restored	  endothelium	  and	  fibrinoid	  layer	  that	  surrounds	  the	  
enEVTs	  50.	  
	  
The	  remodeling	  of	  maternal	  spiral	  arteries	  continues	  until	  the	  mid-­‐second	  trimester,	  and	  can	  be	  
observed	  as	  deeply	  as	  the	  inner-­‐third	  of	  the	  myometrium.	  This	  process	  does	  not	  occur	  uniformly	  
throughout	   the	   entire	   placenta;	   it	   is	   most	   prominent	   in	   the	   central	   placental	   bed	   and	   less	  
prominent	  at	  the	  periphery	  57.	  The	  remodeled	  spiral	  arteries	  are	   increased	   in	   length,	  exhibit	  a	  
several-­‐fold	   increase	   in	   lumen	  diameter	  and	  are	  unresponsive	   to	  vasoconstrictive	  agents	   56,58.	  	  
This	   low-­‐resistance	  and	  high-­‐capacity	  phenotype	  provides	  for	  consistent	  and	   low	  velocity	   flow	  
of	  maternal	  blood	  into	  the	  intervillous	  spaces,	  which	  sustains	  the	  growing	  demands	  of	  the	  fetus	  
throughout	  gestation.	  
	  
Mammalian	   placentation	   represents	   a	   remarkable	   biological	   process,	   during	   which	   diverse	  
trophoblast	  populations	  are	  generated.	  Much	  work	  has	  been	  performed	  to	  identify	  trophoblast	  
subtypes,	  especially	  at	  early	  gestational	   stages,	  when	  trophoblasts	  are	  actively	  differentiating.	  
The	   characterization	   of	   enEVTs	   has	   been	   poorly	   described	   compared	   with	   other	   trophoblast	  
subtypes.	  This	  relative	  lack	  of	  knowledge	  is	  most	  likely	  due	  to	  the	  difficulty	  involved	  in	  accessing	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clinical	   samples	   that	  contain	  deeper	  uterine	  endometrium	  and	   the	  upper	  one-­‐third	  of	  uterine	  
myometrium,	  where	  enEVTs	  are	  abundant.	  	  
4.	  PREECLAMPSIA	  (PE)	  
	  
The	  establishment	  of	   the	   feto-­‐maternal	   interface	   is	   complex	  and	   is	   tightly	   regulated	  by	  many	  
interactions	  of	  a	   large	  group	  of	  molecules	   from	  diverse	  cell	   types.	  Disruption	   in	   the	  pathways	  
involved	   in	   placental	   development,	   especially	   during	   the	   early	   stage	  of	   gestation,	   can	   lead	   to	  
complications	  later	  in	  pregnancy	  such	  as	  preeclampsia	  (PE).	  
4.1	  Etiology	  and	  Pathophysiology	  	  
	  
Preeclampsia	   is	   the	   leading	   cause	   of	   maternal	   morbidity,	   mortality,	   and	   premature	   delivery,	  
affecting	   approximately	   2–8%	   of	   pregnancies	   worldwide	   59.	   While	   mainly	   defined	   as	   a	  
hypertensive	  disease	  of	  pregnancy,	  PE	  is	  increasingly	  seen	  as	  multisystemic,	  seriously	  affecting	  
the	  liver,	  kidneys,	  lungs,	  and	  brain.	  Typically,	  PE	  is	  diagnosed	  after	  20	  weeks	  of	  gestation	  by	  the	  
presence	  of	  hallmark	  symptoms	  in	  the	  mother	  including	  non-­‐preexisting	  hypertension	  (⩾140/90	  
mmHg)	  and	  proteinuria	  (⩾3	  g	  in	  24	  h).	  Although	  PE	  is	  considered	  to	  be	  a	  late-­‐pregnancy	  disorder	  
based	  on	  clinical	  data,	  the	  molecular	  events	  leading	  to	  its	  onset	  have	  been	  suggested	  to	  occur	  
early	  in	  pregnancy.	  It	  is	  generally	  accepted	  that	  the	  presence	  of	  a	  placenta	  is	  a	  major	  cause	  of	  
preeclampsia.	  Specifically,	  placental	  ischemia	  appears	  to	  play	  a	  central	  role	  in	  this	  disease	  60.	  
	  
The	   pathological	   changes	   in	   the	   PE	   placenta	   have	   been	   reported	   in	   an	   increasing	   number	   of	  
studies	   (Figure	   1.6).	   The	   first	   stage	   is	   poor	   development	   of	   the	   early	   placenta	   and	   utero-­‐
placental	   blood	   supply	   that	   occurs	   in	   the	   first	   half	   of	   pregnancy,	   during	   which	   no	   clinical	  
symptoms	  are	  presented	  (Figure	  1.6).	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Figure	  1.6	  Defective	  Mechanisms	  of	  Invasion	  and	  Spiral	  Artery	  Remodeling	  in	  PE	  
(A)	  In	  normal	  pregnancy,	  EVT	  (shown	  in	  green)	  from	  anchoring	  villi	  (AV)	  invade	  the	  decidua	  and	  
maternal	   spiral	   arteries	   remodelling	   them	   up	   to	   the	   inner-­‐third	   of	   the	   myometrium.	   (B)	   In	  
pregnancies	  compromised	  by	  PE,	  the	  population	  of	  EVT	  is	  reduced,	  and	  remodeling	  is	  restricted	  
to	   the	   proximal	   portion	   of	   the	   vessel.	   Insufficient	   remodeling	   in	   PE	   is	   observed	   as	   smaller	  
diameter	  vessels	  accompanied	  by	  variable	  blood	  flow	  with	  increased	  velocity	  to	  the	  intervillous	  
space.	  Used	  with	  permission	  from	  Pennington	  KA.,	  et	  al.	  (2012)	  69.	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The	   second	   stage	   is	   the	   manifestation	   of	   the	   maternal	   syndrome	   that	   arises,	   in	   part,	   from	  
factors	  released	  by	  the	  placenta	  as	  it	  is	  placed	  under	  an	  increasing	  amount	  of	  oxidative	  stress	  70.	  
It	   should	   also	   be	   considered	   that	   maternal	   determinants,	   including	   genetic,	   behavioral,	   and	  




Agreement	  on	  a	  clear	  definition	  of	  PE	  has	  been	  understandably	  difficult.	  One	  reason	  for	  this	  is	  
the	   central	   belief	   that	   PE	   is	   a	   broad	   classification	   for	   a	   number	   of	   diseases	   with	   shared	  
pathophysiology.	  	  
	  
Two	  broad	  categories	  of	  PE	  have	  been	  suggested,	  placental	  PE	  and	  maternal	  PE	  70.	  Maternal	  PE	  
is	   considered	   to	   arise	   from	   the	   interaction	   between	   a	   normal	   placenta	   and	   an	   abnormal	  
maternal	   response.	   In	   this	   regard,	   clinical	   manifestation	   is	   likely	   to	   be	   influenced	   by	   the	  
presence	   of	   preexisting	   microvascular	   or	   metabolic	   diseases,	   as	   well	   as	   environmental	   and	  
nutritional	  factors,	  and	  usually	  occurs	  in	  late	  pregnancy.	  In	  contrast,	  placental	  PE	  is	  considered	  
to	   originate	   from	   a	   malfunctioning	   placenta	   under	   ischemia-­‐reperfusion	   conditions	   and	  
oxidative	  stress.	  However,	  the	  classification	  of	  these	  two	  types	  of	  PE	  has	  not	  been	  well	  defined,	  
and	  the	  combination	  of	  both	  the	  maternal	  and	  placental	  contribution	  has	  been	  most	  commonly	  
presented.	  
	  
Further	   classification	  of	   PE	   as	   early	   versus	   late,	   or	  mild	   versus	   severe	  have	  been	  widely	   used	  
across	  literature.	  The	  initial	  classification	  refers	  to	  the	  gestational	  age	  of	  diagnosis	  and	  severity	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of	   symptoms,	   respectively.	   Specifically,	   onset	   of	   clinical	   symptoms	   prior	   to	   34	   weeks	   of	  
gestation	  is	  classified	  as	  early-­‐onset	  PE,	  while	   late-­‐onset	  PE	  is	  anything	  diagnosed	  at	  34	  weeks	  
onward.	  The	  majority	  of	  clinical	  cases	  fall	  in	  the	  late-­‐onset	  group,	  with	  only	  12	  %	  making	  up	  the	  
early-­‐onset	   cases.	   It	   is	   unclear	   whether	   early-­‐	   or	   late-­‐onset	   PE	   are	   gradients	   of	   the	   same	  
condition	   or	   if	   they	   have	   different	   pathological	   mechanisms.	   While	   few	   comparison	   studies	  
exist,	   there	   is	   evidence	   for	   differential	   risk	   factors	   and	   origins	   associated	   with	   early-­‐PE	  
compared	  to	  the	  late-­‐onset	  cases	  71-­‐74.	  The	  classification	  of	  PE	  based	  on	  severity	  of	  symptoms	  at	  
diagnosis	   has	   been	  discouraged	   in	   recent	   years	   due	   to	   PE	   being	   a	   progressive	   disease.	  While	  
some	  cases	  can	  progress	  very	  slowly	  from	  initial	  diagnosis,	  others	  can	  very	  quickly	  escalate	  into	  
more	  severe	  complication	  75.	  	  
	  
A	  recent	  study	  has	  brought	  more	  insight	  into	  the	  heterogeneity	  of	  this	  condition	  by	  classifying	  
PE	   into	   three	  clinical	  etiologies	   through	  unsupervised	  genome	  clustering	   76.	  The	   first	  cluster	   is	  
believed	   to	   result	   from	  underlying	  maternal	   cardiovascular	   disease	   susceptibility	   and	   fall	   into	  
the	   “maternal	   PE”	   classification.	   It	   was	   characterized	   as	   late-­‐onset	   PE,	   with	   milder	   clinical	  
symptoms,	   appropriate	   for	   gestation	   age	   babies,	   and	   normal	   placentas.	   The	   second	   cluster	  
exhibited	  placenta	  origins	  of	  diseases	  and	  the	  canonical	  definition	  of	  PE.	  It	  was	  characterized	  by	  
severe	  early-­‐onset	  cases,	  fetal	  complication	  such	  as	  intrauterine	  growth	  restriction	  (IUGR),	  and	  
systemic	  maternal	  pathology.	  The	  last	  group	  was	  classified	  as	  “immunologic”	  PE,	  characterized	  
by	  a	  maternal-­‐fetal	  incompatibility	  coupled	  with	  a	  poor	  maternal	  response.	  Understanding	  of	  PE	  
has	   greatly	   progressed	   in	   the	   last	   decade.	   However,	   the	   search	   for	   reliable	   biomarkers	   and	  
potential	  therapies	  still	  remains	  a	  challenge.	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4.3	  Biomarkers	  and	  Treatment	  
	  
Currently,	   the	   only	   effective	   treatment	   available	   for	   PE	   is	   termination	   of	   pregnancy	   and	  
premature	   delivery.	   If	   left	   untreated,	   PE	   can	   result	   in	   serious	   health	   consequences	   or	   even	  
death	   for	   both	   the	   mother	   and	   fetus.	   The	   major	   challenges	   are	   to	   effectively	   diagnose	   the	  
condition	   early,	   and	   develop	   preventive	   and	   therapeutic	   strategies	   that	   will	   minimize	   the	  
burden	   of	   PE.	   Finding	   a	   reliable	   biomarker	   that	   can	   predict	   the	   onset	   of	   PE	   prior	   to	   clinical	  
symptoms	   has	   proven	   to	   be	   a	   difficult	   task,	   with	   studies	   focused	   on	   finding	   predictive	  
biochemical	  markers	  proposing	  several	  candidates.	  
	  
Among	  the	  first	  studied	  serum	  biomarkers	  of	  PE	  are	  vascular	  endothelial	  growth	  factor	  (VEGF)	  
and	  placental	  growth	  factor	  (PGF),	  and	  their	  antagonists,	  soluble	  fms-­‐like	  tyrosine	  kinase	  1	  (sFlt-­‐
1),	  and	  soluble	  endoglin	  (sEng).	  A	  significant	  downregulation	  of	  VEGF	  and	  PGF	  was	  reported	  in	  
second	  trimester	  serum	  prior	  to	  diagnosis	  of	  early-­‐onset	  severe	  PE	  77,78.	  Upregulation	  of	  sFlt-­‐1	  
was	  able	  to	  predict	  onset	  of	  PE	  on	  average	  11.2	  weeks	  prior	  to	  the	  onset	  of	  clinical	  symptoms	  79.	  
Other	  studies	  also	  showed	  a	  similar	  increase	  of	  sFlt-­‐1	  limited	  to	  several	  weeks	  prior	  to	  the	  onset	  
of	  clinical	  symptoms	  78,80.	  On	  the	  other	  hand,	  sEng	  levels	  were	  significantly	  higher	  starting	  at	  17	  
weeks	   or	   25	  weeks	   of	   gestation	   in	  women	   destined	   to	   develop	   early-­‐onset	   or	   late-­‐onset	   PE,	  
respectively	  81.	  The	  ratio	  of	  sFlt-­‐1:PGF	  has	  shown	  to	  increase	  ability	  to	  predict	  PE	  compared	  to	  
either	  marker	  alone	  	  81,82.	  Another	  study	  showed	  that	  combining	  maternal	  physical	  parameters	  
(i.e.	  uterine	  artery	  pulsatility	  index	  (PI),	  mean	  arterial	  pressure)	  and	  serum	  PGF	  at	  11-­‐	  13	  weeks	  
gestation	  was	  able	  to	  predict	  75%	  of	  early	  and	  47%	  of	  late-­‐onset	  PE	  cases	  83.	  	  The	  heterogeneity	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in	  patterns	  of	  prediction	  is	  most	  likely	  a	  result	  of	  low	  detection	  limits,	  mixed	  tissue	  origins	  (fetal	  
and/or	  maternal),	  and	  biomolecule	  reactivity	  and	  stability	  within	  maternal	  circulation	  84.	  	  
	  
Many	   studies	   have	   looked	   into	   the	   usefulness	   of	   placenta	   protein	   13	   (PP13),	   an	  
immunoregulatory	  galectin,	  as	  an	  early	  biomarker	  of	  PE.	  Unlike	  the	  angiogenic	  biomarkers,	  PP13	  
is	  only	  produced	  by	  the	  placenta	  STB	  cells	  85.	  Furthermore,	  patients	  destined	  to	  develop	  PE	  had	  
a	  downregulation	  of	  PP13	  as	  early	  as	  7	  weeks	  of	  gestation	  86,87.	  However,	  the	  downregulation	  of	  
PP13	  in	  the	  first	  trimester	  did	  not	  discriminate	  between	  PE	  and	  other	  complications	  such	  as	  pre-­‐
term	  birth	  and	  IUGR	  88.	  	  Also,	  in	  another	  study	  that	  combined	  maternal	  characteristics	  and	  other	  
serum	  biomarkers,	  PP13	  proved	  to	  be	  inadequate	  for	  screening	  purposes	  89.	  	  
	  
Discovery	  of	  microRNAs	  (miRNAs)	  in	  maternal	  plasma	  has	  opened	  up	  a	  new	  area	  for	  biomarker	  
discovery	  90.	  	  The	  differential	  expression	  of	  >130	  miRNAs	  between	  normal	  and	  PE	  placenta	  has	  
been	   reported	   91.	   However,	   nearly	   90%	   of	   the	   dysregulated	  miRNA	   have	   only	   been	   reported	  
once.	   Similar	   inconsistent	   findings	   are	   true	   of	   circulating	   serum	  miRNA	   early	   in	   gestation.	   A	  
study	  conducted	  on	  sera	  from	  12-­‐14	  weeks	  of	  gestation	  revealed	  19	  significantly	  dysregulated	  
miRNAs	  in	  patients	  destined	  with	  severe	  PE	  92.	  	  On	  the	  other	  hand,	  a	  similar	  study	  on	  sera	  from	  
the	  same	  gestation	  period	  found	  no	  circulating	  miRNA	  that	  were	  useful	  in	  predicting	  PE	  93.	  The	  
large	   variation	   between	   studies	   could	   be	   the	   result	   of	   many	   factors,	   including	   small	   sample	  
sizes,	   differences	   in	   classification	   of	   tissues,	   exclusion	   criteria,	   and	   methodologies	   (RNA	  
processing,	  miRNA	  detection	  etc.).	   In	  spite	  of	   inconsistencies	  in	  literature,	  miRNAs	  represent	  a	  
diverse	  and	  stable	  pool	  of	  potential	  biomarkers	  for	  discovery.	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II.	  MICRORNA	  
	  
MiRNA	   are	   a	   class	   of	   small	   non-­‐coding	   RNAs	   that	   are	   important	   regulators	   of	   post-­‐
transcriptional	   gene	   expression.	   In	   1993,	   landmark	   papers	   by	   Drs.	   Ambros	   and	   Ruvkin	  
introduced	   the	   first	   microRNA,	   lin-­‐4,	   in	   C.	   elegans	   94,95.	   	   They	   demonstrated	   that	   this	   gene,	  
essential	   for	   controlling	   the	   timing	   of	   larval	   development,	   did	   not	   encode	   a	   protein,	   but	  
suppressed	   the	   expression	  of	   lin-­‐14	   through	   a	   RNA-­‐RNA	   interaction	   in	   its	   3’UTR	   (three	  prime	  
untranslated	  region).	  For	  many	  years,	  this	  phenomenon	  remained	  unique	  to	  lin-­‐4	  and	  nematode	  
development.	   In	  2000,	   the	  discovery	  of	   let-­‐7	   in	  C.	  elegans	  demonstrated	   that	  one	  miRNA	  can	  
target	   the	   3’UTR	   of	   several	   mRNAs,	   and	   likewise,	   that	   one	  mRNA	   3’UTR	   can	   be	   targeted	   by	  
many	  miRNAs	   96.	   Intense	   cloning	   efforts	   revealed	   the	   presence	   of	  miRNA	   in	   a	   variety	   of	   cell	  
types	   and	   across	   all	   eukaryotic	   branches,	   suggesting	   that	   regulation	   by	   miRNAs	   was	   a	   more	  
wide-­‐spread	   phenomenon	   than	   previously	   anticipated	   97,98.	   Presently,	   online	   databases	   have	  
annotated	   ~1600	   human	   miRNA	   genes.	   	   While	   the	   function	   of	   most	   of	   these	   miRNAs	   is	  
unknown,	   it	   is	  clear	   they	  make	  up	  an	   important	  and	   large	  class	  of	  molecules	   involved	   in	  gene	  
regulatory	   networks.	   MiRNAs	   have	   been	   reported	   to	   regulate	   nearly	   all	   cellular	   processes,	  
including	   cell	   proliferation,	   differentiation,	   apoptosis,	   and	   development	   99.	   	   Involvement	   of	  
miRNAs	   in	   human	   diseases	   has	   been	   demonstrated	   and	   the	   possibility	   for	   their	   use	   as	  
therapeutic	  targets	  shows	  great	  potential	  100,101.	  	  	  	  
	  
1.	  Biogenesis	  and	  RISC	  Assembly	  
	  
Depending	   on	   their	   genomic	   location,	   miRNA	   can	   be	   broadly	   classified	   as	   “intronic”	   or	  
“intergenic”.	  Approximately	  half	   of	   all	   annotated	  human	  miRNA	  are	   found	  within	  host	   genes,	  
	   25	  
predominantly	   introns	   of	   protein-­‐coding	   genes	   or	   genes	   of	   other	   non-­‐coding	   RNAs	   102.	   The	  
biogenesis	  of	  all	  miRNA	  is	  generally	  consistent;	  however,	  their	  genomic	  location	  influences	  the	  
mechanisms	  of	   transcriptional	   regulation.	   Intronic	  miRNA	  are	   generally	   transcribed	   in	  parallel	  
with	   their	  host	  gene	   transcripts	   through	   the	  host	  gene	  promoter,	  while	   intergenic	  miRNA	  are	  
governed	  by	  their	  own	  promoters.	  However,	   recent	  evidence	  has	  shown	  an	  uncoupling	   in	   the	  
expression	  of	  certain	  miRNAs	  from	  their	  host	  genes	  through	  possible	  independent	  transcription	  
mechanisms	  and	  alternative	  splicing	  103.	  	  
	  
For	  the	  majority	  of	  miRNA,	  transcription	  is	  mediated	  by	  RNA	  polymerase	  II,	  generating	  a	  primary	  
miRNA	  (pri-­‐miRNA)	  transcript	  of	  up	  to	  several	  kilobases	   in	   length,	  containing	  a	  5’	  cap	  and	  a	  3’	  
poly-­‐A	   tail	   (Figure	   1.7).	   The	   pri-­‐miRNA	   is	   processed	   into	  mature	  miRNA	   through	   a	   step-­‐wise	  
process	  with	  specific	   subcellular	   localization	   104.	  The	   first	   step	   in	  processing	   is	  cropping	  of	   the	  
long	  pri-­‐miRNA	  transcript	  into	  a	  ~70nt	  hairpin	  precursor	  miRNA	  (pre-­‐miRNA)	  in	  the	  nucleus	  105.	  	  
The	  cropping	  is	  mediated	  by	  a	  microprocessor	  complex,	  which	  consists	  of	  an	  RNase	  III,	  Drosha,	  
and	   the	   double-­‐stranded-­‐RNA-­‐binding	   protein,	   DGCR8	   (DiGeorge	   syndrome	   Critical	   Region	   8)	  
106.	  Despite	  the	  diversity	  in	  sequence	  among	  pri-­‐miRNA,	  there	  are	  several	  structural	  features	  in	  
common	  that	  are	  essential	  for	  processing.	  
	  
Pri-­‐miRNAs	   form	   an	   imperfect	   double	   stranded	   stem	   structure	   of	   ~3	   helical	   turns,	  which	   are	  
flanked	  at	  one	  end	  by	  a	  ssRNA	  apical	  loop	  and	  long	  ssRNA	  base	  segments	  on	  the	  opposite	  end	  
108.	   Several	  models	   of	  microprocessor	   cleavage	   determination	   have	   been	   proposed;	   however	  
they	  all	  center	  on	  the	  recognition	  of	  the	  ssRNA-­‐dsRNA	  junctions.	  


































Figure	  1.7	  Model	  for	  microRNA	  Biogenesis	  and	  Mechanism.	  	  
First	   step	   of	   biogenesis	   is	   the	   transcription	   of	   primary	   miRNA	   transcripts	   (pri-­‐miRNAs)	   that	  
contain	  a	  double	  stranded	  stem,	  a	   loop,	  ssRNA	  tails,	  a	  5’	  cap	  and	  3’	  poly-­‐A	  Tail.	  Processing	  by	  
Drosha	   and	   DGCR8	   leads	   to	   the	   formation	   of	   the	   precursor	  miRNA	   (pre-­‐miRNA)	   that	   is	   then	  
exported	  out	  of	  the	  nucleus	  by	  Exportin	  5.	  DICER	  and	  TRPB	  complete	  the	  final	  processing	  from	  
pre-­‐miRNA	   to	   the	   mature	   miRNA	   duplex.	   The	   guide	   strand	   is	   loaded	   into	   one	   of	   the	   AGO	  
proteins	  and,	  along	  with	  other	  accessory	  proteins,	  RISC	  is	  complete.	  Target	  recognition	  can	  lead	  
to	   endonucleolytic	   cleavage	   (which	   only	   applies	   to	   AGO2	   loaded	   miRNA)	   or	   translational	  
repression	  and	  deadenylation.	  Used	  with	  permission	  from	  Filipowicz	  W.,	  et	  al.	  (2008)	  107.	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Namely,	   the	  cleavage	  occurs	  approximately	  one	  helical	   turn	   (~11bp)	   from	  the	  basal	   segments	  
and	   two	   helical	   turns	   (~22bp)	   from	   the	   apical	   loop	   109,110.	   The	   binding	   of	   the	  microprocessor	  
complex	  to	  the	  pri-­‐miRNA	  is	  mediated	  through	  the	  direct	  binding	  of	  DGCR8,	  which	  serves	  as	  an	  
anchor.	   DGCR8	   recognition	   of	   pri-­‐miRNA	   over	   other	   secondary	   structures	   in	   the	   transcript	   is	  
facilitated	   by	   the	   marking	   of	   pri-­‐miRNA	   though	   methylation,	   by	   methyltransferase-­‐like	   3	  
(METTL3),	   for	   example	   111.	   Subsequently,	   the	   cleavage	   by	   Drosha	   generates	   one	   end	   of	   the	  
mature	  miRNA	   and	   therefore	   determines	   the	   final	   miRNA	   sequence.	   Once	   the	   pre-­‐miRNA	   is	  
formed	  it	  is	  exported	  out	  of	  the	  nucleus	  by	  a	  member	  of	  the	  nuclear	  transport	  receptor	  family,	  
Exportin	  5	  (EXP5),	  that	  is	  bound	  to	  Ran	  small	  GTPase	  112.	  In	  the	  cytoplasm,	  the	  pre-­‐miRNA	  binds	  
to	  a	  second	  RNase-­‐III	  protein,	  Dicer,	  which,	  in	  combination	  with	  Trans-­‐activation	  response	  RNA-­‐
binding	  protein	   (TRBP),	   cleaves	  ~22nt	   from	   the	  pre-­‐existing	  pre-­‐miRNA	   terminus,	   forming	   the	  
miRNA:miRNA*	   duplex	   	   112-­‐114.	   The	   dsRNA	   duplex	   is	   short	   lived,	   and	   quickly	   undergoes	   the	  
coordinated	  process	  of	  RNA-­‐induced	  silencing	  complex	  (RISC)	  assembly.	  	  
	  
At	   the	   center	   of	   RISC	   are	   the	   ubiquitous	   post-­‐transcriptional	   regulators,	   the	   AGO	   family	   of	  
proteins.	  There	  are	   four	  main	  AGO	  proteins	  expressed	   in	  humans	   (AGO	  1-­‐4)	   that	  bind	  miRNA	  
indiscriminately	  115.	  The	  multi-­‐step	  process	  of	  RISC	  assembly	  can	  be	  generally	  summarized	  into:	  
1)	   loading	   of	   the	  miRNA	   duplex	   and	   2)	   subsequent	   RISC	  maturation	   116.	  With	   the	   aid	   of	   the	  
HSC70/HSP90	   chaperone	  machinery	   and	  ATP,	   the	  newly	   formed	  miRNA	  duplex	   is	   loaded	   into	  
AGO	   117.	   The	  miRNA	  duplex	   consists	  of	   a	   “guide	   strand”	  and	  a	   “passenger	   strand”.	   The	  guide	  
strand	  will	  be	   incorporated	   into	  RISC	  where	   it	  will	  serve	   in	  target	  transcript	  recognition,	  while	  
the	   passenger	   strand	   will	   be	   ejected	   from	   the	   AGO	   protein.	   The	   process	   of	   strand	   selection	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remains	   unclear;	   however	   thermodynamic	   stability	   is	   a	   major	   determining	   factor	   114.	   It	   is	  
generally	  believed	  that	  the	  less	  thermodynamically	  stable	  5’	  end	  of	  the	  miRNA	  will	  be	  anchored	  
by	  AGO,	  while	  the	  strand	  with	  the	  more	  stable	  5’	  end	  will	  be	  ejected	  through	  RISC	  maturation.	  
Ultimately,	  the	  guide	  stand	  is	  positioned	  so	  that	  its	  phosphate	  backbone	  is	  interacting	  with	  the	  
AGO	  while	  both	   its	  5’	  and	  3’	  ends	  are	  anchored,	  exposing	   the	  “seed-­‐region”	   (nucleotides	  2-­‐8,	  
from	  the	  5’	  end)	  for	  target	  recognition	  118.	  	  
	  
2.	  Mechanism	  	  
	  
The	  interaction	  between	  the	  miRNA-­‐containing	  RISC	  and	  its	  mRNA	  target	  is	  driven	  by	  base	  pair	  
complementarity.	   In	   general,	   miRNA:mRNA	   binding	   is	   largely	   dependent	   on	   	   a	   perfect	  
complement	  at	  the	  seed	  region,	  which	  forms	  a	  thermodynamically	  stable	  interaction	  for	  target	  
suppression.	   However,	   some	  miRNA	   have	   shown	   to	   compensate	   for	  mismatches	   in	   the	   seed	  
region	   through	   increased	   complementarity	   at	   the	   3’	   end	   119.	   Several	   mechanisms	   for	  miRNA	  
action	  have	  been	  proposed	  and	  yet	  a	  unified	  model	  remains	  to	  be	  clearly	  defined.	   In	  general,	  
miRNA	   have	   shown	   to	   exert	   their	   repressive	   action	   through	   mRNA	   cleavage,	   mRNA	   decay,	  
and/or	  translational	  repression	  120.	  	  
	  
While	  target	  mRNA	  cleavage	  is	  the	  predominant	  mechanism	  seen	  in	  siRNAs	  and	  plant	  miRNAs,	  it	  
is	  rarely	  observed	  in	  human	  miRNA:mRNA	  interactions	  107.	  Several	  theories	  have	  been	  proposed	  
to	  explain	  this	  observation.	  Unlike	  siRNAs	  and	  plant	  miRNAs,	  the	  majority	  of	  human	  miRNAs	  do	  
not	  exhibit	  perfect	  Watson-­‐Crick	  complementarity	  along	  the	  entire	  length	  of	  the	  mRNA	  target.	  
Since	   the	  AGO	  RNaseH	  domain	  prefers	  perfect	   complementarity	  near	   the	   cut	   region	   (10-­‐11nt	  
from	   the	   5’	   end),	   a	   bulge	   in	   the	   miRNA:mRNA	   interaction	   at	   this	   site	   would	   hinder	   its	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endonuclease	   activity	   120.	   Furthermore,	   while	   all	   four	   human	   AGO	   proteins	   interact	   with	  
miRNAs,	  only	  AGO2	  has	  retained	  this	  “slicer”	  function	  121.	  
	  
The	   second	   mechanism	   of	   miRNA-­‐guided	   gene	   silencing	   is	   through	   the	   destabilization	   and	  
degradation	   of	   mRNA	   targets.	   After	   target	   recognition,	   the	   AGO-­‐interacting	   GW182	   protein	  
family	   is	   essential	   in	   mediating	   the	   downstream	   steps	   of	   target	   repression	   118.	   Apart	   from	  
interacting	  with	  AGO,	  GW182	   is	  capable	  of	   interacting	  with	   the	  poly-­‐A	  binding	  protein	  on	  the	  
poly-­‐A-­‐tail	   of	   the	  mRNA	  as	  well	   as	   cellular	   deadenylases,	   such	   as	   the	   CCR4/NOT	   complex	   122.	  
This	  leads	  to	  the	  deadenylation	  and	  decapping	  of	  mRNA,	  and	  its	  consequential	  degradation.	  	  
	  
The	  third	  mechanism,	   involving	  translational	   repression,	  stemmed	  from	  the	   initial	  observation	  
that	  lin-­‐4	  regulated	  the	  LIN-­‐14	  protein	  without	  affecting	  mRNA	  levels	  95.	  How	  miRNAs	  suppress	  
translation	   is	   still	   unclear;	   however,	   strong	   evidence	   points	   to	   their	   interference	   with	   the	  
process	  of	  translation	  initiation	  123.	  Furthermore,	  the	  suppression	  of	  translation	  was	  suggested	  
to	  precede	  mRNA	  destabilization	  and	  degradation,	  challenging	  the	  initial	  observations	  with	  lin-­‐4	  
123.	  	  
	  
On	   the	   other	   hand,	  miRNAs	   as	   activators	   of	   translation	   have	   also	   been	   reported,	   albeit	   to	   a	  
much	  lesser	  extent.	  This	  mechanism	  involves	  the	  recruitment	  of	  translation	  initiation	  factors	  to	  
the	   site	   of	   miRNA-­‐RISC	   binding	   at	   AU-­‐rich	   elements	   (AREs)	   in	   the	   3’UTR	   124.	   To	   add	   to	   the	  
complexity,	   several	   miRNA	   have	   been	   reported	   to	   switch	   between	   their	   repressive	   and	  
activating	  roles	  depending	  on	  the	  cellular	  context,	  specifically	  in	  growth-­‐arrest	  conditions	  124,125.	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3.	  Target	  Prediction	  
	  
Understanding	   the	   biological	   function	   of	   a	  miRNA	   relies	   on	   identifying	   its	   regulatory	   targets.	  
Considering	   that	  miRNAs	   can	   target	  mRNAs	   through	   imperfect	   binding,	   each	  miRNA	   has	   the	  
potential	  to	  target	  many	  different	  mRNAs.	  Over	  30%	  of	  the	  human	  genome	  shows	  potential	  for	  
miRNA	  regulation,	  making	  predictive	  algorithms	  with	  high	  signal	  to	  noise	  ratios	   imperative	  126.	  
Since	   the	   initial	   discovery	   of	   miRNAs,	   the	   importance	   of	   target	   complementarity	   to	   the	   5’	  
portion	   of	   the	   guide	   strand	   has	   been	   evident,	   and	   the	  mechanism	   of	   target	   recognition	   has	  
proven	  to	  be	  even	  more	  complex.	  	  
Five	  canonical	  “seed”	  types	  on	  mRNA	  targets	  have	  been	  defined	  127	  (Figure	  1.8).	  Those	  with	  the	  
highest	   conservation	   and	   efficacy	   in	   miRNA	   repression	   are	   the	   8mer	   targets	   that	   possess	  
contiguous	  Watson-­‐Crick	  pairing	  to	  2-­‐8	  nucleotides	  in	  the	  seed	  region	  and	  an	  adenosine	  across	  
position	  one.	  	  The	  preference	  for	  nucleotide	  A	  in	  the	  first	  position	  is	  not	  dependent	  on	  miRNA	  
sequence	   identity.	  Rather,	   it	  proved	  to	   increase	  AGO	  affinity	  over	  all	  other	  nucleotides	   in	   this	  
position	  due	  an	  adenosine-­‐binding	  pocket	  in	  AGO	  that	  mediates	  target	  recognition	  128.	  Slightly	  
less	  effective	  are	  seed	  types	  with	  a	  7mer-­‐m8	  site	  (match	  at	  position	  2-­‐8)	  or	  7mer-­‐A1	  site	  (match	  
as	   position	   2-­‐7	  with	   an	   A	   opposite	   position	   1).	   	  While	   the	   6mer	   (match	   at	   position	   2-­‐7)	   and	  
offset-­‐6mer	  (match	  at	  position	  3-­‐8)	  show	  very	  weak	  preferential	  conservation	  and	  much	  lower	  
efficacy.	  	  
	  
Basing	   target	   prediction	  on	   seed-­‐region	   complementarity	   alone	  has	   not	   produced	  predictions	  
with	  high	  specificity.	  Many	  algorithms	   today	  will	  use	  a	  combination	  of	   factors	   to	   increase	   the	  
predictive	  power	  of	  functional	  targets	  129,130.	  	  











Figure	  1.8	  Canonical	  mRNA	  target	  site	  types.	  	  
The	  8mer	  targets	  (match	  nucleotide	  2-­‐8	  of	  miRNA	  “seed”	  region	  and	  have	  an	  adenosine	  across	  
position	  one)	  possess	   the	  highest	   conservation	  and	  efficacy	   in	  miRNA	   repression.	   Slightly	   less	  
effective	  are	  seed	  types	  with	  a	  7mer-­‐m8	  site	  (match	  at	  position	  2-­‐8)	  or	  7mer-­‐A1	  site	  (match	  as	  
position	  2-­‐7	  with	  an	  A	  opposite	  position	  1).	  	  The	  6mer	  (match	  at	  position	  2-­‐7)	  and	  offset-­‐6mer	  
(match	  at	  position	  3-­‐8)	   show	  very	  weak	  preferential	   conservation	  and	  much	   lower	  efficacy	   in	  
target	  repression.	  Used	  with	  permission	  from	  TargetScan	  Human7.	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Most	   often,	   thermodynamic	   stability	   of	   the	  miRNA:mRNA	  duplex	   is	   used.	  While	   conservation	  
across	   species,	   specifically	   of	   the	   7nt	   seed	   region,	   can	   further	   refine	   predicted	   targets	   that	  
otherwise	   score	   well	   in	   both	   complementarity	   and	   stability.	   More	   recently,	   RNA	   secondary	  
structures	   and	   RNA	   binding	   proteins	   and	   their	   influence	   on	   target	   site	   accessibility	   has	   been	  
another	  important	  factor	  to	  consider.	  Likewise,	  an	  increase	  in	  the	  number	  of	  target	  sites	  within	  





A	  consistent	  naming	  scheme	  has	  been	  an	  essential	  part	  in	  facilitating	  the	  exponential	  discovery	  
of	   novel	   miRNAs	   and	   subsequent	   database	   construction	   132.	   The	   naming	   of	   miRNAs	   was	  
conducted	   in	   a	   sequential	   numerical	   order,	   independent	   of	   biological	   function.	   Each	   miRNA	  
begins	  with	  a	  3	  to	  4	  letter	  prefix	  that	  designates	  the	  species	  of	  origin,	  such	  as	  “hsa”	  for	  human	  
miRNAs.	  The	  precursor	  hairpins	  are	  designated	  with	  “mir”,	  while	  the	  mature	  miRNA	  are	  labeled	  
with	   “miR”.	   Paralogous	  miRNAs	   that	  have	  minor	  differences	   in	   sequence	  are	  designated	  by	   a	  
letter	  suffix	  (eg.	  Hsa-­‐miR-­‐376a,	  Hsa-­‐miR-­‐376b,	  Hsa-­‐miR-­‐376c).	  In	  the	  event	  that	  more	  than	  one	  
gene	   gives	   rise	   to	   an	   identical	   mature	   miRNA,	   the	   identifier	   of	   the	   hairpin	   is	   followed	   by	   a	  
numerical	  suffix	  (eg.	  hsa-­‐mir-­‐218-­‐1	  and	  hsa-­‐mir-­‐218-­‐2).	  	  Lastly	  is	  the	  naming	  of	  the	  two	  strands	  
of	   the	   miRNA:miRNA*	   duplex.	   Initially,	   the	   “*”	   designation	   was	   used	   for	   the	   minor	   duplex	  
product	   that	   was	   considered	   to	   be	   non-­‐functional,	   and	   would	   result	   in	   strand	   ejection	   and	  
degradation.	   However,	   with	   further	   investigation	   many	   “*”	   miRNA	   strands	   showed	   similar	  
expression	  levels	  to	  the	  guide	  strand,	  and	  exhibited	  unique	  biological	  functions	  133,134.	  In	  order	  
to	   avoid	   confusion	   in	   annotating	   these	   miRNA	   species,	   the	   miRNA:miRNA*	   designation	   was	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retired	   and	   replaced	   with	   the	   more	   conventional	   -­‐5p	   (processed	   from	   the	   5’	   arm)	   and	   -­‐3p	  
(processed	  from	  the	  3’	  arm)	  suffix	   (hsa-­‐mir-­‐218-­‐1	  hairpin:	  hsa-­‐miR-­‐218-­‐5p	  and	  hsa-­‐miR-­‐218-­‐1-­‐
3p).	  	  
	  
5.	  MiR-­‐218-­‐5p	  in	  Development	  and	  Disease	  
	  
MiR-­‐218-­‐5p	  is	  a	  vertebrate	  specific	  microRNA	  with	  a	  high	  degree	  of	  evolutionary	  conservation.	  
In	   humans,	   there	   are	   two	   genes	   encoding	   miR-­‐218-­‐5p,	   mir-­‐218-­‐1	   (4p15.31)	   and	   mir-­‐218-­‐2	  
(5q35.1),	   located	   in	  Slit2	  and	  Slit3	   introns,	   respectively.	   	   Processing	  of	   the	  Slit2	   and	  Slit3	   pre-­‐
mRNAs	  generates	  mir-­‐218-­‐1	  and	  mir-­‐218-­‐2	  precursors,	  which	  are	  further	  processed	  to	  produce	  
mature	  miR-­‐218-­‐5p.	   	  The	  mature	  miR-­‐218-­‐5p	  sequence	  is	  the	  same	  from	  both	  5’	  arms	  of	  miR-­‐
218-­‐1	   and	  miR-­‐218-­‐2	   precursors;	   however,	   the	  mature	  mRNAs	   formed	   from	   the	   3’	   arms	   are	  
different,	  and	  are	  named	  miR-­‐218-­‐1-­‐3p	  and	  miR-­‐218-­‐2-­‐3p,	  respectively.	  	  
	  
MiR-­‐218-­‐5p	  is	  not	  a	  tissue	  specific	  miRNA	  and	  has	  been	  reported	  in	  a	  variety	  of	  systems.	  First	  
evidence	   for	  miR-­‐218-­‐5p	   function	  was	   in	   the	   brain,	   where	   its	   expression	   correlated	  with	   the	  
progression	  of	  neuronal	  differentiation	  specification	  135,136.	  It	  suppresses	  stem	  cell	  self-­‐renewal	  
in	   part	   through	   the	   direct	   targeting	   of	   Nanog	   Homeobox	   (NANOG),	   a	   transcription	   factor	  
involved	   in	  maintenance	   of	   pluripotency	   137,138.	   On	   the	   other	   hand,	   it	   has	   shown	   to	   promote	  
139,140	  	  and	  suppress	  141	  osteogenic	  differentiation	  through	  different	  mechanisms.	  	  	  
	  
In	  accordance	  with	   its	   location,	  miR-­‐218-­‐5p	  plays	  an	  important	  role	   in	  regulating	  the	  Slit-­‐Robo	  
pathway.	  Slit	  ligands	  are	  best	  known	  as	  molecular	  guidance	  cues	  essential	  in	  both	  nervous	  and	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cardiovascular	  development,	   through	   their	  binding	   to	   the	  Roundabout	   (Robo)	   receptor	   family	  
142.	   Robo-­‐1	   and	   Robo-­‐2	   are	   functional	   targets	   of	   miR-­‐218-­‐5p,	   which	   serves	   to	   fine-­‐tune	   this	  
pathway	  during	  complex	  physiological	  events	  such	  as	  cardiovascular	  development	  and	  vascular	  
patterning	   143,144.	   Slits	   also	   play	   an	   important	   role	   in	   inhibiting	   tumorigenesis,	   cancer	  
progression,	  and	  metastasis	  145.	  Both	  Slit2	  and	  Slit3	  genes	  are	  often	  hypermethylated	  in	  breast,	  
lung,	  colorectal,	  and	  glioma	  tumors	  146,147.	  Likewise,	  the	  hypermethylation	  of	  miR-­‐218-­‐5p	  genes	  
in	  cancer	  has	  been	  reported	  148,149,	  and	  its	  role	  as	  a	  potent	  tumor	  suppressor	  is	  well	  established	  
150.	   MiR-­‐218-­‐5p	   exerts	   its	   action	   by	   suppressing	   a	   variety	   of	   cancer	   phenotypes,	   including	  
proliferation,	   invasion,	   migration,	   epithelial–mesenchymal	   transition,	   and	   metastasis	   151-­‐153.	  
MiR-­‐218-­‐5p	   has	   also	   shown	   to	   suppress	   markers	   of	   cancer	   “stemness”	   154-­‐156	   	   and	   restore	  
sensitivity	  in	  chemoresistant	  cells	  157-­‐159.	  	  
	  
Currently,	   the	   role	   of	   miR-­‐218-­‐5p	   in	   placenta	   development	   is	   not	   known.	   However,	  
downregulation	  of	  miR-­‐218-­‐5p	  in	  preeclampsia	  has	  been	  reported	  160,	  and	  moreover,	  studies	  on	  
the	   Slit-­‐Robo	   family	   may	   provide	   insight	   into	   the	   function	   of	   miR-­‐218-­‐5p	   in	   placenta	  
development.	  For	  example,	  both	  Slit2	  and	  Robo1	  were	  detected	   in	  CTB,	  STB,	  and	  EVT	   in	  tubal	  
pregnancies	   161,162,	  whereas	  overexpression	  of	  Robo1	   in	  PE	   tissue	  has	  been	   reported	   163.	   	   In	  a	  
model	  of	  trophoblast	  vascular	  remodeling,	  iEVT	  near	  the	  site	  of	  active	  remodeling	  were	  strongly	  
positive	  for	  Slit2,	  but	  weak	  for	  Robo1	  162.	  Furthermore,	  enEVT	  in	  later	  stages	  of	  remodeling	  were	  
both	   Slit2	   and	   Robo1	   positive,	   and	   their	   expression	   slowly	   decreased	   with	   remodeling	  
progression	   163.	   Together,	   these	   data	   suggest	   a	  multifaceted	   role	   for	  miR-­‐218-­‐5p	   in	   placenta	  
development,	  in	  both	  early	  and	  late	  stages	  of	  pregnancy.	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III.	  TRANSFORMING	  GROWTH	  FACTOR–β 	  (TGF-­‐β)	  SIGNALING	  
	  
TGF-­‐β	  was	  the	  first	  polypeptide	  characterized	  from	  the	  TGF-­‐β	  family	  nearly	  four	  decades	  ago.	  Its	  
name	  originates	  from	  early	  work	  that	  suggested	  it	  was	  a	  product	  of	  transformed	  (cancer)	  cells	  
164.	  We	   now	   know	   that	   the	   TGF-­‐β	   family	   of	   cytokines	   consists	   of	   a	   large	   group	   of	   secretory	  
proteins	  expressed	  throughout	  all	  mammalian	  tissues.	  	  In	  canonical	  signaling,	  these	  proteins	  act	  
through	   serine/threonine	   receptor	   complexes,	   which	   upon	   phoshphorylation	   recruit	  
intracellular	   signaling	   molecules	   from	   the	   Smad	   (Mothers	   Against	   Decapentaplegic	   homolog)	  
family	   165.	  Activation	  of	  Smads	  propagates	   the	  signal	   to	   the	  nucleus	  and,	   through	   interactions	  
with	   a	   variety	   of	   transcription	   factors,	   are	   known	   to	   regulate	   hundreds	   of	   genes	   166.	   	   TGF-­‐β	  
signaling	  plays	  an	  important	  role	  in	  embryo	  development,	  tissue	  homeostasis,	  and	  most	  disease	  
states,	   including	   cancer.	   Smad-­‐independent	   signaling	   has	   been	   reported	   167,168;	   however	   the	  
focus	  of	  this	  introduction	  will	  be	  on	  the	  canonical,	  Smad-­‐dependent,	  pathway.	  
	  
1.	  TGF-­‐β	  Family:	  Ligands	  
	  
Since	   the	   discovery	   of	   TGF-­‐β1,	   at	   least	   40	   additional	   TGF-­‐β-­‐related	   proteins	   have	   been	  
characterized.	  They	  can	  be	  broadly	  grouped	  into:	  TGF-­‐βs,	  BMPs	  (bone	  morphogenetic	  proteins),	  
GDFs	   (growth	   and	   differentiation	   factors),	   MIS	   (Müllerian	   inhibitory	   substance),	   or	  
Activins/Inhibins.	   In	   mammals,	   there	   are	   three	   isoforms	   of	   TGF-­‐β	   (TGF-­‐β1-­‐3)	   encoded	   by	  
separate	  genes	  169.	  BMPs	  make	  up	  a	  large	  part	  of	  the	  TGF-­‐β	  family,	  consisting	  of	  approximately	  
20	  members	  170.	  First	  identified	  as	  critical	  factors	  in	  skeletal	  development,	  they	  are	  now	  known	  
to	  have	  a	  variety	  of	  important	  functions	  including	  embryogenesis.	  For	  example,	  Nodal	  (BMP-­‐16)	  
is	  essential	   for	  mesoderm	  formation	  and	  axial	  patterning	   in	  early	  embryonic	  development	   171.	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GDFs	  are	  often	  classified	  within	  the	  BMP	  family	  and	  include	  an	  additional	  11	  molecules,	  such	  as	  
Myostatin,	  known	  to	  inhibit	  muscle	  cell	  growth	  and	  differentiation	  172.	  MIS,	  also	  known	  as	  anti-­‐
Müllerian	  hormone,	  has	  predominantly	  been	  studied	  for	  its	  role	  in	  male	  sex	  differentiation,	  but	  
has	   recently	  been	  suggested	  as	  a	  marker	   for	  ovary	  health	  and	   function	   173.	  Activins	  were	   first	  
identified	  as	  promoters	  of	  FSH	  (follicle-­‐stimulating	  hormone)	  biosynthesis	  and	  secretion,	  while	  
Inhibins	   are	   predominantly	   antagonists	   of	   Activins,	   and	   to	   a	   lesser	   degree,	   other	   TGF-­‐β	  
members.	  Structurally,	  they	  are	  very	  similar	  in	  that	  they	  form	  dimers	  consisting	  of	  two	  inhibin-­‐β	  
subunits.	   In	  mammals,	  one	   Inhibin-­‐α	  and	   four	   Inhibin-­‐β	  polypeptides	   (βA,	  βB,	  βC,	  and	  βE)	  have	  
been	   identified.	   Inhibins	   form	   heterodimers,	   containing	   the	   α	   subunit	   and	   one	   of	   the	   four	   β	  
subunits.	  For	  example,	  Inhibin	  A	  is	  composed	  of	  α	  -­‐βA	  subunits.	  On	  the	  other	  hand,	  Activin	  A	  is	  
the	  dimer	  of	  two	  βA	  subunits	  174.	  	  
	  
TGF-­‐β	   family	   cytokines	   are	   secreted	   proteins	   that	   are	   first	   synthesized	   as	   long	   precursor	  
molecules	  with	   similar	   organization.	   In	   general,	   their	   structure	   consists	   of	   an	   amino-­‐terminal	  
signal	  peptide	  (removed	  in	  the	  ER),	  a	  large	  propeptide,	  and	  a	  carboxy-­‐terminal	  polypeptide	  that	  
forms	  the	  mature	  ligand	  upon	  proteolytic	  cleavage.	   It	   is	  these	  carboxy-­‐terminal	  segments	  that	  
display	  the	  high	  sequence	  similarity	  shared	  between	  TGF-­‐β	  family	  members	  169.	  Notably,	  it	  is	  the	  
number	  and	   location	  of	  cysteine	  residues	   in	   the	  carboxy-­‐terminal	  peptide	   that	  are	  conserved.	  
Specifically,	  it	  is	  an	  odd	  number	  of	  cysteines	  (nine	  or	  seven)	  that	  allows	  for	  the	  intermolecular	  
disulfide-­‐linked	  dimer	   formation	  required	   for	  signaling	   175.	  A	   few	  members	   (such	  as	  GFP-­‐3,	   -­‐9,	  
BMP-­‐15,	   and	   Lefty/BMP-­‐17)	   possess	   an	   even	   six	   residues,	   suggesting	   that	   these	  members	   do	  
not	  transduce	  signaling	  as	  dimers	  169.	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2.	  TGF-­‐β	  Signal	  Transduction	  and	  Regulation	  
	  
Initiation	  of	  cell	  signaling	  begins	  with	  the	  binding	  of	  dimerized	  and	  active	  TGF-­‐β	  family	  ligands	  to	  
their	   receptors	   (Figure	   1.9).	   Most	   TGF-­‐β	   family	   members	   exist	   as	   both	   homodimers	   and	  
heterodimers	   169.	  While	   Activins	   and	   BMPs	   are	   secreted	   in	   their	   active	   form,	   TGF-­‐βs	   remain	  
inactive.	  Mature	  TGF-­‐β	  is	  formed	  after	  the	  processing	  of	  the	  prodomain	  from	  precursor	  TGF-­‐β	  
polypeptides	  in	  the	  trans-­‐Golgi	  176.	  However,	  this	  propeptide	  has	  high	  affinity	  for	  mature	  TGF-­‐β	  
and	  remains	  non-­‐covalently	  associated	  upon	  the	  secretion	  of	  the	  C-­‐terminal	  dimer	  177.	  Since	  the	  
TGF-­‐β-­‐associated	  propeptide	  prevents	  its	  interaction	  with	  receptors,	  it	  is	  also	  referred	  to	  as	  the	  
“latency-­‐associated	  protein”	  (LAP).	  Moreover,	  TGF-­‐βs	  are	  known	  to	  complex	  with	  “latent	  TGF-­‐β-­‐
binding	   proteins”	   (LTBPs)	   that	   are	   structurally	   similar	   to	   fibrillins	   178.	   In	   this	   capacity,	   LTBPs	  
regulate	  the	  deposition	  of	  TGF-­‐βs	  into	  the	  extracellular	  matrix,	  where	  they	  can	  be	  stored	  until	  
they	   are	   activated.	   The	   large	   latent	   complex	   (LLC)	   consisting	   of	   the	   TGF-­‐β	   dimer,	   TGF-­‐β	  
propeptide	   dimer	   (or	   LAP),	   and	   the	   LTBP,	   provides	   extensive	   regulation	   of	   the	   TGF-­‐βs	   at	   the	  
ligand	  level	  compared	  to	  other	  cytokines	  in	  this	  family	  179.	  Liberation	  of	  the	  active	  TGF-­‐β	  dimer	  
can	  be	  achieved	  through	  a	  variety	  of	  mechanisms	  that	  largely	  depend	  on	  cellular	  context.	  These	  
activation	   mechanisms	   involve	   proteases	   (i.e.	   plasmin,	   etc.),	   thrombospondin-­‐1,	   integrin	  
binding,	  extreme	  pH,	  and	  free	  radicals	  176.	  	  
	  
This	  large	  group	  of	  ligands	  elicits	  their	  biological	  function	  through	  a	  family	  of	  structurally	  related	  
transmembrane	   receptor	   kinases	   with	   specificity	   towards	   serine	   and	   threonine	   residues.	   In	  
general,	  the	  receptors	  have	  a	  short	  extracellular	  cysteine-­‐rich	  domain,	  a	  single	  transmembrane	  
domain,	  and	  an	  intracellular	  kinase	  domain	  180.	  



































Figure	  1.9	  Canonical	  TGF-­‐β	  Signaling.	  	  
Active	   TGF-­‐β	   dimers	   bind	   to	   the	   constitutively	   active	   type	   II	   receptor	   (TGFβRII),	   which	  
subsequently	  recruits	  the	  type	  I	  receptor	  (TGFβRI)	   into	  the	  complex.	  TGFβRI	  is	  phosphorylated	  
by	   interaction	  with	  the	  TGFβRII.	  Receptor	  smads	  (eg.	  Smad2/3)	  are	  recruited	  by	  Smad	  Anchor	  
for	  Receptor	  Activation	   (SARA)	   to	   the	   TGFβRI	   for	   phosphorylation.	   R-­‐Smads	   oligomerize	  with	  
other	   phosphorylated	   R-­‐Smads	   and	   the	   common	   smad,	   Smad4.	   The	   Smad	   complex	   is	  
translocated	   to	   the	   nucleus	  where	   it	   can	   then	   regulate	   target	   gene	   expression	   or	   repression.	  
Inhibitory	  Smads	  (Smad6/7)	  inhibit	  the	  interaction	  of	  R-­‐Smads	  with	  their	  Type	  I	  receptor.	  Used	  
with	  permission	  from	  SAB	  Signaling	  Antibody	  www.sabbiotech.com.	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The	   receptor	   family	   can	   be	   divided	   into	   two	   classes,	   type	   II	   and	   type	   I,	   which	   differ	  
predominantly	  with	  the	  presence	  of	  a	  glycine-­‐serine	  (GS)	  repeat	  domain	  in	  the	  latter	  181.	  In	  spite	  
of	  the	  large	  size	  of	  the	  ligand	  family,	  only	  five	  type	  II	  (TGF-­‐βRII,	  ACVRII/IIB,	  BMPRII,	  and	  AMHRII)	  
and	   seven	   type	   I	   (Activin	   receptor-­‐like	   kinase	   (ALK)	   1-­‐7)	   receptors	   have	   been	   identified	   in	  
mammals.	  	  
	  
At	   the	   cell	   surface,	   the	   TGF-­‐β	   receptor	   family	   exists	   as	   type	   I	   and	   type	   II	   homodimers	  which	  
assemble	   into	   heterotetramers	   at	   close	   proximity	   181	   (Figure	   1.9).	   In	   general,	   TGF-­‐β	   family	  
ligands	  are	  known	  to	  initiate	  signaling	  by	  binding	  first	  to	  their	  type	  II	  receptors	  165	  (Figure	  1.9).	  
The	  type	  II	  receptors	  are	  considered	  constitutively	  active	  and	  have	  a	  characteristic	  cysteine-­‐rich	  
fold	   in	   their	   extracellular	   region	   that	   is	   important	   for	   ligand	  binding	   182.	   Binding	  of	   the	   ligand	  
facilitates	  their	  interaction,	  allowing	  the	  type	  II	  receptor	  kinase	  domain	  to	  phosphorylate	  the	  GS	  
domain	  of	  the	  type	  I	  receptor.	  Expression	  of	  both	  the	  type	  I	  and	  type	  II	  receptors	  is	  required	  for	  
signal	   transduction	  183.	  Alternatively,	   the	   inherent	  affinity	  between	  the	  receptor	  pair	   is	   ligand-­‐
independent	   184.	   This	   is	   evident	   in	   receptor	   over-­‐expression	   experiments	   where	   signal	  
transduction	   was	   observed	   even	   in	   the	   absence	   of	   ligand	   185,186.	   However,	   in	  most	   cells,	   the	  
relatively	   low	   number	   of	   receptor	   complexes	   necessitates	   the	   ligand’s	   role	   in	   stabilizing	   the	  
heterotetrameric	  complex	  187.	  	  
	  
After	  receptor	  activation,	  the	  signal	  is	  propagated	  to	  the	  nucleus	  through	  downstream	  effectors	  
from	  the	  Smad	  family	  of	  proteins	  (Figure	  1.9).	  The	  Smad	  family	  can	  be	  divided	  into	  three	  groups:	  
Receptor	   Smads	   (R-­‐Smads),	   Common	   Smad	   (co-­‐Smad),	   and	   Inhibitory	   Smads	   (I-­‐Smads)	   188.	   In	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general,	  the	  six	  R-­‐Smads	  (Smad-­‐	  1,	  2,	  3,	  5,	  8,	  and	  9)	  consists	  of	  an	  MH1	  (Mad	  homology	  I)	  and	  an	  
MH2	  domain	  that	  are	  connected	  by	  a	  linker	  region.	  The	  MH2	  domain	  is	  required	  for	  interaction	  
with	   the	   type	   I	   receptor,	   complexing	   with	   Smad	   molecules,	   and	   interacting	   with	   other	  
regulatory	  proteins	  165.	  The	  MH1	  domain	   is	  responsible	  for	   facilitating	  DNA	  binding,	  as	  well	  as	  
interactions	   with	   other	   transcription	   factors.	   However,	   the	   Smad2	  MH1	   domain	   contains	   an	  
insert	   that	   perturbs	   its	  DNA	  binding	   ability	   189.	  Unlike	   the	  MH1	  and	  MH2	  domains,	   the	   linker	  
region	   is	   poorly	   conserved	   between	  R-­‐Smads	   and	   is	   primarily	   involved	   in	   regulation.	  One	   co-­‐
Smad	   (Smad4)	   has	   been	   identified,	   and	   has	   the	   ability	   to	   complex	   with	   all	   R-­‐Smads.	   Like	   R-­‐
Smads,	  it	  contains	  a	  MH1	  and	  MH2	  domain,	  but	  its	  MH2	  domain	  lacks	  the	  C-­‐terminal	  SSXS	  (Ser-­‐
Ser-­‐X-­‐Ser)	  motif	   required	   for	   phosphorylation	   by	   the	   type	   I	   receptor	   190.	   Furthermore,	   the	   I-­‐
Smads	   (Smad	  6	   and	  7)	   have	  no	  distinct	  MH1	  domain,	   but	   do	   contain	  MH2,	   allowing	   them	   to	  
interact	  with	  the	  type	  I	  receptor	  and	  block	  activation	  of	  R-­‐Smads	  191.	  
TGF-­‐β	  signaling	  has	  the	  capacity	  to	  elicit	  a	  vast	  number	  of	  unique	  biological	  responses	  through	  a	  
limited	   number	   of	   mediators.	   This	   can	   be	   explained	   in	   part	   through	   receptor	   promiscuity.	  
Transduced	   signals	   are	   broadly	   grouped	   into	   either	   BMP-­‐like	   or	   TGF-­‐β/Activin-­‐like	  
transcriptional	   responses.	  While	   the	   type	   II	   receptors	   often	   cross	   between	   these	   two	   classes,	  
type	  I	  receptors	  tend	  to	  be	  more	  specific	  180.	   In	  general,	  BMP-­‐like	  signals	  activate	  Alk-­‐1,	  Alk-­‐2,	  
Alk-­‐3,	   and	   Alk-­‐6,	   whereas	   TGF-­‐β/Activin-­‐like	   signals	   engage	   Alk-­‐4,	   Alk-­‐5,	   or	   Alk-­‐7	   type	   I	  
receptors.	   Similarly,	   R-­‐Smads	   activated	   by	   the	   type	   I	   receptors	   can	   typically	   be	   classified	   as	  
downstream	   of	   the	   BMP-­‐like	   pathways	   (Smad1/5/8)	   or	   TGF-­‐β/Activin	   pathways	   (Smad2/3)	  
(Figure	  1.10).	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Figure	   1.10	   Combinatorial	   interactions	   of	   serine-­‐threonine	   kinase	   receptors	   and	   their	  
downstream	  effectors.	  	  	  
Five	  type	  II/RII	  (TGF-­‐βRII,	  ACVRII/IIB,	  BMPRII,	  and	  AMHRII)	  and	  seven	  type	  I/RI	  [Activin	  receptor-­‐
like	   kinase	   (Alk)	   1-­‐7]	   receptors	  have	  been	   identified	   in	  mammals.	   In	   general,	  BMP-­‐like	   signals	  
activate	  Alk-­‐1,	  Alk-­‐2,	  Alk-­‐3,	  and	  Alk-­‐6,	  whereas	  TGF-­‐β/Activin-­‐like	  signals	  engage	  Alk-­‐4,	  Alk-­‐5,	  or	  
Alk-­‐7	  type	  I	  receptors.	  Likewise,	  the	  R-­‐Smads	  activated	  by	  the	  type	  I	  receptors	  can	  typically	  be	  
classified	   as	   downstream	   of	   BMP-­‐like	   pathways	   (Smad1/5/8)	   or	   TGF-­‐β/Activin	   pathways	  
(Smad2/3).	  Used	  with	  permission	  from	  Feng	  X-­‐H,	  et	  al.	  (2005)	  196.	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Cofactors,	  such	  as	  SARA	  (Smad	  Anchor	  for	  Receptor	  Activation),	  are	  required	  to	  present	  the	  R-­‐
Smads	  to	  the	  phosphorylated	  GS	  domain	  of	  type	  I	  receptors	  192.	  The	  R-­‐Smads	  are	  consequently	  
phosphorylated	   by	   type	   I	   receptors	   and	   become	   available	   for	   Smad4	   oligomerization	   165.	   R-­‐
Smads	   are	   often	   found	   in	   trimeric	   complexes	   with	   co-­‐Smad4	   as	   either	   homodimers	   or	  
heterodimers.	  Discordant	  with	  previous	  studies,	  Smad4	  is	  not	  required	  for	  nuclear	  translocation	  
as	   observed	   in	   Smad4-­‐null	   cells	   193.	   Several	   mechanisms	   mediate	   nuclear	   translocation	  
depending	  on	  which	  Smads	  are	  involved,	  such	  as	  the	  Importin-­‐β1/Ran	  system	  or	  CAN/Nup214	  
194,195.	  In	  general,	  shuttling	  of	  Smads	  into	  the	  nucleus	  involves	  release	  from	  cytoplasmic	  anchors,	  
exposure	  of	   their	  nuclear	   localizing	   signal	   (NLS),	  or	   the	  blocking	  of	   their	  nuclear	  export	   signal	  
(NES)	  165.	  	  
	  
Once	   in	   the	  nucleus,	   the	  R-­‐Smad/Co-­‐Smad	  complex	   can	  bind	   to	  DNA	  and	  promote	  or	   repress	  
gene	  transcription.	  On	  their	  own,	  Smads	  have	  a	  low	  affinity	  for	  DNA	  and	  their	  binding-­‐activity	  is	  
not	  highly	  selective	  197.	  Although	  they	  are	  known	  to	  bind	  Smad	  binding	  elements	   (SBE)	  with	  a	  
CAGA	  motif	  as	  well	  as	  GC-­‐rich	  sites,	  no	  TGF-­‐β-­‐	  or	  BMP-­‐responsive	  promoter	  sequence	  common	  
to	  all	  target	  genes	  has	  been	  identified	  198.	  Hence,	  the	  regulation	  of	  Smad	  target	  genes	  depends	  
heavily	  on	  their	  partnered	  DNA-­‐binding	  transcription	  factors	  and	  transcription	  co-­‐repressors	  or	  
co-­‐activators.	   	   Smads	   have	   been	   reported	   to	   interact	   with	   a	   variety	   of	   transcription	   factor	  
families	   including:	   bHLH	   (basic/helix-­‐loop-­‐helix),	   bZIP	   (basic/leucine	   zipper),	   forkhead,	   zinc-­‐
finger,	  and	  Runx	  198.	  	  
	  
The	  TGF-­‐β	  pathway	  is	  regulated	  at	  all	  levels	  of	  signal	  transduction	  in	  order	  to	  fine	  tune	  cellular	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responses.	  As	  previously	  mentioned,	   the	   first	   level	  of	   control	   is	   the	  activity	  and	  availability	  of	  
ligands.	  Unlike	   the	  TGF-­‐βs,	  other	  cytokines	   in	   the	   family	  are	  secreted	   in	   their	  active	   form	  and	  
rely	   largely	   on	   accessory	   proteins	   for	   regulation	   199.	   Follistatin,	   discovered	   as	   an	   inhibitor	   of	  
Follicle-­‐stimulating	   hormone	   (FSH)	   release,	   has	   high	   affinity	   for	   Activin	   and	   blocks	   its	   action	  
through	  masking	  the	  type	  I	  and	  type	  II	  receptor	  binding	  sites	  200.	  Similarly,	  Noggin	  binds	  BMPs,	  
preventing	   receptor	   interaction,	   which	   is	   essential	   for	   proper	   neural,	   somite,	   and	   skeletal	  
development	   201.	   Decorin,	   an	   extracellular	   protein	   from	   the	   small	   Leucine-­‐rich	   proteoglycan	  
family,	   is	   also	   known	   to	   attenuate	   TGF-­‐β	   signaling	   pathways	   202.	   Like	   Inhibins,	   other	   TGF-­‐β	  
members	   can	   also	   negatively	   regulate	   ligand	   availability.	   For	   example,	   Lefty	   proteins	   are	  
important	   negative	   regulators	   of	   Nodal	   signaling,	   as	   demonstrated	   during	   left-­‐right	   axis	  
determination	  during	  embryonic	  development	  203,204.	  	  	  
	  
The	  composition	  of	  the	  activated	  receptor	  complex	  heavily	  defines	  the	  resulting	  transcriptional	  
response.	  Furthermore,	  the	  availability	  of	  co-­‐receptors	  also	  greatly	  influences	  possible	  signaling	  
outcomes.	   	   TGF-­‐β	   type	   III	   receptor	   (Betaglycan)	   is	   required	   for	   efficient	   TGF-­‐β2	  binding	   to	   its	  
type	   II	   receptor	  205.	   It	  also	  serves	  as	  an	   Inhibin	  co-­‐receptor	  which	   lowers	  the	  concentration	  of	  
Inhibin	  needed	   to	  disrupt	  Activin	   signaling	   206.	   Endoglin	  has	  been	   reported	   to	  participate	   in	   a	  
variety	   of	   TGF-­‐β	   receptor	   complexes,	   and	   is	   known	   to	   promote	   or	   suppress	   both	   TGF-­‐β	  
responses,	   depending	   on	   cellular	   context	   207-­‐209.	   Cripto	   is	   another	   important	   co-­‐receptor	   that	  
facilitates	  Nodal	  signaling	  through	  Alk-­‐4,	  while	  antagonizing	  Activin	  210.	  	  
	  
Apart	   from	  activation	  of	   the	  receptor	  complex,	   ligand	  binding	   induces	  receptor	   internalization	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into	  endosomes	  211.	  Endocytic	  regulation	  of	  TGF-­‐β	  signaling	  is	  important	  in	  order	  to	  determine	  if	  
the	   signal	   will	   be	   enhanced	   through	   clathrin-­‐coated	   pits,	   or	   turned	   off	   through	   lipid	   raft-­‐
mediated	   endocytosis	   212.	   From	   the	   receptor	   complex,	   the	   signal	   is	   further	   modulated	  
intracellularly	   through	   the	   availability	   and	   activity	   of	   R-­‐Smads.	   As	   previously	   mentioned,	  
proteins	  such	  as	  SARA	  facilitate	  access	  of	  Smads	  to	  their	  cognate	  receptors,	  while	  I-­‐Smads	  have	  
the	   opposite	   effect	   213.	   Smad	   activity	   can	   further	   be	   regulated	   through	   a	   variety	   of	  
modifications,	   including	   phosphorylation	   of	   the	   linker	   region,	   dephosphorylation	   by	  
phosphatases,	  and	  ubiquitin-­‐mediated	  degradation	  198.	  
	  
3.	  Role	  of	  TGF-­‐β	  Signaling	  in	  Placenta	  Development	  and	  PE	  
	  
Placental	   development	   is	   a	   complex	  process	   involving	   a	  number	  of	   specialized	   cell	   types	   that	  
require	  specific	  spatial	  and	  temporal	  regulation	  for	  a	  successful	  pregnancy.	  Expression	  of	  TGF-­‐β	  
family	  molecules	  has	  been	  reported	  on	  both	  the	  fetal	  and	  maternal	  sides	  of	  the	  placenta.	  They	  
are	  important	  players	  at	  the	  maternofetal	  interface,	  regulating	  a	  variety	  of	  processes	  including	  
decidualization,	  formation	  of	  the	  trophectoderm,	  implantation,	  differentiation	  down	  the	  fusion	  
or	  invasive	  pathway,	  and	  maintenance	  of	  pregnancy.	  Furthermore,	  many	  TGF-­‐β	  family	  members	  
are	  dysregulated	  in	  PE	  and	  a	  few	  have	  been	  identified	  as	  potential	  clinical	  biomarkers.	  	  
	  
On	   the	   maternal	   side,	   the	   process	   of	   endometrial	   decidualization	   is	   vital	   to	   embryo	  
implantation.	  The	  expression	  of	  both	  type	  I	  and	  type	  II	  Activin	  receptors	  in	  endometrial	  stroma	  
and	  endothelial	  cells	  suggest	  they	  are	  capable	  of	  responding	  to	  Activin	  signals	  214.	  Co-­‐expression	  
of	   the	  Activin	  regulators	  Follistatin,	  Betaglycan,	  and	   Inhibin,	  suggest	   that	  Activin	  action	  during	  
	   45	  
this	   process	   is	   tightly	   regulated.	   Furthermore,	   Activin	   A	   was	   shown	   to	   directly	   promote	  
decidualization	  of	  endometrial	  stroma	   in	  vitro	  215.	  TGF-­‐β	  signaling	  through	  ALK-­‐5	  promotes	  the	  
decidual	  enrichment	  of	  pregnancy-­‐associated	  growth	  factors,	  cytokines,	  and	  the	  maturation	  of	  
dNK	   needed	   for	  maternal	   immune	   tolerance	   and	   spiral	   artery	   remodeling	   216.	  Whereas	   BMP	  
signalling	  through	  Alk-­‐3	  is	  essential	  for	  the	  attachment	  of	  the	  blastocyst	  to	  the	  decidua	  during	  
implantation	  217.	  	  
	  
In	  early	  placentation,	  BMP-­‐2	  and	  BMP-­‐4	  promote	  the	  differentiation	  of	  human	  embryonic	  stem	  
cells	   (hESC)	   into	   the	   trophoblastic	   lineage	   218.	   Nodal/Activin	   signaling	   can	   further	   dictate	   the	  
terminal	  differentiation	  of	  hESC-­‐derived	  trophoblasts.	  Inhibition	  of	  Activin/Nodal	  signaling	  leads	  
to	  formation	  of	  EVTs,	  while	  the	  loss	  of	   inhibitors	  associated	  with	  this	  pathway	  promote	  fusion	  
into	   STBs	   219.	   Conversely,	   in	   proliferating	   CTBs	  Activin	  A	   promotes	   the	  differentiation	  of	   EVTs	  
along	  with	  invasive	  markers	  such	  as	  MMP-­‐2	  and	  MMP-­‐9	  220.	  Activin	  A	  also	  has	  a	  positive	  role	  on	  
trophoblast	  proliferation,	  while	  Nodal	  acting	  through	  Alk-­‐7	  inhibits	  trophoblast	  proliferation	  and	  
promotes	   apoptosis	   221.	   TGF-­‐β,	   Nodal	   and	   their	   receptors,	   Alk-­‐5	   and	   Alk-­‐7,	   also	   have	   an	  
inhibitory	  role	  on	  trophoblast	  proliferation	  222,223.	  
	  
TGF-­‐β	   signaling	   further	   regulates	   the	   functions	   of	   both	   STB	   and	   EVT	   lineages.	   Activin	   A	  
stimulates,	   while	   TGF-­‐β1	   inhibits	   the	   production	   and	   secretion	   of	   pregnancy	   maintenance	  
hormones	  hCG,	  Progesterone,	  and	  Estradiol	  224-­‐227.	  However,	  the	  effect	  of	  TGF-­‐βs	  on	  STB	  fusion	  
222,228	   and	   the	   role	   of	   TGF-­‐βs	   and	   Nodal	   on	   trophoblast	   invasion	   have	   been	   inconsistent.	   In	  
general,	   TGF-­‐β1-­‐3	   inhibit	   differentiation	   towards	   the	   invasive	   EVT	   pathway	   in	   part	   by	  
	   46	  
upregulating	   TIMPs	   and	   E-­‐Cadherin,	   while	   downregulating	   urokinase	   plasminogen	   activator	  
(uPA)	   and	   MMP-­‐9	   229-­‐233.	   On	   the	   other	   hand,	   the	   TGF-­‐β	   suppressive	   effects	   are	   lost	   in	  
choriocarcinoma	   cell	   lines,	   possibly	   due	   to	   Smad3	   deficiency	   229.	   Furthermore,	   Smad	  
ubiquitination	   regulatory	   factor	   2	   (Smurf2)	   exhibits	   highest	   expression	   in	   first	   trimester	  
placenta,	   and	   promotes	   trophoblast	   invasion	   and	  migration	   in	   vitro	   via	   Alk-­‐5	   degradation	   234.	  
Nodal	   inhibits	   trophoblast	   invasion	   through	   ALK-­‐7,	   and	   not	   through	   ALK-­‐4	   signaling	   235.	  
Conversely,	  Nodal	  was	  shown	  to	  promote	  trophoblast	  invasion	  possibly	  via	  a	  Smad-­‐independent	  
mechanism	   involving	   β-­‐arrestin/Ral	   and	   Erk1/2	   236.	   Activins	   promote	   trophoblast	   invasion	  
through	   several	   mechanisms,	   including	  MMP-­‐2	   upregulation	   through	   ALK-­‐4,	   and	   Smad2/3/4-­‐
dependent	  upregulation	  of	  N-­‐cadherin	  237,238.	  Furthermore,	  Myostatin	  expression	  was	  localized	  
to	  the	  EVT	  population	  and	  promoted	  trophoblast	  proliferation	  and	  migration	  in	  vitro	  239.	  Studies	  
investigating	   the	   role	  of	  TGF-­‐β	   in	   spiral	  artery	   remodeling	  are	   limited.	  However,	  Activin	  A	  has	  
shown	   to	   promote	   trophoblast	   endothelial-­‐like	   tube	   formation	   in	   vitro	   through	   Smad2/3/4-­‐
dependent	  upregulation	  of	  VEGF-­‐A	  240.	  	  
	  
The	  dysregulation	  of	  TGF-­‐β	  signaling	  in	  PE	  is	  well	  supported.	  The	  soluble	  form	  of	  the	  co-­‐receptor	  
Endoglin	   is	   one	  of	   the	  most	   upregulated	   anti-­‐angiogenic	  markers	   in	   serum	  of	   PE	   patients	   241.	  
Similarly,	  serum	  Activin	  A	  levels	  in	  women	  affected	  with	  PE	  were	  greatly	  increased	  even	  prior	  to	  
onset	  of	  clinical	  symptoms	  242,243.	  Furthermore,	  Activin	  A	  mirrored	  PE	  serum-­‐induced	  oxidative	  
stress,	   and	   endothelial	   activation	   and	   dysfunction	   in	   Human	   Umbilical	   Vein	   Endothelial	   Cells	  
(HUVEC)	   244,245.	   Nodal	   and	   ALK-­‐7	   immunoreactivity	   were	   also	   strongly	   upregulated	   in	   PE	  
placenta	   tissues	   235.	   Interestingly,	   pathological	   levels	   of	   Activin	   A	   were	   shown	   to	   induce	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trophoblast	  apoptosis	   through	  the	  upregulation	  of	  Nodal	   246.	  Activin	  Receptor	  Type	   II	   (ACVRII)	  
has	   been	   implicated	   as	   a	   genetic	   risk	   factor	   for	   PE,	   due	   to	   a	   single	   nucleotide	   polymorphism	  
(SNP)	  in	  its	  promoter	  region	  247,248.	  A	  recent	  study	  proposed	  that	  the	  downregulation	  of	  ACVRII	  
due	  to	  this	  SNP,	  in	  combination	  with	  pathological	  levels	  of	  Activin	  A,	  resulted	  in	  the	  increase	  of	  
Nodal	  in	  PE	  cases	  249.	  SNPs	  in	  TGFB1	  have	  also	  been	  reported	  in	  several	  small	  case	  studies	  250-­‐252.	  
Serum	  TGF-­‐β1	  and	  TGF-­‐β2	  levels	  were	  also	  elevated	  in	  PE	  cases	  253,254,	  while	  inhibition	  of	  TGF-­‐β3	  
in	  PE	  tissues	  restored	  their	  invasive	  capacity	  in	  vitro	  255.	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IV.	  RATIONALE,	  HYPOTHESIS,	  AND	  OBJECTIVES	  	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
During	   normal	   pregnancy,	   EVTs	   invade	   the	   uterus	   and	   differentiate	   into	   interstitial	   and	  
endovascular	  trophoblasts.	  The	  enEVTs	  go	  on	  to	  remodel	  maternal	  spiral	  arteries	  by	  replacing	  
the	  endothelial	  cells	  and	  some	  portion	  of	  the	  smooth	  muscle	  wall	  7.	   In	  PE,	  shallow	  invasion	  of	  
EVTs	  results	  in	  insufficient	  remodeling	  of	  the	  maternal	  vasculature,	  reducing	  placental	  perfusion	  
for	   adequate	   nutrition	   and	   oxygen	   exchange.	   Furthermore,	   EVTs	   in	   PE	   fail	   to	   acquire	   the	  
endovascular	   phenotype	   suggesting	   that	   upregulation	   of	   endovascular	   genes	   is	   required	   for	  
successful	  placentation	  65.	  	  
	  
The	  role	  of	  TGF-­‐β	  signaling	   in	  reproduction	  has	  been	  the	  primary	  focus	  of	  our	   lab.	   In	  previous	  
studies	  we	  have	  demonstrated	  that	  Nodal	  inhibits	  trophoblast	  cell	  proliferation,	  migration,	  and	  
invasion	  while	  promoting	  apoptosis	   221,235.	   Furthermore,	  we	  have	   reported	   that	  Nodal	   and	   its	  
receptor	  ALK-­‐7	  were	  overexpressed	  in	  PE	  placentas	  235.	  TGFD-­‐1,	  -­‐2	  or	  -­‐3	  have	  also been reported 
as negative regulators in trophoblast migration and invasion 231,233. Likewise, miRNA 
suppression of Smad2 was shown to have pro-invasive effects on first trimester trophoblasts 160.	  
	  
Reports	  of	  miRNAs	  regulation	  in	  development	  and	  disease	  are	  increasing.	  However,	  the	  function	  
of	  miRNA	  in	  placental	  development	  and	  pathology	  is	  still	  poorly	  understood.	  A	  microarray	  study	  
from	  our	  collaborators	  revealed	  that	  there	  are	  a	  number	  of	  miRNAs	  aberrantly	  expressed	  in	  PE	  
placentas	  compared	  to	  their	  gestation-­‐age	  matched	  controls.	  We	  were	  interested	  in	  selecting	  a	  
dysregulated	  miRNA	  that	  has	  potential	   in	  regulating	  TGF-­‐β	  family	  members.	  We	   identified	  the	  
specific	   down-­‐regulation	   of	   miR-­‐218-­‐5p	   in	   PE,	   consistent	   with	   previous	   microarray-­‐based	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screening	   studies	   160,256.	   In	   silico	   analysis	   of	   potential	   miR-­‐218-­‐5p	   gene	   targets	   revealed	   an	  
enrichment	   of	   many	   TGF-­‐β	   signaling	   molecule	   targets	   including	   TGF-­‐β2,	   Nodal,	   Smad2,	   and	  
Smad3.	  	  
	  
Since	  dysregulation	  of	  EVT	  invasion	  into	  the	  uterus	  and	  the	  subsequent	  failure	  in	  the	  remodeling	  
of	  the	  maternal	  spiral	  arteries	  are	  the	  key	  mechanisms	  that	  underlie	  the	  development	  of	  PE,	  we	  
investigated	  the	  role	  of	  miR-­‐218-­‐5p	   in	   these	  processes.	  Our	  preliminary	   findings	   indicated	  the	  
miR-­‐218-­‐5p	   promoted	   trophoblast	   invasion	   and	   suppressed	   TGFβ	   signaling.	   Therefore,	   we	  
hypothesize	   that	  miR-­‐218-­‐5p	   is	   involved	   in	   the	  pathogenesis	  of	  PE	   in	  part	  by	   regulating	  TGFβ	  
signaling.	  	  It	  is	  postulated	  that	  a	  down-­‐regulation	  of	  miR-­‐218-­‐5p	  may	  lead	  to	  upregulated	  TGFβ	  
signaling,	  which	   in	   turn,	   results	   in	   shallow	   invasion	   of	   trophoblast	   cells	   into	   the	   decidua	   and	  
poor	  remodeling	  of	  spiral	  arteries.	  	  	  
	  
The	  overall	  objectives	  of	  my	  study	  were	  to	  1)	  Determine	  miR-­‐218-­‐5p	  function	  in	  differentiation	  
of	   the	  EVT	  pathway.	  2)	   Investigate	   the	  TGFβ	  mechanism	  responsible	   for	  miR-­‐218-­‐5p	  action	   in	  
EVT	  differentiation.	  3)	  Further	  characterize	  the	  TGFβ	  pathway	  in	  enEVT	  differentiation.	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CHAPTER	  2:	  MIR-­‐218-­‐5P	  PROMOTES	  ENDOVASCULAR	  
TROPHOBLAST	  DIFFERENTIATION	  THROUGH	  SUPPRESSION	  OF	  
TGF-­‐β	  SIGNALING	  
	  




MicroRNAs	  (miRNA)	  are	  small	  non-­‐coding	  RNAs	  that	  play	  important	  roles	  in	  developmental	  and	  
physiological	  processes.	  In	  this	  study,	  we	  examined	  the	  expression	  and	  function	  of	  miR-­‐218-­‐5p	  
in	  the	  human	  placenta.	  	  We	  show	  that	  miR-­‐218-­‐5p	  was	  highly	  expressed	  in	  second	  trimester	  and	  
its	  level	  was	  significantly	  downregulated	  in	  placentas	  obtained	  from	  patients	  with	  preeclampsia	  
(PE).	  Since	  dysregulation	  in	  the	  invasion	  of	  extravillous	  trophoblasts	  (EVTs)	  into	  the	  uterus	  and	  
the	  subsequent	  failure	  in	  the	  remodeling	  of	  the	  maternal	  spiral	  arteries	  are	  the	  key	  mechanisms	  
that	  underlie	  the	  development	  of	  PE,	  we	  investigated	  the	  role	  of	  miR-­‐218-­‐5p	  in	  these	  processes.	  
The	   functional	   role	   of	   miR-­‐218-­‐5p	   was	   assessed	   using	   the	   immortalized	   first	   trimester	  
trophoblast	  cell	  line	  HTR8/SVneo	  and	  first	  trimester	  human	  tissues.	  Overexpression	  of	  miR-­‐218-­‐
5p	   promoted,	   while	   anti-­‐miR-­‐218-­‐5p	   suppressed,	   trophoblast	   migration,	   invasion,	   EVT	  
outgrowth,	   and	  markers	  of	  enEVT	  differentiation.	   Furthermore,	  miR-­‐218-­‐5p	  accelerated	   spiral	  
artery	  remodeling	  in	  a	  first	  trimester	  decidua-­‐placenta	  co-­‐culture.	  The	  promoting	  effect	  of	  miR-­‐
218-­‐5p	   in	  enEVT	  pathway	  differentiation	  was	  mediated	  by	   the	   suppression	  of	   TGFβ	   signaling.	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1	  Dr.	  Dunk	  performed	  the	  bioplex	  assay	  in	  Supplementary	  Figure	  2.2	  with	  samples	  I	  provided.	  In	  addition,	  the	  
analysis	  of	  the	  in	  vitro	  trophoblast	  mediated	  decidua	  vessel	  remodelling	  experiments	  (Figure	  2.5)	  greatly	  relied	  on	  
her	  expertise.	  	  Jake	  O’Brien	  performed	  the	  experiments	  in	  Supplementary	  Figure	  2.3.	  Dr.	  Fu	  generated	  the	  Mir-­‐218	  
hairpin-­‐containing	  construct	  that	  I	  used	  to	  generate	  stable	  cells.	  He	  also	  performed	  one	  invasion	  experiment	  on	  
HTR8/SVneo	  cells	  that	  was	  pooled	  into	  Figure	  2.4A	  (left	  panel)	  with	  my	  other	  trials.	  He	  also	  processed	  the	  tissues	  
for	  RNA	  from	  clinical	  samples	  that	  I	  used	  in	  this	  study.	  Dr.	  Nadeem	  performed	  one	  EVT	  outgrowth	  experiment	  with	  
first	  trimester	  placenta	  tissues	  that	  was	  pooled	  into	  Figure	  2.4C	  with	  my	  other	  trials.	  Dr.	  Yang	  performed	  one	  of	  the	  
TGF-­‐β2	  invasion	  assays	  that	  was	  pooled	  into	  Figure	  2.	  6F	  with	  my	  other	  trials.	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Specifically,	  miR-­‐218-­‐5p	  suppressed	  TGF-­‐β2	  and	  supplementing	  TGF-­‐β2	  back	  into	  the	  cell	  culture	  
reversed	  some	  of	  the	  effects	  of	  miR-­‐218-­‐5p.	  Taken	  together,	  our	  data	  suggest	  that	  miR-­‐218-­‐5p	  
promotes	   trophoblast	   migration,	   invasion	   and	   differentiation	   into	   enEVTs	   in	   part	   through	   a	  
novel	  miR-­‐218-­‐5p-­‐TGF-­‐β2	  pathway.	  	  This	  study	  is	  first	  to	  elucidate	  the	  role	  and	  mechanism	  of	  a	  
miRNA	   in	   enEVT	   differentiation	   that	   is	   required	   for	   spiral	   artery	   remodeling	   and	   proper	  
placentation.	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INTRODUCTION	  
	  
A	   successful	   pregnancy	   is	   dependent	   on	   the	   health	   and	   functionality	   of	   the	   placenta,	   which	  
requires	   the	   precise	   and	   coordinated	   differentiation	   of	   cytotrophoblast	   cells	   (CTBs)	   into	   both	  
syncytiotrophoblast	  (STB),	  which	  cover	  the	  villous	  tree,	  and	  the	  extravillous	  trophoblasts	  (EVTs)	  
that	  invade	  the	  decidua,	  reaching	  as	  far	  as	  the	  inner	  third	  of	  the	  myometrium.	  A	  subset	  of	  EVTs	  
further	  differentiates	  into	  endovascular	  EVTs	  (enEVTs)	  that	  are	  directly	  involved	  in	  the	  process	  
of	  maternal	  uterine	  spiral	  artery	  remodeling.	  The	  remodeling	  of	  the	  uterine	  spiral	  arteries	  into	  
large	  dilated	   sinusoids	   is	   essential	   for	   the	  adequate	  perfusion	  of	   the	  placenta	   to	   support	   and	  
sustain	   the	   increasing	   requirements	   of	   the	   growing	   fetus	   257.	   The	   molecular	   mechanisms	  
governing	   the	  development	  of	   these	   two	  distinct	   EVT	   subtypes	  are	  now	  a	  major	   focus	  of	   the	  
placental	  research	  field	  258.	  	  
	  
Great	   Obstetrical	   Syndromes	   are	   associated	   with	   disorders	   of	   deep	   placentation,	   collectively	  
affecting	   15%	   of	   pregnancies	   worldwide	   259,260.	   The	   greatest	   proportion	   is	   attributed	   to	  
preeclampsia	  (PE),	  the	  leading	  direct	  cause	  of	  maternal	  and	  neonatal	  morbidity	  and	  mortality	  59.	  
Currently,	  PE	   is	  described	  as	  a	  two-­‐stage	  disorder.	   In	  the	  first	  stage,	  shallow	  EVT	  invasion	   into	  
the	   decidua	   along	   with	   poor	   enEVT	   mediated	   remodeling	   of	   spiral	   arteries	   remains	   a	   key	  
precursor	   to	   stage	   two,	   the	   oxidative	   stress	   and	   ischemia-­‐reperfussion	   injury,	   leading	   to	  
increased	  shedding	  of	  necrotic	  placental	  debris	  and	  systemic	  maternal	  endothelial	  dysfunction	  
261.	   The	   diagnosis	   of	   PE	   is	   currently	   limited	   to	   late	   second	   trimester	   at	   the	   onset	   of	   clinical	  
maternal	  symptoms,	  and	  predictive	  markers	  remain	  unreliable	  to	  date	  262.	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Most	   recently	  much	   interest	  has	   focused	  on	   the	  pool	  of	  RNA	   regulatory	   factors	   including	   the	  
miRNAs;	  many	  of	  which	  have	  been	  identified	  in	  the	  placenta	  and	  are	  thought	  to	  play	  an	  active	  
role	  in	  the	  regulation	  of	  trophoblast	  and	  endothelial	  cell	  turnover	  and	  fate	  263,264.	  Furthermore	  
the	   recent	   discovery	   of	   miRNAs	   in	   the	   maternal	   serum	   has	   suggested	   their	   potential	   use	   in	  
noninvasive	  prenatal	  diagnostics	  91.	  	  
	  
MiR-­‐218-­‐5p	   is	   processed	   from	   two	   precursor	   genes,	   mir-­‐218-­‐1	   and	   mir-­‐218-­‐2,	   encoded	   in	  
introns	  of	  Slit2	  and	  Slit3,	  respectively.	  Initial	  studies	  investigating	  the	  Slit-­‐Robo	  pathway	  focused	  
on	  its	  role	  as	  a	  guidance	  cue	  important	  for	  proper	  neuronal	  and	  vascular	  development	  143,265-­‐268.	  
The	   Slit-­‐Robo	   pathway	   has	   been	   investigated	   at	   the	   feto-­‐placental	   interface	   suggesting	   its	  
involvement	  in	  STB	  function	  and	  angiogenesis	  in	  the	  placental	  bed	  163,269,	  and	  Slit-­‐2,	  Robo-­‐1	  and	  
Robo-­‐4	   are	   reported	   to	   be	   lower	   in	   PE	   placentas	   270.	   Interestingly,	   a	   recent	   study	   on	   human	  
tubal	   pregnancies	   reported	   that	   migratory	   iEVT	   and	   actively	   remodeling	   enEVT	   were	   both	  
strongly	  positive	  for	  Slit2	  162.	  More	  recent	  studies	  suggest	  that	  miR218-­‐5p	  is	  a	  tumor	  suppressor	  
and	  a	  potential	  prognostic	  and	  predictive	  biomarker	  in	  a	  variety	  of	  cancers	  271-­‐274.	  MiR-­‐218-­‐5p	  is	  
expressed	   in	   human	   placenta	   and	   its	   levels	   are	   also	   down-­‐regulated	   in	   PE	   placental	   tissues	  
160,275.	  However,	  the	  functional	  role	  of	  miR-­‐218-­‐5p	  in	  the	  placenta	  has	  not	  been	  reported.	  
	  
The	   transforming	   Growth	   Factor	   (TGF)-­‐β	   family	   is	   a	   large	   group	   of	   multifunctional	   peptide	  
growth	   factors	   that	   play	   fundamental	   roles	   in	   many	   cellular	   processes,	   such	   as	   cellular	  
proliferation,	  differentiation,	  apoptosis,	  and	  angiogenesis	  276.	  They	  signal	  through	  a	  complex	  of	  
type-­‐I	  and	   type-­‐II	   serine/threonine	   receptors.	  Upon	  phosphorylation	  of	   the	   type	   I	   receptor	  by	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the	   type	   II	   receptor,	   a	   family	   of	   intracellular	   signaling	   molecules,	   Smads,	   are	   activated	  
propagating	   the	   signal	   to	   the	   nucleus.	   	   Many	   studies,	   including	   those	   from	   our	   lab,	   have	  
demonstrated	  that	  the	  TGFβ	  signaling	  pathway	  plays	   important	  roles	   in	  regulating	  trophoblast	  
survival,	  proliferation,	  and	  invasion	  223,277,278.	  	  
	  
In	  this	  study,	  we	  investigated	  the	  expression	  and	  function	  of	  miR-­‐218-­‐5p	  in	  human	  placenta.	  We	  
confirmed	  that	  miR-­‐218-­‐5p	  was	  decreased	  in	  PE	  placental	  tissues	  as	  has	  previously	  been	  shown	  
160,275.	   Using	   both	   established	   cell	   lines	   and	   human	   tissues,	  we	   demonstrate	   that	  miR-­‐218-­‐5p	  
promotes	   enEVT	   differentiation	   and	   accelerates	   the	   spiral	   artery	   remodeling	   process	  ex	   vivo.	  
We	  also	   identify	  TGF-­‐β2	  as	  a	  gene	   inhibited	  by	  miR-­‐218-­‐5p	  and	  observed	  that	   treatment	  with	  
recombinant	   human	   TGF-­‐β2	   suppresses	   differentiation	   into	   enEVT.	  Our	   study	   reveals	   a	   novel	  
miR-­‐218-­‐5p	  mediated	  mechanism	   regulating	  enEVT	  differentiation	   that	  may	  contribute	   to	   the	  
uteroplacental	  pathology	  associated	  with	  PE.	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MATERIALS	  AND	  METHODS	  
	  
Patients	  and	  Tissue	  Collection	  
All	   fresh	   and	   frozen	   human	   tissues	   used	   in	   this	   study	   were	   collected	   through	   the	   BioBank	  
program	   at	   the	   Research	   Centre	   for	   Women's	   and	   Infants'	   Health	   at	   Mount	   Sinai	   Hospital	  
(Toronto,	   ON,	   Canada),	   and	   approved	   by	   the	   Mount	   Sinai	   Hospital	   Research	   Ethics	   Board.	  
Placental	   and	   decidual	   tissue	   samples	   from	   first	   and	   second	   trimester	   were	   collected	   with	  
informed	   consent	   from	  healthy	   patients	   undergoing	   elective	   termination	   of	   pregnancy	   at	   the	  
Morgentaler	  Clinic,	  Toronto.	  At	  the	  point	  of	  collection	  the	  research	  nurse	  excluded	  all	  samples	  
with	  known	  HIV	  or	  Hepatitis	  infection	  and	  any	  that	  have	  been	  classified	  as	  a	  missed	  miscarriage.	  
Third-­‐trimester	  placentas	  were	   from	  vaginal	  delivery	  or	  cesarean	  section	  with	  Appropriate	   for	  
Gestation	   Age	   babies.	   For	   the	   evaluation	   of	   miR-­‐218-­‐5p	   expression	   across	   gestation,	   72	  
placentas	   were	   used.	   Specifically,	   13	   from	   first-­‐trimester	   (5-­‐12	   weeks),	   12	   from	   second-­‐
trimester	  (13-­‐25	  weeks),	  23	  from	  pre-­‐term	  (26-­‐36	  weeks),	  and	  24	  from	  term	  (37-­‐40	  weeks)	  were	  
analyzed.	   To	   assess	   if	   there	   is	   dysregulation	   of	   miR-­‐218-­‐5p	   in	   preeclampsia,	   we	   used	   16	  
placentas	  from	  PE	  patients	  delivered	  pre-­‐term,	  and	  11	  placentas	  from	  PE	  patients	  delivered	  at	  
term.	   Control	   preterm	   tissues	   were	   collected	   from	   laboring	   cesarean	   deliveries	   after	   fetal	  
distress	   or	   from	   premature	   rupture	   of	   membrane	   spontaneous	   labor.	   Examination	   by	   a	  
placental	  pathologist	  determined	  that	  all	  control	  preterm	  placenta	  lacked	  gross	  abnormalities	  or	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Table	  2.1	  Clinical	  Data	  for	  PE	  patients	  and	  Controls	  
	  
	   Pre-­‐Term	  Control	   Pre-­‐Term	  PE	   Term	  Control	   Term	  PE	  
Gestational	  age	  
(week)	   29.83±0.51	   30.27±0.36	   38.32±0.14	   36.55±0.41	  
Maternal	  age	   31.95±1.15	   30.8±1.85	   33.36±0.73	   34.8±2.21	  
Systolic	  blood	  
pressure	  (mmHg)	   120.56±2.9	   165.13±2.93	   118.88±2.11	   166.8±6.05	  
Diastolic	  blood	  
pressure	  (mmHg)	   73.83±2.27	   106.67±1.9	   77.04±1.79	   101.2±1.46	  
Proteinuria	   –	   3.46±0.13	   –	   2.41±0.25	  
	  
Mean	  ±	  SEM,	  PE:	  preeclampsia	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Cell	  culture	  	  
An	  immortalized	  human	  first	  trimester	  trophoblast	  cell	  line,	  HTR8/SVneo,	  was	  obtained	  from	  Dr.	  
Charles	   Graham	   (Queen’s	   University,	   Kingston,	   ON,	   Canada),	   and	   was	   cultured	   as	   previously	  
described	   279.	   Briefly,	   cells	  were	  maintained	   in	   HyClone™	   Classical	   Liquid	  Media	   RPMI	   1640	   -­‐	  
With	  L-­‐Glutamine	  (Fisher	  Scientific)	  supplemented	  with	  10%	  Fetal	  Bovine	  Serum	  (FBS)	  (GIBCO),	  
Streptomycin	  (100μg/ml),	  and	  Penicillin	  (100	  IU/ml),	  in	  an	  atmosphere	  of	  5%	  CO2	  at	  37°C.	  Cells	  
were	   periodically	   checked	   for	  mycoplasma	   contamination	   using	   a	  Mycoplasma	  Detection	   Kit-­‐
QuickTest	   (BioTools),	   and	   when	   needed,	   treated	   with	   MycoSmash	   Mycoplasm	   Removal	   Kit	  
(BioTools)	  following	  the	  manufacturers	  directions.	  All	  experiments	  were	  carried	  out	  on	  cells	   in	  
between	  passage	  73	  and	  85.	  	  
Transfections	  and	  Recombinant	  Protein	  Treatment	  
Transient	   transfection	   of	   miRNA	   or	   siRNA	   oligomers	   (100nM)	   was	   carried	   out	   using	  
Lipofectamine	   RNAiMax	   (Invitrogen).	   All	   plasmid	   transfection	   were	   carried	   out	   using	  
Lipofectamine	   2000	   (Invitrogen).	   A	   modified	   protocol	   was	   used	   to	   optimize	   for	   transfection	  
efficiency	   and	   cell	   survival.	   Transfections	  were	   carried	   out	   in	   6-­‐well	   plates	   on	   70%	   confluent	  
cultures.	  For	  each	  transfection	  reaction,	  2µl	  of	   lipofectamine	  reagent	  was	  used	  and	   incubated	  
with	   nucleotides	   for	   15min	   at	   room	   temperature	   in	   Opti-­‐MEM	  media	   (GIBCO).	   Transfections	  
were	  carried	  out	  for	  5h,	  then	  allowed	  to	  recover	  with	  10%	  FBS	  containing	  media	  for	  16hr.	  Cells	  
used	   for	  marker	   analysis	  were	  allowed	   to	   recover	   for	   an	  additional	   24h	   in	   serum-­‐free	  media.	  
MiR-­‐218-­‐5p,	   siTGFβ2,	   siSmad2	   and	   non-­‐targeting	   negative	   controls	   were	   purchased	   from	  
GenePharma	   Co.	   (Shanghai,	   China)	   (Table	   2.2).	   MirVana™	   anti-­‐miR-­‐218-­‐5p	   and	   a	   negative	  
control	  were	  purchased	  from	  Ambion.	  Recombinant	  human	  TGF-­‐β2	  protein	  (R&D)	  was	  used	  at	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10ng/mL	  in	  serum-­‐free	  media.	  Cells	  for	  marker	  experiments	  were	  treated	  for	  24h,	  while	  cells	  for	  
functional	  assays	  were	  pre-­‐treated	  overnight	  prior	  to	  seeding	  for	  downstream	  assays.	  	  
Generation	  of	  Mir-­‐218	  stable	  cells	  
A	  portion	  of	  the	  Slit2	  intron	  (NG_047105;	  281231	  to	  281568	  bp)	  bracketing	  the	  Mir-­‐218-­‐1	  stem-­‐
loop	  sequence	  was	  cloned	   into	  a	  GFP	  expressing	  pEGP-­‐miR	  vector	   in	   the	  NheI/BamHI	  cut	   site	  
using	   FP:	  TCGGTAGTAATACTCTTACTGTGGTC	   and	   RP:	  CAAGG-­‐CAAATAGATATACTCAGGC.	  
HTR8/SVneo	  cells	  were	  subsequently	  transfected	  with	  the	  empty	  pEGP-­‐miR	  vector	  (referred	  to	  
as	   EV)	   or	  Mir-­‐218-­‐1	   construct,	   followed	   by	   addition	   of	   2μg/ml	   Puromycin	   treatment	   for	   two	  
weeks.	   All	   viable	   colonies	   were	   assessed	   for	   overexpression	   by	   detecting	   green	   fluorescent	  
protein	  (GFP)	  signal	  and	  by	  measuring	  miR-­‐218-­‐5p	  levels.	  	  
RNA	  Extraction,	  Reverse	  Transcription	  and	  qRT-­‐PCR	  
Total	   RNA	   from	   cells	   and	   tissues	   was	   extracted	   using	   TRIzol	   reagent	   (Invitrogen)	   as	   per	  
manufacturer’s	  protocol.	  Reverse	  transcription	  was	  performed	  on	  1.5μg	  total	  RNA	  with	  M-­‐MuLV	  
Reverse	  Transcriptase	  (New	  England	  Biolabs).	  All	  miRNA	  quantification	  was	  performed	  with	  the	  
NCode™	  miRNA	   First-­‐Strand	   cDNA	   Synthesis	   Kit	   (Thermo	   Fisher),	   following	   the	  manufacturer	  
directions.	  Quantitative	  Real	  Time	  PCR	  (qRT-­‐PCR)	  was	  carried	  out	  with	  EvaGreen	  qPCR	  Master	  
Mix	  (ABM),	  following	  manufacturer	  directions,	  on	  a	  RotorGene	  Q	  thermocycler	  (QIAGEN).	  MiR-­‐
218-­‐5p	   levels	   were	   normalized	   to	   U6	   snRNA	   levels,	   and	   all	   other	   genes	   were	   normalized	   to	  
Cytochrome	   c1	   (Cyc1).	   The	   relative	   mRNA	   level	   was	   calculated	   using	   the	   2-­‐ΔΔct	   method.	   All	  
primers	   (Table	  2.2)	  used	   in	   this	   study	  were	  validated	   for	   specificity	  with	  primer-­‐BLAST	   (NCBI),	  
and	  amplified	  products	  were	  run	  on	  an	  agarose	  gel	  to	  ensure	  a	  single	  band	  product.	  
	  
	   59	  
Microarray	  
A	  gene	  expression	  analysis	  was	  conducted	  at	  the	  Princess	  Margaret	  Genomics	  Centre	  on	  a	  mir-­‐
218-­‐1	   overexpressing	   cell	   line	   and	   a	   control	   EV	   cell	   line	   (n=3),	   using	   the	   Human	   HT-­‐12	   V4	  
BeadChip,	  which	  comprises	  a	  total	  of	  47323	  probes.	  Data	  were	  checked	  for	  overall	  quality	  using	  
R	   (v3.0.2)	   with	   the	   Bioconductor	   framework	   and	   the	   LUMI	   package	   installed.	   Data	   were	  
imported	   in	   GeneSpring	   v12.6	   for	   analysis.	   During	   import,	   the	   data	  were	   normalized	   using	   a	  
standard	  (for	  Illumina	  arrays)	  quantile	  normalization	  followed	  by	  a	  “per	  probe”	  median	  centred	  
normalization.	  Only	  probes	  that	  were	  above	  the	  20th	  percentile	  of	  the	  distribution	  of	  intensities	  
in	  100%	  of	  any	  of	  the	  groups	  were	  allowed	  to	  pass	  through	  the	  filtering.	  A	  one-­‐way	  ANOVA	  with	  
a	   Benjamini-­‐Hochberg	   FDR	   corrected	   p<0.05	   showed	   4106	   significantly	   varying	   probes.	   Heat	  
maps	  were	  created	  using	  the	  MultiExperiment	  Viewer	  (MeV)	  Microarray	  Software	  Suite.	  	  
EVT	  Column	  Markers	  
First-­‐trimester	   placentas	   were	   collected	   as	   described	   above.	   Tissues	   between	   8-­‐10	   weeks	   of	  
gestation	  were	  dissected	  for	  EVT-­‐containing	  villi.	  To	  assess	  changes	  in	  desired	  gene	  markers,	  the	  
tips	  of	  villi	  were	  carefully	  dissected	  with	  curved	  scissors	  and	  incubated	  with	  200nM	  of	  miR-­‐218-­‐
5p,	  anti-­‐miR-­‐218-­‐5p,	  or	  non-­‐targeting	  control	  oligomers,	   in	   serum-­‐free	  DMEM-­‐F12	  phenol-­‐red	  
free	  media	  (Life	  Technologies)	  at	  37°C	  with	  3%	  O2	  and	  5%	  CO2.	  For	  each	  treatment	  group	  within	  
the	  experiment,	  approximately	  50	  villi	  tips	  were	  used.	  After	  48hr,	  tissues	  were	  collected,	  snap	  
frozen	  in	  liquid	  nitrogen	  and	  stored	  at	  -­‐80°C	  until	  further	  processing	  for	  RNA	  extraction.	  Due	  to	  
tissue	  size,	  only	  one	  to	  two	  replicates	  were	  used	  per	  trial,	  and	  each	  experiment	  was	  repeated	  on	  
at	  least	  five	  unique	  tissues.	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Table	  2.2	  Primers	  and	  Oligomers	  
	  
Name	   Sequence:	  5’	  à	  3’	   NCBI	  BLAST	  	  
Cyc1	   F:	  CAGATAGCCAAGGATGTGTG	  R:	  CATCATCAACATCTTGAGCC	   Cytochrome	  c1	  
VE-­‐cad	   F:	  GCCAGTTCTTCCGAGTCACA	  R:	  TTTCCTGTGGGGGTTCCAGT	   Cadherin	  5	  
PECAM1	   F:	  ATTGCAGTGGTTATCATCGGAGTG	  R:	  CTCGTTGTTGGAGTTCAGAAGTGG	  
Platelet	  and	  Endothelial	  Cell	  
Adhesion	  Molecule	  1	  
MMP1	   F:	  GTCTCACAGCTTCCCAGCGA	  R:	  ATGGCATGGTCCACATCTGC	   Matrix	  Metallopeptidase	  1	  
IL1b	   F:	  AATCTGTACCTGTCCTGCGTGTT	  R:	  TGGGTAATTTTTGGGATCTACACTCT	   Interleukin	  1	  beta	  
IL8	   F:	  CAGAGACAGCAGAGCACACA	  R:	  GGCAAAACTGCACCTTCACA	   C-­‐X-­‐C	  motif	  chemokine	  ligand	  8	  
ECSCR	   F:	  ACAACTCCCAGCCCACAATG	  R:	  GTGGTCAGACTTAGACCGCC	  
Endothelial	  Cell-­‐Specific	  Chemotaxis	  
Regulator	  
CXCL1	   F:	  CAGGGAATTCACCCCAAGAACA	  R:	  GGATGCAGGATTGAGGCAAGC	   C-­‐X-­‐C	  motif	  chemokine	  ligand	  1	  
ITGA1	   F:	  GCTGGCTCCTCACTGTTGTT	  R:	  CACCTCTCCCAACTGGACAC	   Integrin	  subunit	  alpha	  1	  
TGFβ2	   F:	  ATTGATGGCACCTCCACATATA	  	  R:	  ACGTAGGCAGCAATTATCCTG	   Transforming	  Growth	  Factor	  beta	  2	  
miR-­‐218-­‐5p	   F:	  TTGTGCTTGATCTAACCATGT	  R:	  N-­‐Code	  Universal	  Primer	   N/A	  
U6	  snRNA	   F:	  CGCAAGGATGACACGCAAATTC	  	  R:	  N-­‐Code	  universal	  primer	   N/A	  
siTGFβ2	   Sense:	  ACCAAATACTTTGCCAGAAACTAT	  Anti-­‐sense:	  ATAGTTTCTGGCAAAGTATTTGGT	   Transforming	  Growth	  Factor	  beta	  2	  
siSmad2	   Sense:	  GUCCCAUGAAAAGACUUAAtt	  Anti-­‐sense:	  UUAAGUCUUUUCAUGGGACtt	  	   SMAD	  family	  member	  2	  
NC	   UUCUCCGAACGUGUCACGUtt	  ACGUGACACGUUCGGAGAAtt	   No	  match	  
hsa-­‐miR-­‐218-­‐5p	   Sense:	  UUGUGCUUGAUCUAACCAUGU	  Anti-­‐sense:	  ACAUGGUUAGAUCAAGCACAA	   	  
Anti-­‐NC	   mirVana™	  miRNA	  Inhibitor,	  	  Negative	  Control	  #1	   	  
Anti-­‐hsa-­‐miR-­‐
218-­‐5p	   hsa-­‐miR-­‐218-­‐5p	  mirVana™	  Inhibitor	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Transwell	  Migration	  and	  Invasion	  Assay	  
Transwell	  inserts	  with	  8	  μm	  pores	  (Costar,	  Corning	  Inc)	  were	  coated	  with	  150	  μg/ml	  Matrigel	  in	  
serum	  free	  media	  (Cultrex	  Reduced	  Growth	  Factor	  BM	  extract-­‐PathClear,	  Trevigen)	  and	  allowed	  
to	  polymerize	  overnight	  at	  37°C.	  Cells	  were	  gently	  removed	  from	  culture	  plates	  using	  Accutase	  
(Innovative	  Cell	   Technologies),	   and	   seeded	  at	   a	  density	  of	  20,000	   cells	  per	  well	   in	   serum-­‐free	  
RMPI-­‐1640	  media.	  As	  a	  chemotactic	  agent,	  10%	  serum	  containing	  medium	  was	  seeded	  on	  the	  
outside	   of	   the	   transwell.	   After	   24h,	  membranes	  were	   fixed	   for	   2	  min	   in	   100%	  methanol	   and	  
stained	  using	  Harleco	  Hemacolor	   Staining	  Kit	   (EMD	  Chemicals).	   Similarly,	   for	  migration	  assays	  
10,000	   cells	   per	  well	  were	   seeded	   on	   8	   μm	  pore	   transwell	  membranes	  without	   any	  matrigel	  
coating.	   Invaded	   or	   migrated	   cells	   were	   counted	   with	   ImageJ	   280	   and	   the	   invasion/migration	  
index	  was	  calculated	  as	  a	  fold	  of	  invaded/migrated	  cells	  in	  the	  treated	  groups	  compared	  to	  the	  
control	  group.	  Each	  experiment	  was	  repeated	  in	  a	  minimum	  of	  three	  independent	  trials.	  
First-­‐Trimester	  Human	  Placental	  Explant	  Culture	  
Explant	   cultures	   were	   performed	   as	   previously	   described	   277,281.	  Briefly,	   villous	   explants	   with	  
potential	  EVT	  columns	  were	  carefully	  dissected	  and	  positioned	  on	  Transwell	   inserts	  (Millipore)	  
pre-­‐coated	  with	   200μL	  of	   undiluted	  phenol	   red-­‐free	  Matrigel	   (BD	  Biosciences).	   Explants	  were	  
left	  overnight	  to	  attach	  to	  the	  matrigel,	  at	  37°C	  with	  3%	  O2	  and	  5%	  CO2,	  before	  adding	  serum-­‐
free	  DMEM-­‐F12	  media	   supplemented	  with	   100	  U/ml	   of	   penicillin,	   100	  U/ml	   of	   streptomycin,	  
100	   μg/ml	   Normacin™.	   After	   two	   days	   of	   culture,	   villous	   tips	   were	   examined	   under	   the	  
dissecting	  microscope	   for	   successful	   EVT	   outgrowths.	   All	   successfully	   attached	   explants	  were	  
selected	   for	   treatment	   with	   200nM	   oligomers	   (Table	   2.2).	   Explants	   were	   photographed	  
immediately	   after	   adding	   treatment,	   and	   subsequently	   at	   24	   and	   48hr,	   using	   a	   Leica	  DFC400	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camera	   attached	   to	   a	   dissecting	   microscope.	   ImageJ	   was	   used	   to	   measure	   the	   area	   of	   EVT	  
outgrowth.	  	  Specifically,	  total	  outgrowth	  area	  was	  calculated	  by	  subtracting	  the	  area	  at	  the	  end	  
of	  the	  treatment	  with	  the	   initial	  area	  before	  treatment.	  Each	  experiment	  was	  designed	  with	  a	  
minimum	  of	  four	  replicates,	  and	  was	  repeated	  on	  at	  least	  three	  unique	  placenta	  samples.	  	  
First-­‐Trimester	  Placenta-­‐Decidua	  Explant	  Co-­‐culture	  
Placenta-­‐decidua	  co-­‐culture	  was	  performed	  as	  previously	  described	  282.	  Briefly,	  small	  sections	  of	  
decidua	   parietalis	   and	   placental	   villi	   with	   EVT	   columns	   from	   the	   same	   patient	  were	   carefully	  
dissected	   from	   tissues	   collected	   as	   described.	   Decidua	   were	   carefully	   placed	   at	   a	   45°	   angle,	  
epithelial	   side	   facing	   up,	   on	   Transwell	   inserts	   (Millipore)	   pre-­‐coated	  with	   120μL	   of	   undiluted	  
phenol	   red-­‐free	   Matrigel	   (BD	   Biosciences).	   Placental	   explants	   were	   placed	   in	   serum-­‐free	  
medium	  containing	  200nM	  miR-­‐218-­‐5p	  or	  non-­‐targeting	  control	  (NC).	  Tissues	  were	  incubated	  at	  
37°C	   with	   3%	   O2	  and	   5%	   CO2	   for	   24h.	   Treated	   placenta	   explants	   were	   carefully	   washed	   five	  
times	  in	  1X	  Phosphate	  Buffered	  Saline	  to	  remove	  residual	  oligomers.	  Villi	  were	  gently	  placed	  on	  
the	   exposed	   epithelial	   surface	   of	   decidua	   and	   anchored	   with	   50ul	   of	   matrigel.	   Tissues	   were	  
covered	   with	   serum-­‐free	   DMEM-­‐F12	   media	   supplemented	   with	   estradiol	   (0.3ng/mL)	   and	  
progesterone	  (20ng/mL),	  and	  allowed	  to	  incubate	  for	  an	  additional	  six	  days,	  at	  which	  point	  the	  
tissues	  were	  fixed	  in	  4%	  paraformaldehyde	  (Electron	  Microscopy	  Sciences)	  for	  1hr.	  Tissues	  were	  
dehydrated	  in	  ascending	  concentration	  of	  ethanol,	  cleared	  in	  xylene,	  and	  embedded	  in	  paraffin.	  
Blocks	  were	  sectioned	  to	  5	  μm	  thickness,	  and	  every	   tenth	  slide	  was	  histologically	  assessed	  by	  
standard	  Haematoxylin	  and	  Eosin	  staining.	  Decidua	  alone	  samples	  served	  as	  a	  control	  to	  ensure	  
selected	  tissue	  was	  not	  decidua	  basalis	  in	  origin.	  Experiment	  was	  performed	  on	  three	  individual	  
placenta-­‐decidua	  matched	  tissues	  with	  similar	  findings.	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Immunohistochemical	  analysis	  
Immunohistochemical	   analysis	   was	   performed	   using	   the	   streptavidin	   peroxidase	   method	   as	  
previously	  described	  282.	  Paraffin-­‐embedded	  tissues	  were	  baked	  overnight,	  de-­‐waxed	  in	  xylene,	  
and	   rehydrated	   in	   descending	   grades	   of	   ethanol,	   and	   incubated	   in	   3%	   hydrogen	   peroxide	   in	  
methanol	   for	   50	  min	   to	   quench	   any	   endogenous	   peroxidase	   activity.	   Antigen	   retrieval	   for	   all	  
antibodies	   used	   was	   performed	   by	   briefly	   boiling	   slides	   in	   10mM	   sodium	   citrate.	   A	   blocking	  
buffer	  of	  10%	  goat	  serum	  and	  2%	  rabbit	  serum	  (Dako	  X0909)	  was	  used	  in	  a	  humidified	  chamber	  
for	  1h	  at	  room	  temperature	  following	  an	  overnight	  incubation	  at	  4°C	  in	  primary	  antibody	  (Table	  
2.3).	  Incubation	  with	  mouse	  IgG	  (1:100,	  Dako,	  X0931)	  in	  place	  of	  primary	  antibody	  served	  as	  a	  
negative	  control.	  Excess	  antibody	  was	  washed	  off	  and	  subsequent	  incubations	  with	  anti-­‐mouse	  
or	   anti-­‐rabbit	   biotinylated	   secondary	   antibody	   (1:300,	   Dako	   E0464	   and	   E0432)	   and	   the	  
streptavidin-­‐HRP	  conjugated	  tertiary	  reagent	  (Invitrogen	  SA1007)	  were	  performed	  for	  1h	  each	  
at	   room	  temperature.	  Specific	   signals	  were	  detected	  using	  a	  Dako	  DAB	  staining	  kit	   containing	  
0.02%	   H2O2	  and	   0.075%	   3,3′-­‐diaminobenzidine	   in	   1×PBS.	   Slides	   were	   counterstaining	   using	  
Harris	   hematoxylin	   (1:2;	   Sigma-­‐Aldrich	  Corp.),	   and	  dehydrated	   in	   ascending	   series	   of	   ethanol,	  
cleared	  in	  xylene,	  and	  mounted	  with	  Cytoseal	  (Fisher	  Scientific).	  Photographs	  were	  taken	  with	  
an	  Olympus	  DP72	  camera	  mounted	  on	  a	  BX61	  Olympus	  microscope	  using	  the	  cellSens	  standard	  
program.	  	  
Reporter	  Constructs	  and	  Luciferase	  Assay	  
Luciferase	   3’UTR	   reporter	   constructs	   were	   generated	   by	   cloning	   a	   portion	   of	   the	   3’UTR,	  
containing	  the	  proposed	  miR-­‐218-­‐5p	  seeding	  sequence,	  into	  pMIR	  REPORT™	  miRNA	  Expression	  
Reporter	   	  (Ambion),	  downstream	  of	  a	   luciferase	  gene.	  Specifically,	  TGFB2	  3’UTR	  was	  amplified	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from	   nucleotide	   178	   to	   813	   with	   primers	   TGFB2	   3’UTR1	   FP:	   AGGACTAGTAGTATGCA-­‐
AGTGGGCAGCAA	   and	   TGFB2	   3’UTR1	   RP:	   ACTACGCGTACAAC-­‐CAACCCCAGAAAGCA.	   Both	  
constructs	  were	  cloned	  using	  the	  SPEI	  and	  MLUI	  restriction	  enzyme	  cut	  sites.	  Luciferase	  assays	  
were	   performed	   using	   the	   Dual-­‐Luciferase®	   Reporter	   assay	   system	   as	   per	   manufacturer’s	  
direction	   (Promega).	  Renilla	  construct	   (10ng/mL)	  was	  co-­‐transfected	  with	  all	  experiments	  as	  a	  
normalization	  control.	  TGF-­‐β	  signaling	  was	  assessed	  using	  the	  PAR3-­‐Lux	  reporter	  and	  FAST2	  as	  
previously	  described	  283.	  	  
Primary	  HUVEC	  isolation	  
Umbilical	  cords	  of	  term	  placentas	  were	  collected	  from	  Mackenzie	  Richmond	  Hill	  Hospital	  after	  
caesarean	   delivery.	   	   The	   use	   of	   tissues	   was	   approved	   by	   the	   research	   ethics	   committee	   at	  
Mackenzie	  Health	  and	  patients	  provided	   informed	  consent.	  Human	  Umbilical	  Vein	  Endothelial	  
cells	   (HUVEC)	  were	   isolated	  as	  previously	  published	   284.	   In	  brief,	   umbilical	   veins	  were	  washed	  
with	  1x	  Hank’s	  Buffered	  Salt	   Solution	   (CellGro	  21-­‐021CV),	  and	   injected	  with	  0.1%	  Collagenase	  
Type	  I	   (Worthington)	  prepared	  in	  1x	  Dulbecco's	  PBS	  (GIBCO	  14287).	  The	  cells	  were	  allowed	  to	  
dissociate	  for	  15	  min	  at	  37°C.	  Cells	  were	  plated	  in	  M199	  media	  (GIBCO)	  supplemented	  with	  10%	  
FBS,	  streptomycin	   (100μg/ml)	  and	  penicillin	   (100	   IU/ml),	  and	  5mg/mL	  Endothelial	  Cell	  Growth	  
Supplement	   (BD	   BioScience).	   Validation	   of	   HUVEC	   isolation	   was	   performed	   each	   time	   by	  
examining	  morphology	  and	  positive	  staining	  for	  VEGF-­‐A	  and	  PECAM-­‐1,	  and	  discarded	  after	  ten	  
passages.	  	  
Network	  Formation	  Assay	  and	  HUVEC	  Co-­‐culture	  
On	  ice,	  96-­‐well	  plates	  were	  quickly	  coated	  with	  50μl	  of	  matrigel	  (Celtrex	  Reduced	  Growth	  Factor	  
BM	   extract-­‐PathClear,	   Trevigen),	   and	   allowed	   to	   polymerize	   at	   37°C	   for	   30min.	   For	   network	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formation	  assays,	  25,000	  HTR8/SVneo	  cells	  were	  seeded	  per	  well	  in	  100ul	  of	  10%	  FBS	  containing	  
RPMI1640.	  After	  16-­‐20h	  of	  culture,	  cells	  were	  stained	  with	  1μM	  Calcein	  AM	  (Corning)	  for	  15min,	  
and	   pictures	   were	   taken	   at	   20X	   magnification	   on	   a	   fluorescence	   microscope.	   For	   co-­‐culture	  
assays,	   HUVEC	   and	   HTR8/SVneo	   cells	   were	   stained	   for	   45min	   with	   1μM	   CellTracker™	   Red	  
CMTPX	  (Invitrogen)	  or	  CellTracker™	  Green	  CMFDA	  (Sigma-­‐Aldrich),	   respectively.	  Once	  stained,	  
cells	  were	  seeded	  in	  a	  one	  to	  one	  ratio	  with	  a	  total	  of	  25,000	  cells	  per	  well.	  Total	  network	  length	  
was	  quantified	  in	  ImageJ	  using	  the	  NeuronJ	  plugin	  285.	  Each	  experimental	  group	  had	  a	  minimum	  
of	  3	  replicates,	  and	  was	  repeated	  at	  least	  three	  individual	  trials.	  	  
Protein	  Extraction	  and	  Immunoblot	  Analysis	  
Cells	   were	   lysed	   using	   HEPES	   lysis	   buffer	   (10mM	   HEPES,	   10mM	   NaCl,	   0.1mM	   EDTA,	   0.1mM	  
EGTA,	   1.0mM	   DTT,	   0.1%	   NP-­‐40,	   pH7.9)	   freshly	   supplemented	   with	   a	   Pierce	   Protease	   and	  
Phosphatase	   inhibitor	   (Thermo	   Scientific).	   Equal	   amounts	   of	   protein	  were	   separated	   by	   SDS-­‐
polyacrylamide	   gel	   electrophoresis	   and	   were	   transferred	   to	   a	   polyvinylidene	   difluoride	  
membrane	  (Immobilon-­‐P,	  Millipore	  Corp.).	  Membranes	  were	  blocked	  in	  5%	  blocking	  buffer	  (5%	  
skim	  milk	  in	  1x	  Tris-­‐buffered	  Saline	  and	  Tween-­‐20)	  for	  1h	  at	  room	  temperature,	  then	  incubated	  
overnight	   in	  primary	  antibody	  at	  4°C	  (Table	  2.3).	  Membranes	  were	  subsequently	  probed	  using	  
horseradish	  peroxidase–conjugated	  secondary	  antibodies	  at	   room	  temperature	   for	  2h.	  Signals	  
were	  detected	  using	  the	  ECL	  Plus	  Kit	  (Amersham	  Biosciences).	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Table	  2.3	  Primary	  Antibodies	  and	  Staining	  Reagents	  
	  





Cytokeratin-­‐7	   Dako	   M7018	   Mouse	   1:100	   PBS	  
PECAM1	   Dako	   M0823	   Mouse	   1:100	   PBS	  
SMA	   Dako	   M0851	   Mouse	   1:100	   PBS	  
CD45	   Dako	   M0701	   Mouse	   1:100	   PBS	  
HLA-­‐G	   ExBio	   11-­‐499	   Mouse	   1:300	   PBS	  
Ac-­‐α-­‐tubulin	   Sigma-­‐Aldrich	   T6793	   Mouse	   1:500	   1%	  BSA-­‐PBST	  
TGFβ2	   Santa	  Cruz	   sc-­‐90	   Rabbit	   1:100	   5%Milk-­‐TBST	  
Smad2/3	   Cell	  Signaling	   3102S	   Rabbit	   1:1000	   5%BSA-­‐TBST	  
GAPDH	   Santa	  Cruz	   sc-­‐47724	   Mouse	   1:5000	   5%Milk-­‐TBST	  




Sigma-­‐Aldrich	   C2925	   N/A	   1μM	   Serum-­‐free	  media	  
CellTracker™	  Red	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ELISA	  
Mir-­‐218-­‐1	   overexpressing	   stable	   cells	   were	   seeded	   on	   12-­‐well	   plates	   at	   100,000	   cells/well	   in	  
10%	  FBS	  containing	  1640	  RPMI	  media.	  Conditioned	  medium	  was	  collected	  after	  72h	  and	  spun	  
down	  at	  500g	  for	  5min.	  TGF-­‐β2	  was	  measured	  using	  the	  Human	  TGF-­‐beta	  2	  Quantikine	  ELISA	  Kit	  
(R&D	  Systems)	  following	  the	  manufacturer’s	  directions.	  Briefly,	  samples	  were	  activated	  with	  1N	  
HCl	  and	  subsequently	  neutralized	  with	  1.2N	  NaOH/0.5M	  HEPES.	  Neutralized	  samples	  were	  not	  
further	  diluted,	  and	  were	  immediately	  assayed	  for	  total	  active	  TGF-­‐β2	  levels.	  The	  color	  reaction	  
was	  quantified	  on	  the	  BioTek	  Synergy	  H4	  Plate	  Reader	  at	  450nm	  and	  background	  detected	  at	  
540nm	   was	   subtracted.	   Quantification	   of	   total	   TGF-­‐β2	   levels	   in	   conditioned	   media	   was	  
calculated	  from	  the	  standard	  curve	  generated	  during	  each	  assay.	  	  
Cell	  Growth	  Assay	  
Mir-­‐218-­‐1	  and	  EV	  stable	  cells	  were	  seeded	  at	  50,000	  cells	  per	  6-­‐well	  plate	  in	  10%	  FBS	  containing	  
RPMI1640	  media.	  Cells	  were	  detached	  and	  counted	  on	  a	  hemocytometer	  at	  24h,	  48h	  and	  72h	  
post-­‐seeding.	  Each	  time	  point	  was	  done	  in	  triplicate	  and	  repeated	  three	  independent	  times.	  To	  
account	  for	  possible	  differences	  in	  apoptosis,	  dead	  cells	  were	  counted	  at	  each	  time	  point.	  	  
Immunofluorescence	  
EV	  control	  and	  Mir-­‐218-­‐1	  overexpressing	  cells	  were	  seeded	  in	  a	  monolayer	  on	  glass	  coverslips	  
and	  allowed	  to	  attach	  overnight.	  Cells	  were	  wounded	  down	  the	  middle	  with	  a	  tip,	  and	  covered	  
in	  serum-­‐free	  medium	  for	  16h.	  Cells	  were	  fixed	  in	  ice	  cold	  Acetone:Methanol	  (1:1	  solution)	  for	  
20min	  then	  washed	  three	  times	  in	  1xPBS.	  Cells	  were	  permeabilized	  with	  0.2%	  Tween	  for	  15min	  
then	  blocked	  in	  1%	  BSA-­‐PBS-­‐T	  for	  1h.	  Cells	  were	  probed	  for	  acetylated	  alpha	  tubulin	  (Table	  2.3)	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for	  2h	  at	  room	  temperature,	  followed	  by	  secondary	  anti-­‐mouse	  antibody	  for	  1h.	  Coverslips	  were	  
mounted	  on	  slides,	  and	  pictures	  were	  taken	  on	  the	  Zeiss	  LSM	  700	  Confocal	  Microscope.	  	  
Statistical	  Analysis	  
Statistical	  analysis	  was	  performed	  using	  Graphpad	  Prism	  7	   (p<0.05,	  95%	  CI).	  One-­‐way	  ANOVA	  
followed	  by	  a	  Tukey’s	  multiple	  comparisons	  test	  determined	  differences	  among	  several	  groups.	  
Unpaired,	   two-­‐tailed,	   Student’s	  t	  test	   was	   used	   for	   comparison	   between	   two	   groups.	   When	  
necessary,	  alternative	  statistical	  tests	  were	  used	  and	  specified	  in	  corresponding	  figure	  legends.	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RESULTS	  
	  
Expression	  of	  miR-­‐218-­‐5p	  in	  placentas	  from	  healthy	  and	  PE	  pregnancies	  
MiR-­‐218-­‐5p	   is	   a	   highly	   conserved	   miRNA.	   A	   closer	   comparison	   across	   several	   hemochorial	  
placenta	   species	   (human,	   chimpanzee,	  mouse	   and	   rat)	   showed	   complete	   conservation	   of	   the	  
entire	   21	   nucleotide	   sequence	   (Figure	   2.1A).	   	   To	   assess	   the	   possible	   role	   of	   miR-­‐218-­‐5p	   in	  
placenta	  function,	  we	  analyzed	  a	  total	  of	  72	  healthy	  placenta	  samples	  across	  gestation.	  Second	  
trimester	  tissues	  (13-­‐25	  weeks)	  showed	  a	  significantly	  higher	  (p<0.0001)	  expression	  of	  miR-­‐218-­‐
5p	   compared	   to	   all	   other	   stages	   of	   gestation	   (Figure	   2.1B).	   A	   set	   of	   placenta	   tissues	   from	  
pregnancies	  diagnosed	  with	  preeclampsia	  (PE)	  delivered	  preterm	  (25-­‐36	  weeks)	  and	  term	  (37-­‐
40	  weeks)	  were	  analyzed	  for	  miR-­‐218-­‐5p	  level,	  and	  compared	  to	  placenta	  from	  healthy	  patients	  
during	   the	   same	   gestation	   period.	   Only	   placenta	   from	   PE	   patients	   delivered	   at	   term	   had	   a	  
significantly	   lower	   (p<0.0005)	   expression	   of	   miR-­‐218-­‐5p	   compared	   to	   their	   gestational	   age	  
matched	  controls	  (Figure	  2.1C).	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Figure	  2.1	  Expression	  pattern	  of	  miR-­‐218-­‐5p	  in	  human	  healthy	  and	  PE	  placentas.	  
(A)	  miR-­‐218-­‐5p	  across	  hemochorial	  placenta	  species	   (ptr:	   chimpanzee,	  mmu:	  mouse,	   rno:	   rat)	  
shows	   complete	   conservation,	   including	   the	   full	   seeding	   region	   responsible	   for	   target	  
complementarity.	   (B)	   Healthy	   placenta	   from	   patients	   at	   Mount	   Sinai	   Hospital	   undergoing	  
elective	  termination	  or	  Caesarean	  section	  were	  assessed	  for	  miR-­‐218-­‐5p	  level	  by	  qRT-­‐PCR	  and	  
normalized	   to	   endogenous	   U6	   snRNA.	   A	   significant	   increase	   (p<0.0001)	   in	   miR-­‐218-­‐5p	   levels	  
occurred	  during	  second	  trimester	  (13-­‐25	  weeks	  gestation)	  was	  observed	  compared	  to	  all	  other	  
gestational	   periods.	   (C)	   Placenta	   from	   patients	   diagnosed	   with	   preeclampsia	   (PE)	   delivered	  
preterm	  (26-­‐36	  weeks)	  or	  at	   term	  (37-­‐40	  weeks)	  were	  assessed	   for	  miR-­‐218-­‐5p	   levels	  as	   in	  B,	  
and	  compared	  to	  pregnancies	  that	  were	  found	  to	  have	  no	  placental	  abnormalities.	  A	  significant	  
decrease	   (p<0.0005)	   of	   miR-­‐218-­‐5p	   was	   observed	   in	   the	   PE-­‐Term	   placenta	   group	   when	  
compared	  to	  its	  gestational	  age	  matched	  control.	  Error	  bars	  represent	  SEM.	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Overexpression	  of	  mir-­‐218	  induced	  differentiation	  towards	  the	  enEVT	  pathway	  
	  
To	   investigate	   the	   role	   of	   miR-­‐218-­‐5p	   in	   placental	   development,	   we	   generated	   a	   stable	  
HTR8/SVneo	   trophoblast	   cell	   line	   stably	   overexpressing	   mir-­‐218-­‐1.	   	   The	  mir-­‐218-­‐1	   stem-­‐loop	  
sequence	   was	   cloned	   into	   the	   miRNASelect™	   pEGP-­‐miR	   expression	   vector	   (Figure	   2.2A,	   top	  
panel).	   After	   transfection	   into	   the	   immortalized	   first	   trimester	   trophoblast	   cell	   line,	  
HTR8/SVneo,	  positive	   clones	  were	   selected	  with	  Puromycin	   treatment.	   Twenty-­‐two	   single-­‐cell	  
colonies	  were	   assessed	   for	  miR-­‐218-­‐5p	   level	   (Figure	   S2.1).	   HTR8/SVneo,	   positive	   clones	  were	  
selected	   with	   Puromycin	   treatment.	   For	   simplicity,	   we	   present	   the	   findings	   from	   a	   single	  
representative	  over-­‐expressing	  clone	  (mir-­‐218-­‐1).	  	  It	  is	  important	  to	  note	  that	  we	  independently	  
re-­‐created	  these	  stable	  cells	  three	  times	  and	  observed	  similar	  key	  functional	  findings	  (data	  not	  
shown).	  The	  chosen	  miR-­‐218-­‐5p	  clone	  was	  shown	  to	  significantly	  overexpress	  (p<0.05)	  mature	  
miR-­‐218-­‐5p	   six	   fold	   over	   the	   endogenous	   level	   (Figure	   2.2B).	   The	   rate	   of	   mir-­‐218-­‐1	  
overexpressing	  cell	   growth	  was	   significantly	   (p<0.05)	   slower	  as	   compared	   to	   the	  control	   cells,	  
and	  this	  decrease	  was	  not	  due	  to	  increase	  in	  dead	  cells	  (Figure	  2.2C).	  When	  seeded	  at	  equal	  cell	  
density,	   the	   mir-­‐218-­‐1	   overexpressing	   cells	   displayed	   clear	   morphological	   differences	   in	   that	  
they	  were	   smaller	   and	  more	   spindle-­‐shaped,	   and	   grew	   in	   a	  more	   diffuse	   pattern	   lacking	   the	  
characteristic	  epithelial	  cell-­‐cell	  contact	  normally	  observed	  in	  the	  parental	  and	  EV	  cells	  (Figure	  
2.2D).	   Confocal	   microscopy	   revealed	   more	   disorganized	   microtubules	   with	   asymmetric	  
distribution	  in	  the	  Mir-­‐218-­‐1	  overexpressing	  cells	  as	  compared	  to	  the	  control	  cells	  (Figure	  2.2E).	  
Finally,	  using	  an	  in	  vitro	  endothelial-­‐like	  network	  formation	  assay	  we	  showed	  that	  the	  mir-­‐218-­‐1	  
overexpressing	  cells	  formed	  more	  richly	  branched	  and	  extensive	  networks	  as	  compared	  to	  the	  
control	  cells.	  (Figure	  2.2F).	  	   	  




Figure	  2.2	  Legend	  found	  on	  next	  page	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Figure	  2.2	  Generation	  and	  Initial	  Characterization	  of	  mir-­‐218-­‐1	  stable	  cells.	  
	  (A)	   A	   portion	   of	   the	   Slit2	   intron	   (primers	   underlined),	   bracketing	   the	   Mir-­‐218-­‐1	   stem-­‐loop	  
sequence,	   was	   cloned	   into	   the	   miRNASelect™	   pEGP-­‐miR	   expression	   vector.	   An	   immortalized	  
human	   first	   trimester	   trophoblast	   cell	   line,	  HTR8/SVneo,	  was	  used	   to	  create	  stably	  expressing	  
clones	  through	  Puromycin	  selection.	  (B)	  MiR-­‐218-­‐5p	  was	  significantly	  increased	  (p<0.05)	  in	  the	  
Mir-­‐218-­‐1	  stable	  cells	  when	  normalized	  to	   the	  endogenous	  control,	  U6	  snRNA.	   (C)	  Over	   three	  
days,	  cells	  were	  counted	  and	  Mir-­‐218-­‐1	  overexpressing	  cells	  showed	  an	  overall	  decreased	  rate	  
of	  growth	  that	  was	  not	  explained	  by	  cell	  death.	  	  Stable	  Mir-­‐218-­‐1	  and	  control	  cells	  were	  seeded	  
in	   equal	   number	   under	   normal	   growing	   conditions.	  Multiple	   t-­‐tests	   (α=0.05)	  were	   performed	  
and	  corrected	  for	  multiple	  comparisons	  with	  the	  Holm-­‐Sidak	  method	  using	  Graphpad	  Prism.	  (D)	  
Morphological	   examination	   with	   bright	   field	   microscopy	   showed	   that	   Mir-­‐218-­‐1	   cells	   were	  
smaller	  and	  spindle	  shaped,	  growing	  with	   less	  cell-­‐cell	   contact	  compared	   to	   the	  empty	  vector	  
(EV)	   cells.	   Scale	   bar:	   200	   μm	   (E)	   Mir-­‐218-­‐1	   cells	   stained	   for	   acetylated-­‐alpha-­‐tubulin	   show	   a	  
more	   disorganized	   microtubule	   network	   and	   asymmetric	   organization.	   Scale	   bar:	   10	   μm	   (F)	  
When	   seeded	  on	  matrigel-­‐coated	  wells,	  mir-­‐218-­‐1	   cells	  displayed	  an	   increased	  ability	   to	  align	  
into	   network	   structures	   compared	   to	   the	   control	   cells.	   Scale	   bar:	   500	   μm.	   Data	   are	  
representative	  of	  three	  independent	  experiments.	  Error	  bars	  represent	  SEM.	  	  
	   	  

















Figure	  S	  2.1	  Mir-­‐218	  stable	  cell	  single	  colony	  screening.	  
First	  trimester	  trophoblast	  cell	  line,	  HTR8/SVneo,	  was	  stably	  transfected	  with	  empty	  vector	  (EV)	  
or	  mir-­‐218-­‐1	  stem-­‐loop	  construct.	  Single	  colonies	  were	  selected	  with	  Puromycin	  treatment	  for	  
two	  weeks.	  Mir-­‐218-­‐5p	  levels	  were	  quantified	  using	  hsa-­‐miR-­‐218	  TaqMan	  MicroRNA	  Assay.	  All	  
future	  experiments	  were	  performed	  on	  EV-­‐6	  and	  mir-­‐218-­‐1-­‐14	  clones.	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MiR-­‐218-­‐5p	  upregulated	  key	  markers	  of	  invasion	  and	  pseudovasuclarization	  
To	   determine	  which	   genes	   are	   regulated	  by	  mir-­‐218-­‐1,	   a	   cDNA	  microarray	  was	   performed	   to	  
identify	  differentially	  expressed	  genes	  between	  control	  and	  mir-­‐218-­‐1	  stable	  cells.	  Interestingly,	  
markers	   associated	   with	   trophoblast	   invasion	   and	   the	   enEVT	   pseudo-­‐vascularization	   process	  
that	   is	   needed	   for	   proper	   spiral	   artery	   remodeling	   were	   among	   the	   top	   upregulated	   genes	  
(Figure	  2.3A).	  To	  confirm	  these	  results,	  we	  assessed	  mRNA	  levels	  of	  several	  key	  markers	   from	  
the	  microarray	  using	  qRT-­‐PCR.	  Matrix	  Metallopeptidase-­‐1	  (MMP1),	  Integrin	  α	  1	  (ITGA1),	  Platelet	  
and	   Endothelial	   Cell	   Adhesion	   Molecule	   1	   (PECAM1),	   Vascular	   Endothelial	   Cadherin	   (VE-­‐
cadherin),	   Endothelial	   Cell-­‐Specific	   Chemotaxis	   Regulator	   (ECSCR),	   Interleukin-­‐8	   (IL8),	  
Interleukin-­‐1b	   (IL1b),	   and	   Chemokine	   C-­‐X-­‐C	   motif	   ligand	   1	   (CXCL1)	   were	   all	   significantly	  
upregulated	  in	  the	  mir-­‐218-­‐1	  overexpressing	  cells	  (Figure	  2.3B).	  Similar	  results	  were	  seen	  using	  
primary	  1st	  trimester	  EVT,	  collected	  via	  dissection	  of	  anchoring	  EVT	  cell	  columns	  (8-­‐10	  weeks),	  
and	  treated	  with	  control,	  miR-­‐218-­‐5p,	  or	  anti-­‐miR-­‐218-­‐5p	  oligomers,	  prior	  to	  processing	  for	  EVT	  
RNA.	  Compared	  to	  the	  non-­‐targeting	  control	  (NC),	  miR-­‐218-­‐5p	  oligomer	  treatment	  upregulated	  
MMP1,	  ITGA1,	  PECAM1,	  CHD5,	  IL8,	  and	  IL1b	  mRNA	  levels	  (Figure	  2.3C).	   In	  contrast,	  treatment	  
with	  anti-­‐miR-­‐218-­‐5p,	  downregulated	  these	  markers	  as	  compared	  to	  the	  anti-­‐scramble	  control	  













































Figure	  2.3	  Legend	  found	  on	  next	  page	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Figure	  2.3	  MiR-­‐218-­‐5p	  promotes	  key	  markers	  of	  trophoblast	  invasion	  and	  endovascular	  
differentiation.	  
	  (A)	  A	  gene	  expression	  analysis	  report	  was	  conducted	  at	  the	  Princess	  Margaret	  Genomics	  Centre	  
on	  control	  and	  mir-­‐218-­‐1	  overexpressing	  cells	  using	  the	  Human	  HT-­‐12	  V4	  BeadChip.	  Markers	  of	  
trophoblast	  differentiation	  were	  greatly	  upregulated	  in	  mir-­‐218-­‐1	  cells.	  (B)	  Several	  key	  markers	  
were	  validated	  with	  qRT-­‐PCR	  and	  the	  trend	  was	  consistent	  with	   initial	  microarray	   findings.	  All	  
markers	  were	  significantly	  upregulated	  in	  mir-­‐218-­‐1	  cells.	  Results	  represent	  three	  independent	  
trials.	   (C)	   First	   trimester	   placental	   tissues	   were	   dissected	   to	   enrich	   extravillous	   trophoblasts	  
(EVT)	  columns	  and	  treated	  with	  miR-­‐218-­‐5p	  or	  a	  scrambled	  non-­‐targeting	  control	  (NC)	  for	  48	  hrs	  
prior	   to	   RNA	   isolation.	   MiR-­‐218-­‐5p	   upregulated	   key	   markers	   of	   trophoblast	   differentiation.	  
Results	  represent	  six	  independent	  placentas.	  	  (D)	  Similar	  to	  C,	  tissues	  were	  incubated	  with	  anti-­‐
miR-­‐218-­‐5p	  for	  48	  hrs	  and	  assessed	  for	  marker	  mRNA	  levels.	  All	  markers	  were	  downregulated	  
by	   anti-­‐miR-­‐218-­‐5p	   compared	   to	   the	   scramble	   control.	   	   Transfection	   efficiency	  was	   validated	  
(top	  panel)	  by	  quantifying	  miR-­‐218-­‐5p	  levels.	  Results	  represent	  six	  independent	  tissue	  samples.	  
Statistical	  analysis	  was	  performed	  using	  (A)	  multiple	  t-­‐tests	  (α=0.05)	  and	  corrected	  for	  multiple	  
comparisons	  with	  the	  Holm-­‐Sidak	  method	  and	  (C	  and	  D)	  a	  two-­‐tailed	  paired	  t-­‐test	  (p<0.05,	  95%	  
CI)	  using	  Graphpad	  Prism.	  Error	  bars	  represent	  SEM.	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Secreted	   proteins	   in	   the	   conditioned	   media	   collected	   from	   control-­‐	   or	   miR-­‐218-­‐5p-­‐treated	  
explants	  were	  measured	  using	  a	  Bio-­‐Plex	  assay.	  The	  conditioned	  medium	  from	  the	  miR-­‐218-­‐5p	  
treatment	  group	   showed	  a	  marked	  upregulation	  of	  many	   secretory	  proteins	   important	   in	   the	  
establishment	   of	   the	   feto-­‐placental	   interface	   (Figure	   S2.2).	   In	   agreement	   with	   our	   earlier	  
findings	  both	  IL8	  and	  CXCL1	  were	  increased	  in	  the	  miR-­‐218-­‐5p	  conditioned	  media	  (Figure	  S2.2	  A	  
and	  B).	  Other	  secretory	  proteins	  enriched	  in	  our	  miR-­‐218-­‐5p	  treatment	  group	  were	  interleukin-­‐
6	  (IL6),	  chemokine	  C-­‐C	  motif	  ligand	  2	  (CCL2),	  chemokine	  C-­‐X-­‐C	  motif	  ligand	  16	  (CXCL16),	  C-­‐X3-­‐C	  
motif	   chemokine	   ligand	  1	   (CX3CL1),	   and	  macrophage	  migration	   inhibitory	   factor	   (MIF)	   (Figure	  
S2.2	  C-­‐G).	  	  
MiR-­‐218-­‐5p	  promoted	  first	  trimester	  trophoblast	  migration	  and	  invasion.	  
To	  assess	   the	  effect	  of	  miR-­‐218-­‐5p	  on	   the	   invasive	   function	  of	   first	   trimester	   trophoblasts	  we	  
transfected	   the	   parental	   HTR8/SVneo	   cell	   line	   with	   NC,	   miR-­‐218-­‐5p,	   or	   anti-­‐miR-­‐218-­‐5p	  
oligomers.	   Transfection	   of	  mir-­‐218-­‐5p	   significantly	   increased	   the	   number	   of	   trophoblast	   cells	  
that	   crossed	   the	  matrigel	   barriers	   compared	   to	   control	   (p<0.0001	   Figure	   2.4A	   left	   panel).	   In	  
contrast,	   anti-­‐miR-­‐218-­‐5p	   significantly	  decreased	   invasion	   (p<0.0005,	   Figure	  2.4A	   right	  panel).	  
As	  expected,	   the	  mir-­‐218-­‐1	  overexpressing	   cells	   also	  had	   significantly	  higher	   invasive	   capacity	  
compared	  to	  control,	  and	  this	  effect	  was	  reversed	  with	  transient	  anti-­‐miR-­‐218-­‐5p	  transfection	  
(p<0.0001,	  Figure	  2.4B).	  To	  confirm	  the	  miR-­‐218-­‐5p	  effect	  on	  invasion,	  we	  used	  a	  more	  recently	  
established	  immortalized	  first	  trimester	  trophoblast	  cell	  line,	  Swan71.	  As	  in	  the	  HTR8/SVneo,	  we	  
observed	  a	  marked	  upregulation	  of	  invasion	  in	  the	  miR-­‐218-­‐5p	  treated	  cells	  (Figure	  S2.3A).	  	  
	  


































Figure	  S	  2.2	  miR-­‐218-­‐5p	  upregulates	  the	  secretion	  of	  pro-­‐invasive	  pro-­‐angiogenic	  factors.	  
First	   trimester	  placenta	  was	  treated	  with	  negative	  control	  or	  miR-­‐218-­‐5p	  (200	  nM)	  for	  48	  hrs.	  
The	  condition	  media	  was	  collected	  and	  used	  to	  assess	  the	  abundance	  of	  secretory	  proteins	   in	  
the	  Bio-­‐Plex	  assay.	  Upregulation	  of	  (A)	   Interleukin-­‐8	  (IL8),	  (B)	  Chemokine	   ligand	  1	  (CXCL1),	  (C)	  
Interleukin-­‐6	  (IL6),	  (D)	  Chemokine	  C-­‐C	  motif	   ligand	  2	  (CCL2),	  (E)	  Chemokine	  C-­‐X-­‐C	  motif	   ligand	  
16	   (CXCL16)	   (F)	   C-­‐X3-­‐C	   motif	   chemokine	   ligand	   1	   (CX3CL1)	   and	   (G)	   Macrophage	   migration	  
Inhibitory	  Factor	  (MIF)	  were	  observed	  in	  conditioned	  media	  of	  miR-­‐218-­‐5p	  treated	  tissues.	  Error	  
bars	  represent	  SD.	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Figure	  2.4	  Legend	  found	  on	  next	  page	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Figure	  2.4	  MiR-­‐218-­‐5p	  promotes	  trophoblast	  invasion	  and	  EVT	  outgrowth.	  
(A)	  Parental	  HTR8/SVneo	  cells	  were	  transfected	  with	  miR-­‐218-­‐5p	  (100	  nM)	  or	  control	  (NC,	   left	  
panel),	  anti-­‐miR-­‐218-­‐5p	  (100	  nM)	  or	  control	  (a-­‐NC,	  right	  panel)	  and	  seeded	  on	  matrigel-­‐coated	  
membranes.	  MiR-­‐218-­‐5p	  significantly	   increased	  (p<0.0001),	  while	  anti-­‐miR-­‐218-­‐5p	  significantly	  
decreased	   (p<0.0005)	   the	   invasive	   ability	   of	   these	   cells.	   Results	   represent	   six	   (left	   panel)	   and	  
three	  (right	  panel)	  independent	  experiments.	  (B)	  Mir-­‐218-­‐1	  stable	  cells	  were	  used	  in	  a	  matrigel	  
invasion	  assay	  as	  in	  A	  and	  were	  found	  to	  significantly	  increase	  (p<0.0001)	  their	  invasive	  ability.	  
Transient	  anti-­‐miR-­‐218-­‐5p	  transfection	  completely	  reversed	  this	  effect.	  A	  representative	  graph	  
is	  shown	  from	  three	  independent	  experiments.	  (C)	  Explants	  from	  first	  trimester	  placenta	  were	  
placed	  on	  matrigel	   and	   treated	  with	  miR-­‐218-­‐5p	  or	   control	   (200	  nM)	   for	  24h.	   EVT	  outgrowth	  
was	   measured	   in	   ImageJ	   at	   treatment	   time	   (0	   hr)	   and	   termination	   of	   experiment	   (24	   hr).	  
Difference	  of	  EVT	  outgrowth	  was	  calculated	   relative	   to	  0	  hr.	  A	   significant	   increase	   (p<0.05)	   in	  
EVT	  outgrowth	  was	  observed	  in	  miR-­‐218-­‐5p	  treated	  tissues.	  Results	  represent	  four	  independent	  
tissues	  with	  each	  experiment	  having	  a	  minimum	  of	  N=	  4	   replicates.	  A	   representative	   image	   is	  
shown.	  (D)	  Similar	  to	  C,	  tissues	  were	  treated	  with	  anti-­‐miR-­‐218-­‐5p	  or	  the	  control	  (200	  nM)	  for	  
48	   hrs.	   A	   significant	   decrease	   (p<0.05)	   in	   EVT	   outgrowth	  was	   observed	  with	   anti-­‐miR-­‐218-­‐5p	  
treatment.	   Results	   represent	   three	   independent	   tissues,	   with	   each	   experiment	   having	   a	  
minimum	  of	  N=	  4	  replicates.	  A	  representative	   image	   is	  shown.	  Statistical	  analysis	   for	   (A,	  C,	  D)	  
using	  a	  two-­‐tailed	  unpaired	  t-­‐test	  (p<0.05,	  95%	  CI)	  and	  (B)	  a	  one-­‐way	  ANOVA	  with	  a	  Dunnett's	  
multiple	   comparisons	   test	   (p<0.05,	   95%	   CI)	   using	  GraphPad	   Prism	  was	   performed.	   Error	   bars	  
represent	  SEM.	  Scale	  bars:	  500	  μM.	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Figure	  S	  2.3	  miR-­‐218-­‐5p	  has	  anti-­‐invasive	  effect	  in	  cancer	  cells.	  
	  (A)	  A	  first	  trimester	  immortalized	  cell	  line,	  Swan71,	  was	  transfected	  with	  miR-­‐218-­‐5p	  (100	  nM)	  
and	   seeded	   on	  matrigel-­‐coated	   transwells.	  Mir-­‐218-­‐5p	   had	   a	   greater	   number	   of	   cells	   invade	  
over	  24	  hrs	  compared	  to	  control	  (B)	  miR-­‐218-­‐5p	  was	  transfected	  into	  ovarian	  cancer	  cells,	  ES2,	  
and	   seeded	   on	  matrigel	   coated	   transwells.	  MiR-­‐218-­‐5p	   downregulated	   the	   invasive	   ability	   of	  
these	  cancer	  cells.	  Error	  bars	  represent	  SEM.	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MiR-­‐218-­‐5p	  has	  been	   reported	   to	   inhibit	   cancer	  cell	   invasion	   151,153,286,	  we	   therefore	   repeated	  
the	  matrigel	  transwell	  invasion	  assay	  in	  an	  ovarian	  cancer	  cell	  line,	  ES2.	  We	  found	  that	  similar	  to	  
studies	   on	   other	   cancer	   cells,	  miR-­‐218-­‐5p	   had	   the	   opposite	   effect	   in	   cancer	   cells,	   decreasing	  
invasion	  compared	  to	  control	  (Figure	  S2.3B).	  	  
	  
Uncoated	  transwells	  were	  used	  to	  assess	  the	  migratory	  ability	  of	  HTR8/SVneo	  transfected	  with	  
control	  or	  miR-­‐218-­‐5p	  oligomers.	  MiR-­‐218-­‐5p	  significantly	  upregulated	  (p<0.05)	  the	  number	  of	  
migrated	   cells	   across	   the	   transwell	   membrane	   compared	   to	   control	   (Figure	   S2.4A).	   Similarly,	  
Mir-­‐218-­‐1	   stable	   cells	   significantly	   increased	   the	   migratory	   ability	   of	   the	   trophoblast	   cells	  
(p<0.0005)	   (Figure	   S2.4B).	   	   Transient	   transfection	   with	   anti-­‐miR-­‐218-­‐5p	   significantly	  
downregulated	  (p<0.05)	  the	  number	  of	  migrated	  cells	  (Figure	  S2.4C).	  To	  investigate	  the	  invasive	  
and	  migratory	   effect	   of	  miR-­‐218-­‐5p	   further,	   we	   used	   a	   first	   trimester	   EVT	   outgrowth	  model.	  
Established	   EVT	   outgrowths	   were	   treated	   with	   control,	   miR-­‐218-­‐5p	   or	   anti-­‐miR-­‐218-­‐5p	  
oligomers.	  We	   found	   that	   miR-­‐218-­‐5p	   significantly	   promoted	   (p<0.05)	   the	   outgrowth	   of	   EVT	  
columns	  as	  quantified	  by	  outgrowth	  area,	  while	  anti-­‐miR-­‐218-­‐5p	  significantly	  impeded	  (p<0.05)	  
this	  process	  (Figure	  2.4C	  and	  D,	  respectively).	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Figure	  S	  2.4	  miR-­‐218-­‐5p	  promotes	  migration	  in	  first	  trimester	  trophoblast	  cells.	  
	  (A)	   NC	   or	   miR-­‐218-­‐5p	   (100	   nM)	   were	   transfected	   into	   HTR8/SVneo	   cells	   and	   seeded	   on	  
uncoated	   transwells.	   MiR-­‐218-­‐5p	   significantly	   upregulated	   (p<0.05)	   the	   number	   of	   migrated	  
cells	   compared	   to	   the	   scramble	   control.	   (B)	   Mir-­‐218-­‐1	   stable	   cells	   seeded	   on	   uncoated	  
transwells	  showed	  a	  significant	  increase	  (p<0.0005)	  in	  cell	  migration	  compared	  to	  control	  cells.	  
(C)	   HTR8/SVneo	   cells	   transfected	   with	   anti-­‐miR-­‐218-­‐5p	   showed	   a	   significant	   downregulation	  
(p<0.05)	  of	  migration	  compared	  to	  the	  control.	  	  
Error	  bars	  represent	  SEM.	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MiR-­‐218-­‐5p	  accelerates	  spiral	  arteriole	  remodeling.	  	  
As	  EVT	  invade	  and	  reline	  the	  uterine	  spiral	  arteries	  they	  acquire	  endothelial-­‐like	  properties.	  An	  
established	  three-­‐dimensional	  dual	  cell	   co-­‐culture	  assay	  was	  used	  to	  assess	   the	  effect	  of	  miR-­‐
218-­‐5p	  on	  trophoblast	  ability	  to	  interact	  with	  endothelial	  cells.	  Specifically,	  control	  or	  mir-­‐218-­‐1	  
stable	  trophoblast	  cells	  were	  co-­‐cultured	  on	  matrigel	  in	  a	  one-­‐to-­‐one	  ration	  with	  freshly	  isolated	  
human	   umbilical	   vein	   endothelial	   cells	   (HUVEC).	   In	   order	   to	   differentiate	   the	   two	   cell	   types,	  
staining	   with	   cell	   tracker	   green	   and	   red	   dye,	   respectively,	   was	   done	   prior	   to	   seeding.	   As	  
expected,	   both	   control	   and	   mir-­‐218-­‐1	   trophoblast	   cells	   co-­‐localized	   with	   HUVEC.	   Mir-­‐218-­‐1-­‐
HUVEC	   co-­‐culture,	   however,	   had	   a	   more	   complex	   network	   and	   overall	   larger	   total	   network	  
length	   (Figure	   S2.5B).	   Interestingly,	   in	   co-­‐culture	   with	   control	   cells,	   HUVEC	   formed	   intact	  
networks.	   However,	   in	   co-­‐culture	   with	  mir-­‐218-­‐1-­‐overexpressing	   cells,	   trophoblasts	   displaced	  
the	   HUVEC	   to	   form	   the	   network	   branches,	   suggesting	   that	   the	   mir-­‐218-­‐1	   enhances	   the	  
integration	  of	  trophoblasts	   into	  the	  endothelial	  network	  (Figure	  S2.5C).	  To	  confirm	  the	  overall	  
push	   into	   enEVT	   differentiation	   by	   miR-­‐218-­‐5p,	   we	   used	   a	   novel	   tissue	  ex	   vivo	   model	   of	  
trophoblast-­‐mediated	   decidual	   blood	   vessel	   remodeling.	   First	   trimester	   (9-­‐10	   week)	   placenta	  
and	   decidua	   paretalis	   from	   the	   same	   patients	   were	   used.	   Placental	   explants	   with	   intact	   EVT	  
columns	  were	  pre-­‐incubated	  with	  control	  or	  miR-­‐218-­‐5p	  oligomers	  prior	  to	  placement	  onto	  the	  
decidua	   epithelial	   surface	   (Figure	   S2.6).	   	   All	   decidual	   tissue	   used	   was	   negative	   for	   the	  
cytotrophoblast	  (epithelial)	  marker	  cytokeratin-­‐7	  (CK-­‐7)	  and	  histocompatibility	  antigen,	  class	  I,	  G	  
(HLA-­‐G)	  (Figure	  2.5	  A	  and	  B,	  black	  arrows)	  confirming	  no	  prior	  in	  utero	  invasion.	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Figure	  S	  2.5	  Mir-­‐218	  promotes	  network	  formation	  and	  endothelial	  replacement.	  
(A)	   To	  verify	   the	   specificity	  of	   stains,	  HUVEC	  were	   stained	  with	  CellTracker™	  Red	  CMTPX	  and	  
photos	  were	  taken	  with	  blue	   filter	   (left	  panel)	  or	  green	  filter	   (right	  panel).	   (B)	  Control	  or	  Mir-­‐
218-­‐1	  stable	  trophoblasts	  were	  pre-­‐stained	  green	  and	  seeded	  on	  matrigel	  in	  a	  one-­‐to-­‐one	  ratio	  
with	  human	  umbilical	  vein	  endothelial	  cells	  (HUVEC)	  pre-­‐stained	  red.	  Cells	  were	  allowed	  to	  co-­‐
localize	  and	  form	  networks	  for	  24	  hrs	  prior	  to	  imaging.	  Mir-­‐218-­‐1	  trophoblast-­‐HUVEC	  co-­‐culture	  
showed	   a	   more	   complex	   network	   with	   an	   overall	   larger	   total	   length.	   (C)	   In	   co-­‐culture	   with	  
control	   cells,	   HUVEC	   formed	   intact	   networks.	   	   However,	   in	   co-­‐culture	   with	   mir-­‐218-­‐1-­‐
overexpressing	   cells,	   trophoblasts	   displaced	   the	   HUVEC	   to	   form	   the	   branches	   (white	   arrow	  
heads),	   suggesting	   that	   the	   mir-­‐218-­‐1	   enhances	   the	   integration	   of	   trophoblasts	   into	   the	  






















Figure	  S	  2.6	  In	  vitro	  model	  of	  decidua	  spiral	  artery	  remodeling.	  
Labeled	  representative	  image	  of	  the	  in	  vitro	  model	  used	  for	  first	  trimester	  placenta-­‐decidua	  co-­‐
culture.	  Scale	  bars:	  500	  μM.	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Figure	  2.5	  Legend	  found	  on	  next	  page	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Figure	  2.5	  MiR-­‐218-­‐5p	  accelerates	  spiral	  artery	  remodeling.	  
(A-­‐E)	  Decidua	  parietalis	  was	  assessed	  for	  in	  utero	  trophoblast	  remodeling.	  	  Tissue	  was	  negative	  
for	   Cytokeratin-­‐7	   (CK-­‐7)	   and	   histocompatibility	   antigen,	   class	   I,	   G	   (HLA-­‐G)	   (A	   and	   B,	   black	  
arrows).	   Tight,	   non-­‐invaded	   arterioles	   stained	   positive	   for	   smooth	   muscle	   actin	   (SMA)	   and	  
Platelet	   and	   Endothelial	   Cell	   Adhesion	   Molecule	   1	   (PECAM1)	   (C	   and	   D,	   black	   arrows).	  
Lymphocyte	  common	  antigen,	  CD45,	  was	  spread	  evenly	  throughout	  the	  tissue	  (E).	  (F-­‐J)	  Placenta	  
tissue	  pre-­‐treated	  with	   scrambled	   sequence	  was	  assessed	   for	  degree	  of	   vessel	   remodeling.	   (F	  
and	   G)	   EVT	   cells	   positive	   for	   CK-­‐7	   and	   HLA-­‐G	   (black	   asterisk)	   entered	   the	   proximal	   arteriole	  
(black	   arrows).	   (H)	  Distal	   portion	   of	   the	   spiral	   arteriole	   stained	   positive	   for	   an	   intact	   smooth	  
muscle	  layer,	  (black	  arrow).	  (I)	  Black	  arrows	  point	  to	  intact	  endothelial	  cells	  stained	  positive	  for	  
PECAM1.	   (J)	  CD45	  positive,	   Leukocyte	   recruitment	   at	   site	   of	   remodeling	   is	   indicated	  by	   black	  
arrows.	   (K-­‐O)	   Placenta	   tissue	   pre-­‐treated	  with	  miR-­‐218-­‐5p	  was	   assessed	   for	   degree	   of	   vessel	  
remodeling.	  (K	  and	  L)	  CK7	  and	  HLA-­‐G	  positive	  EVT	  (black	  asterisk)	  entered	  the	  distal	  portion	  of	  
the	   arteriole	   (black	   arrows).	   (M)	   Several	   cells	   positive	   for	   SMA	   (black	   arrows)	   remain	   at	   the	  
distal	   portion	   of	   the	   arteriole.	   (N)	   PECAM1	   positive	   endothelial	   cells	   (black	   arrow)	   remain	   at	  
distal	  portion	  of	  arteriole.	  EVT	  are	  weakly	  positive	   for	  PECAM1	   in	   the	  placenta	  column	  and	  at	  
the	   site	   of	   remodeling	   (black	   asterisk).	   (O)	   Abundant	   recruitment	   of	   leukocytes	   at	   site	   of	  
remodeling	   (black	   arrows)	   and	   clearing	   of	   leukocytes	   from	   surrounding	   tissue	  was	   observed.	  
Similar	   trend	   is	   observed	   in	   three	   unique	   tissue	   samples,	   where	   representative	   images	   are	  
shown.	  Scale	  bar:	  100	  μM	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As	  expected,	  we	  observed	  many	   intact	  tight,	  un-­‐remodeled	  arterioles	  that	  stained	  positive	  for	  
the	   smooth	   muscle	   marker,	   smooth	   muscle	   actin	   (SMA),	   and	   the	   endothelial	   cell	   marker,	  
PECAM1	  (Figure	  2.5	  C	  and	  D,	  black	  arrows).	  As	  expected	  in	  non-­‐invaded	  tissues,	  the	  leukocytes	  
that	  stained	  for	  lymphocyte	  common	  antigen	  (CD45)	  were	  spread	  evenly	  throughout	  the	  tissue	  
and	  were	  not	   found	   to	  be	  associated	  with	  any	  observed	  vessels	   (Figure	  2.5E).	  Placenta	   tissue	  
pre-­‐treated	  with	  NC	  had	  a	  large	  EVT	  invasive	  column,	  as	  shown	  by	  the	  CK-­‐7	  and	  HLA-­‐G	  positive	  
staining	  (Figure	  2.5F	  and	  G,	  asterisk).	  EVT	  cells	  are	  seen	  entering	  the	  lumen	  of	  a	  cross-­‐sectioned	  
arteriole	  at	  the	  proximal	  end	  (Figure	  2.5F	  and	  G,	  black	  arrow).	  As	  shown	  by	  SMA	  and	  PECAM1	  
staining,	   the	   distal	   portion	   of	   the	   arteriole	   is	   still	   intact	   and	   un-­‐invaded	   by	   the	   trophoblasts	  
(Figure	   2.5	   I	   and	   J,	   black	   arrows).	   Surrounding	   CD45	   positive	   leukocytes	   were	   found	   to	   be	  
associated	  with	  the	  vessel	  throughout	  the	  entire	  observable	  length	  (Figure	  2.5J,	  black	  arrows).	  
Placenta	   pre-­‐treated	   with	   miR-­‐218-­‐5p	   showed	   an	   accelerated	   process	   of	   vessel	   remodeling	  
compared	   to	   the	   scramble	   control.	   The	   placenta	   of	  miR-­‐218-­‐5p,	   like	   the	   control,	   had	  healthy	  
large	   EVT	   columns	   positive	   for	   both	   CK-­‐7	   and	   HLA-­‐G	   (Figure	   2.5	   K	   and	   L,	   asterisk).	   The	   CK-­‐7	  
positive	   cells	   entered	   the	   proximal	   portion	   of	   the	   vessel	   and	   had	   invaded	   to	   the	   end	   of	   the	  
observable	  vessel,	  where	  they	  were	  seen	   lining	   the	  walls	  and	   interacting	   in	   the	   lumen	  (Figure	  
2.5K,	   black	   arrows).	   The	   HLA-­‐G	  marker	  was	   lightly	   positive	   in	   the	   deep	   invaded	   trophoblasts	  
(Figure	   2.5L,	   black	   arrow).	   Staining	   for	   smooth	   muscle	   cells	   showed	   that	   nearly	   all	   were	  
removed	   during	   remodeling	   (Figure	   2.5M,	   black	   arrows).	   Likewise,	   endothelial	   cell	   marker	  
PECAM1	   was	   only	   observed	   on	   a	   few	   cells	   in	   the	   vessels	   (Figure	   2.5N,	   black	   arrows).	  
Interestingly,	   the	   EVT	   in	   the	   distal	   portion	   of	   the	   vessel	   were	   weakly	   stained	   for	   the	  
endovascular	   marker,	   PECAM1	   (Figure	   2.5N,	   asterisk).	   Similar	   to	   the	   control	   tissue,	   in	   the	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miR218-­‐5p	   cocultures	   the	   leukocyte	   recruitment	   to	   the	   site	   of	   vascular	   remodeling	   was	  
observed,	  however	  higher	  numbers	  of	  leukocytes	  were	  directly	  associated	  with	  the	  wall	  and	  in	  
the	  lumen	  with	  the	  transformed	  vessel	  (Figure	  2.5O,	  black	  arrows).	  	  
	  
Mir-­‐218-­‐5p	  promotes	  trophoblast	  invasion	  and	  differentiation	  into	  enEVT	  though	  suppression	  
of	  TGFβ2	  signaling.	  	  
	  
For	  this	  study,	  we	  used	  the	  miRanda	  algorithm	  that	  calculates	  a	  prediction	  score	  based	  on	  3’UTR	  
complementarity,	   position	   within	   the	   3’UTR,	   energy	   of	   formed	   duplex,	   and	   the	   evolutionary	  
conservation	   of	   the	   target.	   Based	   on	   these	   parameters,	   a	   good	   score	   (miRSVR:-­‐0.7857)	   was	  
assigned	   to	   the	   seeding	   region	  within	   the	   TGFβ2	   3’UTR	   (Figure	   2.6A,	   top	   panel).	   In	   order	   to	  
confirm	  miR-­‐218-­‐5p	  binding,	  we	   constructed	  a	   luciferase	   reporter	  by	   cloning	  a	  portion	  of	   the	  
TGFβ2	  3’UTR	  bracketing	   the	  miR-­‐218-­‐5p	  seeding	   region	  downstream	  of	   the	   luciferase	  gene	   in	  
the	   pMir-­‐Report	  miRNA	   expression	   reporter	   vector	   (Figure	   2.6A,	   bottom	   panel).	   	   Preliminary	  
findings	   suggest	   that	  miR-­‐218-­‐5p	   transient	   transfection	   significantly	  downregulated	   Luciferase	  
activity	   compared	   to	   cell	   transfected	   with	   the	   non-­‐targeting	   control,	   while	   no	   change	   was	  
observed	  in	  the	  empty	  vector-­‐transfected	  cells	  (p<0.5,	  Figure	  2.6	  B).	  Mir-­‐218-­‐1	  overexpressing	  
cells	  significant	  downregulated	  expression	  of	  TGFβ2	  mRNA	  and	  secretion	  of	  TGFβ2	  compared	  to	  
control	  cells	   (p<0.05,	  Figure	  2.6C	  and	  D).	  Treatment	  of	  parental	  HTR8/SVneo	  trophoblast	  cells	  
with	   recombinant	   human	   TGFβ2	   significantly	   decreased	   (p<0.05)	   differentiation	   markers	   VE-­‐
cadherin,	   MMP1,	   IL1b	   and	   IL8	   while	   PECAM1	   was	   unaffected	   (Figure	   2.6E).	   Treatment	   with	  
recombinant	  human	  TGFβ2	  also	  significantly	  decreased	  (p<0.001)	  invasion	  of	  HTR8/SVneo	  cells	  
across	  the	  matrigel-­‐coated	  membrane	  (Figure	  2.6F).	  	  
	  




Figure	  2.6	  Legend	  found	  on	  next	  page	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Figure	  2.6	  MiR-­‐218-­‐5p	  predicted	  target,	  TGF-­‐β2,	  suppresses	  EVT	  invasion	  and	  enEVT	  
differentiation.	  
(A)	  miRNA	  target	  prediction	  algorithm,	  	  MiRanda,	  shows	  a	  notable	  miRSVR	  score	  (<-­‐0.1)	  for	  miR-­‐
218-­‐5p	  and	  TGFβ2	  mRNA	  (top	  panel).	  A	  portion	  of	  the	  TGFβ2	  mRNA	  containing	  the	  miR-­‐218-­‐5p	  
seeding	  region	  was	  cloned	  into	  the	  pMIR-­‐REPORT™	  miRNA	  Expression	  Reporter,	  downstream	  of	  
the	   Luciferase	   gene.	   (B)	   Transient	   transfection	   of	   miR-­‐218-­‐5p	   significantly	   downregulated	  
(p<0.05)	   Luciferase	   activity	   through	   the	   TGFβ2	   3’UTR	   compared	   to	   control	   cells.	   A	  
representative	  experiment	  is	  shown.	  (C)	  TGFβ2	  mRNA	  is	  significantly	  downregulated	  (p<0.05)	  in	  
Mir-­‐218-­‐1	  cells	  compared	  to	  the	  control.	  Results	  represent	  three	  independent	  experiments.	  (D)	  
ELISA	   quantification	   of	   TGFβ2	   showed	   a	   significant	   downregulation	   in	   mir-­‐218-­‐1	   stable	   cells	  
compared	   to	   EV.	   (E)	   Parental	   HTR8/SVneo	   cells	   treated	  with	   recombinant	   human	   TGFβ2	   (10	  
ng/mL)	   significantly	   downregulated	   key	   markers	   of	   invasion	   and	   endovascular	   EVT	  
differentiation.	   Results	   represent	   six	   independent	   experiments.	   (F)	   Cells	   pre-­‐treated	   with	  
recombinant	  human	  TGFβ2	   (10	  ng/mL)	   invaded	   the	  matrigel	   covered	  membranes	  significantly	  
less	   (p<0.001)	   than	   vehicle	   treated	   control	   cells.	   Results	   represent	   four	   independent	  
experiments.	   (G)	   siTGFβ2	   significantly	   suppressed	   (p<0.0001)	   TGFβ2	   mRNA	   level	   and	  
significantly	  increased	  (p<0.05)	  HTR8/SVneo	  cell	  invasion.	  Results	  represent	  three	  independent	  
experiments.	  (H)	  Tissues	  were	  treated	  with	  siTGFβ2	  or	  the	  non-­‐targeting	  control	   (200	  μM)	  for	  
24	  hrs.	  A	  significant	  increase	  (p<0.01)	  in	  EVT	  outgrowth	  was	  observed	  with	  siTGFβ2	  treatment.	  
Results	   represent	   four	   independent	   tissues,	  with	  each	  experiment	  having	  a	  minimum	  of	  N=	  4	  
replicates.	  Scale	  bars:	  500	  μM.	  (I)	  Cells	  pre-­‐treated	  with	  recombinant	  human	  TGFβ2	  (10	  ng/mL)	  
showed	   a	   significantly	   decreased	   (p<0.001)	   ability	   to	   form	   network	   structures	   on	   matrigel	  
compared	   to	   the	   vehicle	   treated	   control.	   Scale	   bar:	   500	   μM.	   Results	   represent	   three	  
independent	   experiments.	   A	   two-­‐tailed	   unpaired	   t-­‐test	   (p<0.05,	   95%	   CI)	   (	   for	   C,D	   F-­‐I)	   or	   a	  
multiple	  t-­‐tests	  (α=0.05)	  corrected	  for	  multiple	  comparisons	  with	  the	  Holm-­‐Sidak	  method	  (for	  B	  
and	  E)	  was	  performed,	  using	  Graphpad	  Prism.	  Error	  bars	  represent	  SEM.	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Conversely,	  transfection	  with	  validated	  siTGFβ2	  siRNA	  resulted	  in	  a	  significant	  increase	  (p<0.05)	  
in	  invasion	  compared	  to	  scrambled	  control	  (Figure	  2.6G).	  
	  
While	   first	   trimester	   EVT	   outgrowths	   mimicked	   the	   miR-­‐218-­‐5p	   phenotype,	   significantly	  
increasing	  (p<0.01)	  the	  EVT	  outgrowth	  area	  in	  response	  to	  siTGFβ2	  siRNA	  (Figure	  2.6H).	  Lastly	  in	  
the	   in	   vitro	   endothelial-­‐like	  network	   formation	  assay,	   recombinant	  human	  TGFβ2	   significantly	  
decreased	  (p<0.001)	  total	  network	  length	  and	  overall	  network	  size	  in	  the	  parental	  HTR8/SVneo	  
cell	   line	   (Figure	   2.6I).	  Healthy	  placenta	   tissues	   collected	   from	   the	  Mount	   Sinai	   Bio	  Bank	  were	  
randomly	   selected	   based	   on	   gestational	   age	   to	   represent	   a	   spectrum	   across	   the	   entire	  
gestational	  period.	  Findings,	  based	  on	  a	  small	  sample	  size,	  showed	  that	  mature	  TGFβ2	  protein	  
was	   expressed	   in	   placenta	   tissues	   throughout	   pregnancy	   (Figure	   S2.7).	   To	   substantiate	   our	  
findings,	   we	   turned	   to	   the	   mir-­‐218-­‐1	   stable	   cell	   model	   to	   rescue	   the	   miR-­‐218-­‐5p	   effect	   by	  
reintroducing	   TGFβ2	   without	   the	   3’UTR	   regulatory	   region.	   For	   this	   purpose,	   we	   used	   the	  
recombinant	   human	   TGFβ2	   protein.	   As	   observed	   in	   the	   parental	   cells,	   TGFβ2	   treatment	  
significantly	  suppressed	  (p<0.05)	  VE-­‐cadherin,	  MMP1,	   IL1b,	  and	  IL8	  mRNA	  levels,	  compared	  to	  
mir-­‐218-­‐1	  treated	  with	  vehicle	  only	  (Figure	  2.7A).	  	  Mir-­‐218-­‐1	  cells	  treated	  with	  TGFβ2	  reversed	  
the	   pro-­‐invasive	   phenotype	   observed	   in	   control	   mir-­‐218-­‐1	   cells	   (Figure	   2.7B).	   As	   previously	  
reported,	  mir-­‐218-­‐1	  cells	  seeded	  on	  matrigel	  formed	  a	  network	  with	  significantly	  larger	  (p<0.05)	  
total	  length	  compared	  to	  control	  cells.	  This	  effect	  was	  lost	  after	  TGFβ2	  treatment	  (Figure	  2.7C).	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Figure	  S	  2.7	  Placental	  TGFβ2	  expression	  across	  gestation.	  
Healthy	   snap	   frozen	   placenta	   tissues	   collected	   from	   the	   Mount	   Sinai	   Bio	   Bank	   were	  
homogenized	  in	  RIPA	  protein	  lysis	  buffer	  and	  loaded	  in	  equal	  quantities	  on	  a	  15%	  SDS-­‐PAGE	  gel.	  
Probing	   for	   TGFβ2	   showed	   a	   variable	   expression	   of	   the	   mature	   protein	   across	   gestation.	  
Recombinant	  human	  TGFβ2	  protein	  was	  loaded	  on	  a	  separate	  gel	  as	  a	  positive	  antibody	  control.	  
GAPDH	  was	   used	   as	   a	   loading	   control.	   Relative	   Protein	   Density	   was	  measured	   using	   the	   Gel	  
Analyzer	  plugin	  in	  ImageJ,	  relative	  to	  GAPDH.	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Figure	  2.7	  MiR-­‐218-­‐5p	  exerts	  its	  effect	  through	  the	  suppression	  of	  TGF-­‐β2.	  
(A)	  EV	  control	  and	  mir-­‐218-­‐1	  overexpressing	  stable	  cells	  were	  treated	  with	  recombinant	  human	  
TGFβ2	   (10	   ng/mL).	   TGFβ2	   treatment	   significantly	   decreased	   key	   trophoblast	   differentiation	  
markers	  in	  both	  EV	  and	  mir-­‐218-­‐1	  cells.	  Results	  represent	  three	  independent	  experiments.	  	  (B)	  
Recombinant	  human	  TGFβ2	  (10	  ng/mL)	  treated	  stable	  mir-­‐218-­‐1	  cells	  reversed	  the	  pro-­‐invasive	  
effect.	   A	   representative	   experiment	   is	   shown.	   (C)	   Recombinant	   human	   TGFβ2	   (10	   ng/mL)	  
treated	  stable	  mir-­‐218-­‐1	  cells	  significantly	  reversed	  (p<0.05)	  the	  network	  forming	  ability	  of	  the	  
cells	  on	  matrigel.	  A	  representative	  experiment	  is	  shown.	  Two-­‐way	  ANOVA	  with	  Tukey’s	  multiple	  
comparison	   test	   (p<0.05,	   95%	   CI)	   was	   performed	   using	   Graphpad	   Prism.	   Scale	   bar:	   500	   μM.	  
Error	  bars	  represent	  SEM.	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It	   is	   important	   to	   note	   that	   in	   addition	   to	   TGFβ2,	   our	   microarray	   data	   indicated	   that	   other	  
signaling	  molecules	  of	  the	  TGFβ	  pathway	  were	  also	  downregulated	  (Figure	  S2.8A).	  To	  verify	  the	  
overall	  effect	  of	  miR-­‐218-­‐5p	  on	  TGFβ	  signaling,	  we	  used	  the	  activin	  response	  element	  reporter,	  
pAR3-­‐Lux,	   co-­‐transfected	   with	   FAST-­‐2.	   Both	   miR-­‐218-­‐5p	   transient	   and	   mir-­‐218-­‐1	   stable	   first	  
trimester	   trophoblast	   cell	   lines	   showed	   a	   downregulation	   of	   TGFβ	   signaling	   (Figure	   S2.8B).	  
Interestingly,	   treatment	   with	   recombinant	   human	   TGFβ2	   was	   only	   partially	   able	   to	   rescue	  
suppression	  by	  mir-­‐218-­‐1	  (Figure	  S2.8C).	  As	  indicated	  by	  our	  microarray	  findings,	  Smad2	  protein	  
was	   downregulated	   in	   both	   miR-­‐218-­‐5p	   transient	   and	   Mir-­‐218-­‐1	   stable	   overexpressing	   cells	  
(Figure	   S2.8D).	   To	   test	   if	   suppression	   of	   Smad2	   is	   involved	   in	   miR-­‐218-­‐5p	   action,	   we	   co-­‐
transfected	  anti-­‐miR-­‐218-­‐5p	  and	  siSmad2	  into	  parental	  HTR8/SVneo	  trophoblast	  cells.	  SiSmad2	  
siRNA	   mimicked	   both	   the	   pro-­‐invasive	   and	   pro-­‐angiogenic	   phenotype	   of	   miR-­‐218-­‐5p.	  
Furthermore,	   co-­‐transfection	   of	   siSmad2	   reversed	   the	   inhibitory	   effect	   of	   anti-­‐miR-­‐218-­‐5p	   in	  
both	  invasion	  (Figure	  S2.8E)	  and	  network	  formation	  (Figure	  S2.8F).	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Figure	  S	  2.8	  miR-­‐218-­‐5p	  suppresses	  TGFβ2	  signaling	  components.	  
(A)	   Microarray	   finding	   shows	   an	   overall	   downregulation	   of	   several	   TGFβ	   ligands	   and	  
downstream	  signaling	  molecules	  (SMADs).	  (B)	  A	  TGFβ	  response	  reporter,	  PAR3-­‐Lux,	  was	  used	  to	  
measure	   activity	   of	   the	   TGFβ	   pathway.	   Both	   transient	   miR-­‐218-­‐5p	   and	   stable	   Mir-­‐218-­‐1	  
overexpression	  downregulated	  TGFβ	  signaling	  in	  first	  trimester	  trophoblast	  cells.	  (C)	  Treatment	  
with	  recombinant	  human	  TGFβ2	  protein	  only	  partially	  reversed	  the	  suppressed	  TGFβ	  signaling.	  
(D)	  Total	  Smad2	  protein	  level	  was	  decreased	  by	  both	  miR-­‐218-­‐5p	  transient	  and	  Mir-­‐218-­‐1	  stable	  
overexpression	  in	  HTR8/Svneo	  cells.	  Transfection	  with	  anti-­‐miR-­‐218-­‐5p	  and	  siSmad2	  siRNA	  was	  
able	  to	  rescue	  the	  anti	  invasive	  (E)	  and	  anti-­‐angiogenic	  (F)	  effect	  of	  anti-­‐miR-­‐218-­‐5p.	  Statistical	  
analysis	   for	   (B)	   using	   a	   two-­‐tailed	   unpaired	   t-­‐test	   (p<0.05,	   95%	   CI)	   and	   (C	   and	   D)	   a	   one-­‐way	  
ANOVA	  with	   a	   Tukey's	  multiple	   comparisons	   test	   (p<0.05,	   95%	  CI)	   using	  GraphPad	  Prism	  was	  
performed.	  Scale	  bar:	  500	  μM.	  Error	  bars	  represent	  SEM.	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DISCUSSION	  
	  
The	   precise	   mechanisms	   underlying	   the	   development	   of	   preeclampsia	   (PE)	   are	   still	   illusive.	  
While	   it	   is	  clear	  there	  is	  a	  complex	  interplay	  of	  both	  placental	  and	  maternal	  factors,	  there	  is	  a	  
consensus	   that	   a	   disruption	   in	   the	   invasive	   trophoblast	   pathway	   is	   part	   of	   the	   etiology.	  
Histological	  studies	  of	  PE	  tissues	  have	  consistently	  shown	  superficial	  cytotrophoblast	   invasion,	  
absence	   of	   the	   epithelial-­‐to-­‐endovascular	   switch,	   and	   consequent	   insufficient	   remodeling	   of	  
maternal	  spiral	  arteries	  287-­‐289.	  The	  process	  of	  vascular	  mimicry	  that	  takes	  place	  in	  first	  trimester	  
trophoblasts	   has	   not	   been	   well	   studied.	   In	   this	   study,	   we	   demonstrate	   that	   miR-­‐218-­‐5p,	  
downregulated	   in	   PE	   placentas,	   promotes	   enEVT	   differentiation	   and	   induces	   trophoblast	  
invasion	  and	  spiral	  artery	  remodeling.	  To	  the	  best	  of	  our	  knowledge,	  this	  is	  the	  first	  report	  that	  a	  
miRNA	  is	  implicated	  in	  enEVT	  differentiation	  and	  spiral	  artery	  remodeling.	  	  
	  
We	  found	  that	  miR-­‐218-­‐5p	   is	  downregulated	   in	  placenta	  tissues	   from	  patients	  diagnosed	  with	  
PE.	  These	   findings	  align	  with	  previous	  microarray	  and	  tissue	  studies	   160,275.	  While	  studying	  the	  
dysregulation	   of	   miRNA	   in	   PE	   is	   a	   valid	   approach	   to	   tackling	   this	   question,	   it	   does	   pose	   the	  
problem	  of	  interpreting	  whether	  the	  findings	  are	  contributors	  to	  the	  causation	  of	  the	  disorder	  
or	  are	  a	   response	   to	   the	  clinical	   condition	   itself.	   This	   is	  why	  examining	   the	  miRNA	  expression	  
profile	  across	  gestation	  in	  healthy	  tissues	  is	  an	  important	  mirror	  into	  the	  biological	  relevance	  of	  
miRNA	   function.	   The	   period	   of	   deep	   placental	   invasion	   and	   spiral	   artery	   remodeling	   in	   early	  
second	   trimester	   is	   of	   particular	   importance	   in	   the	  onset	   of	   PE	   290.	  Our	   findings	   indicate	   that	  
miR-­‐218-­‐5p	  expression	  spikes	  during	  this	  period	  suggesting	  it	  may	  play	  a	  role	  in	  regulating	  the	  
establishment	  of	  proper	  placental	  perfusion.	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In	   an	   effort	   to	   better	   understand	   the	   function	   of	   miR-­‐218-­‐5p	   in	   these	   processes,	   we	   first	  
analyzed	   the	   consequence	   of	   mir-­‐218-­‐1	   overexpression	   in	   the	   well-­‐established	   immortalized	  
first	   trimester	   trophoblast	   cell	   line,	   HTR8/SVneo	   279.	   The	   changes	   in	   cell	   morphology,	  
cytoskeletal	   structure,	   increase	   in	   matrigel	   network-­‐formation,	   as	   well	   as	   a	   reduction	   in	  
proliferation	   rate,	   all	   suggest	   a	   switch	   from	   a	   plastic	   phenotype	   to	   a	   differentiated	   state	  
291,292.These	   findings	   align	   with	   the	   Highet	   et	   al.	   2016	   gene-­‐expression	   microarray	   study	  
comparing	   HTR8/SVneo	   cells	   cultured	   on	   and	   off	   matrigel.	   Interestingly,	   they	   reported	   that	  
while	  the	  network-­‐forming	  cells	  expressed	  genes	  associated	  with	  cytoskeleton	  organization,	  cell	  
migration	   and	   blood	   vessel	   development,	   the	   latter	   group	   was	   enriched	   for	   mitotic	   genes	  
associated	  with	  proliferation.	  Strikingly,	  Slit2,	  which	  houses	  the	  intronic	  gene	  of	  mir-­‐218-­‐1,	  was	  
among	  the	  pro-­‐angiogenic	  genes	  upregulated	  293.	  
	  
The	  miR-­‐218-­‐5p	   upregulated	  markers	   of	   differentiation	   in	   our	   study	   are	   well	   documented	   in	  
previous	  work	  as	  promoters	  of	   trophoblast	   invasiveness	  and	  endovascular	  differentiation.	  VE-­‐
cadherin	  and	  IL-­‐8	  were	  the	  most	  congruent	  genes	  regulated	  by	  miR-­‐218-­‐5p	  in	  both	  our	  cell	  and	  
tissue	  models.	  Studies	  of	  feto-­‐maternal	  interface	  sections	  showed	  that	  the	  upregulation	  of	  VE-­‐
cadherin	   in	   healthy	   tissue	   cytotrophoblasts	   was	   absent	   in	   PE	   affected	   tissues.	   They	   further	  
demonstrated	  that	  VE-­‐cadherin	  promoted	  primary	  CTB	  invasiveness	  in	  culture	  288.	  Likewise,	  IL-­‐8	  
promoted	   primary	   CTB	   and	   HTR8/SVneo	   cell	   migration	   and	   invasion	   in	   a	   dose-­‐dependent	  
manner	  through	  the	  upregulation	  of	  gelatinases,	  matrix	  metalloproteinase	  (MMP)-­‐2	  and	  -­‐9	  294.	  
MMP-­‐1	  is	  one	  of	  the	  top	  upregulated	  genes	  in	  the	  mir-­‐218-­‐1	  cells.	  As	  a	  collagenase,	  MMP-­‐1	  is	  
responsible	   for	   the	   degradation	   of	   fibrillar	   collagen-­‐rich	   extracellular	  matrices,	   such	   as	   those	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found	  in	  the	  distal	  part	  of	  the	  decidua	  and	  the	  myometrium.	  A	  study	  of	  MMP	  profile	  in	  decidua	  
basalis	   reported	  MMP-­‐1	   as	   the	  highest	   down-­‐regulated	  MMP	  between	  healthy	   and	  PE	   cases.	  
Specifically,	   there	   was	   a	   clear	   reduction	   in	   the	   MMP-­‐1+	   EVT	   population,	   suggesting	   its	  
involvement	  in	  the	  reduced	  invasiveness	  observed	  in	  the	  pathophysiology	  of	  PE	  295.	  Zymography	  
studies	   have	   shown	   an	   upregulation	   of	   MMP2/9	   and	   MT-­‐MMP1/2	   by	   IL1b	   treatment	   296.	  
Interestingly,	   trophoblasts	   have	   been	   shown	   to	   regulate	   the	   degree	   of	   their	   invasiveness	  
through	   IL1b	   secretion	   and	   the	   subsequent	   downregulation	   of	   Metalloproteinase	   inhibitor,	  
TIMP3,	   in	   human	   decidualized	   endometrial	   stromal	   fibroblasts	   297.	   Macrophage	   migration	  
inhibitory	   factor	   (MIF)	  was	   detected	   in	   EVT,	   and	   shown	   to	   promote	   trophoblast	   invasion	   and	  
migration	  through	  upregulation	  of	  ITGA1	  and	  MMP2/9	  298.	  	  
	  
Placental	  explants	  pre-­‐treated	  with	  miR-­‐218-­‐5p	  accelerated	  the	  spiral	  artery	  remodeling	  process	  
in	  vitro.	   	  The	  remodeling	  of	  maternal	  spiral	  arteries	   is	  a	  complex,	  multi-­‐step	  process,	   involving	  
the	   priming	   of	   the	   vessels	   by	   decidual	   immune	   cells	   and	   the	   subsequent	   infiltration	   of	  
endovascular	   EVTs	   299-­‐301.	   One	   mechanism	   of	   miR-­‐218-­‐5p	   action	   may	   be	   through	   the	  
upregulation	  of	  genes	  involved	  in	  the	  epithelial-­‐to-­‐endovascular	  switch	  resulting	  in	  an	  increased	  
pool	   of	   enEVT	   available	   for	   remodeling.	   Both	   PECAM1	   and	   VE-­‐cadherin	   were	   identified	   in	  
cytotrophoblasts	   at	   the	   decidual-­‐endothelial	   junctions,	   while	   VE-­‐cadherin	   was	   shown	   to	   be	  
essential	   in	   the	   trans-­‐endothelial	   migration	   of	   enEVTs	   during	   spiral	   artery	   remodeling	   302.	  
Similarly,	  both	  PECAM1	  and	  VE-­‐cadherin	  were	  critical	   in	  endothelial	  cell	  network	  formation	  on	  
matrigel	   303.	   Strong	   ECSCR	   immunoreactivity	   was	   detected	   in	   enEVT	   of	   decidua	   basalis	   and	  
within	   the	   enEVT	   of	   the	   myometrial	   microvessels	   304.	   Interestingly,	   while	   CX3CL1	   has	   been	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detected	  in	  several	  trophoblast	  cell	  lines,	  its	  receptor,	  CX3CR1,	  has	  been	  specifically	  detected	  in	  
enEVT,	  while	  absent	  in	  iEVT,	  suggesting	  a	  possible	  paracrine	  role	  in	  enEVT	  function	  305.	  
	  
The	  second	  mechanism	  responsible	  for	  the	  acceleration	  of	  spiral	  artery	  remodeling	  by	  miR-­‐218-­‐
5p	   may	   lie	   in	   the	   upregulation	   of	   immune-­‐responsive	   chemokines.	   Crosstalk	   between	  
trophoblasts	   and	   the	   decidualized	   uterus	   are	   vital	   to	   the	   establishment	   of	   a	   healthy	   feto-­‐
maternal	   interface.	   Paracrine	   signals	   from	   the	   invading	   trophoblasts	   have	   been	   shown	   to	  
contribute	   to	   the	   enriched	   cytokine	   milieu	   at	   the	   implantation	   site	   responsible	   for	   immune	  
modulation	   and	   angiogenesis.	   In	   decidual	   endometrial	   stromal	   cells	   cultured	   in	   conditioned	  
media	   from	   primary	   first	   trimester	   trophoblasts,	   CXCL1,	   IL6,	   IL8,	   and	   Intercellular	   Adhesion	  
Molecule-­‐1	   (ICAM1),	  are	  among	   the	  most	  highly	  upregulated	  genes	   297.	  Closer	  examination	  of	  
our	  miR-­‐218-­‐5p	  co-­‐culture	  tissues	  shows	  an	  abundant	  recruitment	  of	  CD45	  positive	  leukocytes	  
along	   the	   entire	   length	   of	   the	   visible	   vessel	   compared	   to	   the	   control.	   These	   data	   support	   a	  
leukocyte	   chemotaxis	   effect	   of	  miR-­‐218-­‐5p-­‐treated	   trophoblasts	   on	   the	   surrounding	  maternal	  
tissue.	   During	   the	   invasive	   period	   of	   gestation,	   dNK	   and	  monocytes	   are	   predominant	   CD45+	  
leukocytes	   in	   the	   decidua	   basalis.	   	   Trophoblast-­‐derived	   CCL2	   in	   the	   promotion	   of	   monocyte	  
migration	  has	  previously	  been	  reported,	  although	  not	  in	  the	  context	  of	  spiral	  artery	  remodeling	  
306,307.	  CCL2	  has	  also	  been	  shown	  to	  promote	  the	  pro-­‐anigogenic	  dNK	  phenotype	   important	   in	  
spiral	  artery	  remodeling;	  however	  the	  CCL2	  was	  dNK	  in	  origin	  308.	  Likewise,	  trophoblast	  secreted	  
CXCL16	  has	  been	   implicated	   in	   the	  recruitment	  of	  monocytes	  and	  T-­‐cells	   in	   the	   first-­‐trimester	  
decidua	  309.	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While	   the	   TGFβ	   pathway	   has	   been	   implicated	   in	   placental	   development,	   its	   role	   in	   enEVT	  
differentiation	  and	  spiral	  artery	  remodeling	  has	  not	  been	  reported.	   In	  this	  study,	  we	  observed	  
that	   the	   TGFβ	   signaling	   pathway	   is	   downregulated	   in	   the	  mir-­‐218-­‐1	   cells.	   	   	   First,	   microarray	  
analysis	   revealed	  that	  TGF-­‐β2	  and	  several	  downstream	  Smads,	  such	  as	  Smad2,	  3,	  and	  4,	  were	  
significantly	   lower	   in	  mir-­‐218-­‐1	   stable	   cells	  when	   compared	   to	   the	   cells	   expressing	   an	   empty	  
vector	  conrol.	  The	  downregulation	  of	  these	  signaling	  molecules	  were	  confirmed	  with	  qRT-­‐PCR	  in	  
mir-­‐218-­‐1	   cells.	   Second,	   mir-­‐218-­‐1	   significantly	   repressed	   TGFβ	   signaling	   as	   indicated	   by	   the	  
PAR-­‐3Lux	  luciferase	  reporter	  assay.	  Finally,	  silencing	  of	  TGF-­‐β2	  mimicked	  some	  of	  the	  miR-­‐218-­‐
5p	   phenotype.	   Specifically,	   in	   both	   HTR-­‐8/SVneo	   cells	   and	   placental	   explants,	   we	   found	   that	  
TGF-­‐β2	   inhibited	   invasion	   and	   explant	   outgrowth	   and	   incubation	  with	   TGF-­‐β2	   resulted	   in	   the	  
down-­‐regulation	   of	   enEVT	   markers	   in	   the	   trophoblast	   cell	   line.	   The	   TGF-­‐β2	   treatment	   also	  
partially	  reversed	  the	  effect	  of	  mir-­‐218-­‐1.	  	  These	  findings	  suggest	  that	  the	  TGFβ	  pathway	  may	  be	  
involved	  in	  the	  miR-­‐218-­‐5p-­‐regulated	  enEVT	  differentiation	  and	  invasion.	  Mir-­‐218-­‐1	  was	  shown	  
to	   suppress	   TGF-­‐β2	   mRNA	   and	   protein	   levels.	   These	   findings	   suggest	   that	   TGF-­‐β2	   exerts	   a	  
negative	   effect	   on	   enEVT	   differentiation	   and	   its	   down-­‐regulation	   by	   miR-­‐218-­‐5p	   is	   in	   part	  
responsible	  for	  the	  promotion	  of	  enEVT	  differentiation	  and	  spiral	  artery	  remodeling.	  The	  direct	  
downregulation	   of	   TGF-­‐β2	   by	   miR-­‐218-­‐5p	   through	   its	   3’UTR	   is	   suggested,	   although	   further	  
validation	   is	  needed	   to	  ensure	   this	   is	  a	   specific	   ineraction.	  The	   three	  TGFβ	   isoforms	  and	   their	  
downstream	   regulatory	   molecules	   have	   been	   located	   at	   the	   feto-­‐maternal	   interface.	   Most	  
studies	  suggest	  that	  the	  TGFβ	  pathway	  is	  a	  negative	  regulator	  of	  trophoblast	  invasion.	  An	  early	  
study	  of	  integrin	  regulation	  showed	  that	  TGFβ-­‐2	  treated	  first	  trimester	  primary	  cytotrophoblasts	  
decreased	   both	   migration	   and	   invasion	   by	   promoting	   cell	   attachment	   310.	   Primary	   EVT	   cells	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treated	   with	   TGFβ-­‐1,	   -­‐2	   or	   -­‐3	   had	   a	   dose-­‐dependent	   inhibition	   of	   invasion.	   Likewise,	  
neutralization	   of	   all	   three	   endogenous	   isoforms	   promoted	   the	   EVT	   invasive	   ability	   311.	   In	  
addition,	  another	  study	  reported	  that	  TGFβ-­‐2	  treated	  first	  trimester	  explants	  had	  a	  reduction	  in	  
EVT	  outgrowth	  area;	  however	  TGFβ-­‐1	  or	  -­‐3	  had	  no	  effect	  233.	  Suppression	  of	  Smad2	  by	  miR-­‐18a	  
was	   also	   shown	   to	   promote	   trophoblast	   invasion	   160.	   While	   the	   effect	   of	   TGFβ-­‐2	   on	   the	  
endovascular	   EVT	   pathway	   has	   not	   been	   previously	   reported,	   primary	   trophoblast	   treatment	  
with	   TGFβ-­‐1	   has	   been	   shown	   to	   reduce	   trophoblast	   invasion	   through	   suppression	   of	   VE-­‐
cadherin	   312.	   On	   the	   contrary,	   a	   pro-­‐invasive	   effect	   of	   TGFβ2	   in	   HTR8/SVneo	   cells	   has	   been	  
recently	   reported	   313.	   It	   is	   important	   to	   mention	   that	   interpretation	   of	   findings	   from	   an	  
immortalized	  cell	  line	  alone	  should	  be	  approached	  with	  caution.	  A	  study	  examining	  the	  role	  of	  
TGFβ-­‐1	  on	  HTR8/SVneo	  cells	   reported	  that	  after	  passage	  90,	   the	  cell	   line	  no	   longer	  accurately	  
represented	   the	   parental	   trophoblasts	   314.	   	   Likewise,	   an	   earlier	   study	   on	   MMP	   secretion	   in	  
HTR8/SVneo	  cells	  showed	  a	  TGFβ-­‐1	  upregulation	  of	  MMP-­‐2	  activity,	  however	  this	  was	  through	  a	  
Smad2-­‐independent	  mechanism	  315.	  	  
	  
In	   summary,	   this	   study	   provides	   the	   first	   evidence	   that	   miR-­‐218-­‐5p	   plays	   important	   roles	   in	  
healthy	  placentation	  and	  may	  be	  involved	  in	  the	  pathogenesis	  of	  PE.	  Using	  a	  combination	  of	  cell	  
and	   human	   tissue	  models,	   we	   showed	   that	   miR-­‐218-­‐5p	   promoted	   the	   pro-­‐invasive	   and	   pro-­‐
angiogenic	  phenotype	  seen	  in	  the	  differentiation	  of	  endovascular	  EVTs.	  While	  miR-­‐218-­‐5p	  was	  
upregulated	  during	  the	  peak	  period	  of	  deep	  trophoblast	  invasion	  and	  spiral	  artery	  remodeling,	  it	  
was	  down	  in	  tissues	  affected	  by	  PE.	  We	  further	  showed	  that	  suppression	  of	  TGFβ-­‐2	  was	  partially	  
responsible	  for	  the	  effect	  of	  miR-­‐218-­‐5p	  in	  trophoblast	  differentiation	  and	  invasion.	  The	  use	  of	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microRNAs	  as	  potential	  plasma	  biomarkers	  has	  been	  investigated	  223,316,	  and	  the	  utility	  of	  miR-­‐
218-­‐5p	   as	   both	   a	   predictive	   and	   prognostic	   marker	   in	   cancer	   has	   been	   suggested	   by	   others	  
272,274.	  A	  significant	  increase	  in	  serum	  TGFβ-­‐2	  was	  reported	  in	  cases	  of	  severe	  PE	  and	  eclampsia	  
compared	  to	  control	  254.	  These	  data,	  taken	  together	  with	  our	  findings,	  suggest	  great	  potential	  of	  
miR-­‐218-­‐5p	  as	  a	  biomarker	  of	  PE	  and	  possibly	  other	  hypertensive	  disorders	  of	  pregnancy.	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CHAPTER	  3:	  DIFFERENTIAL	  ROLE	  OF	  SMAD2	  AND	  SMAD3	  IN	  
ENDOVASCULAR	  EVT	  DIFFERENTIATION	  AND	  PREECLAMPSIA	  
	  




Proper	  placental	  development	   is	  key	  for	  healthy	  pregnancy	  outcomes.	   In	  the	  first	  20	  weeks	  of	  
gestation	   the	   placenta	   needs	   to	   invade	   the	   uterus,	   remodel	   maternal	   spiral	   arteries,	   and	  
establish	  proper	  placental	  perfusion	   to	  sustain	   the	  needs	  of	   the	  growing	   fetus.	  Dysfunction	   in	  
the	   precise	   regulation	   of	   these	   processes	   can	   lead	   to	   the	   development	   of	   pregnancy	  
complications,	  such	  as	  preeclampsia	  (PE).	  TGF-­‐β/Nodal/Activin	  signaling	  components	  have	  been	  
reported	  at	  the	  feto-­‐maternal	  interface	  and	  are	  known	  to	  both	  promote	  and	  inhibit	  the	  invasive	  
extravillous	  trophoblast	  (EVT)	  pathway.	  These	  ligands	  signal	  through	  serine/threonine	  receptor	  
complexes	  to	  activate	  receptor	  Smads,	  Smad2	  and	  Smad3.	  Using	  first	  trimester	  trophoblast	  cell	  
line,	   HTR8/SVneo,	   and	   first	   trimester	   tissues	   we	   show	   that	   silencing	   of	   Smad2	   and	   Smad3	  
produced	   opposite	   effects.	   Smad2	   suppressed,	   while	   Smad3	   promoted,	   trophoblast	   invasion	  
and	  enEVT	  marker	  gene	  expression.	  Furthermore,	  we	  found	  that	  while	  total	  Smad2/3	  levels	  are	  
relatively	   constant	   across	   gestation,	   phosphorylated	   Smad2	   (pSmad2)	   levels	   are	   significantly	  
lower,	  while	  pSmad3	  are	  significantly	  higher,	  in	  the	  first	  20	  weeks	  of	  pregnancy	  when	  invasion	  
and	  spiral	  artery	  remodeling	  occur.	  Additionally,	  pSmad3	  was	  significantly	  downregulated,	  while	  
pSmad2	  was	  upregulated,	  in	  placentas	  from	  PE	  patients.	  These	  findings	  suggest	  that	  Smad2	  and	  
Smad3	  have	  distinct	   functions	   in	   trophoblasts	   and	   that	   their	   dysregulation	  may	   contribute	   to	  
events	  that	  lead	  to	  PE.	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INTRODUCTION	  
	  
Serving	   as	   the	   interface	   between	   the	   fetal	   and	   maternal	   environments,	   the	   placenta	   plays	  
critical	   roles	   in	   maintaining	   and	   protecting	   the	   developing	   fetus	   throughout	   pregnancy.	   The	  
polarized	   outer	   cells	   of	   the	   blastocyst	   differentiate	   into	   cells	   of	   the	   trophoblast	   lineage	   that	  
make	   up	   the	   placenta.	   Once	   the	   trophectoderm	   is	   in	   intimate	   contact	   with	   the	   decidua	   the	  
process	  of	  placentation	  can	  begin.	  The	  cytotrophoblast	  progenitor	   cells	   (CTBs),	   located	  at	   the	  
basement	   membrane	   of	   the	   placental	   villi,	   differentiate	   in	   two	   general	   pathways	   257.	   In	   the	  
fusion	   pathway,	   CTBs	   form	   multinucleated	   syncytial	   cells	   that	   line	   the	   placental	   villi.	   In	   the	  
invasive	   pathway,	   proliferative	   CTB	   form	   anchoring	   columns	   that	   attach	   to	   the	   uterine	  
epithelium	   and	   differentiate	   into	   two	   populations	   of	   extravillous	   cytotrophoblasts	   (EVTs).	  
Interstitial	  EVTs	  (iEVTs)	  invade	  the	  decidua	  and	  differentiate	  into	  giant	  cells.	  Endovascular	  EVTs	  
(enEVTs)	   acquire	   endothelial-­‐like	   characteristics	   and	   remodel	   maternal	   spiral	   arteries,	   which	  
provide	  the	  steady,	  low-­‐velocity	  blood	  flow	  to	  the	  placenta	  in	  order	  to	  meet	  the	  requirements	  
of	  the	  growing	  fetus.	  While	  syncytial	  cell	  turnover	  continues	  throughout	  pregnancy,	  the	  invasive	  
pathway	  is	  mainly	  restricted	  to	  the	  first	  and	  second	  trimester	  290,317.	  Disruption	  in	  the	  pathways	  
involved	   in	   placental	   development	   in	   this	   invasive	   period	   has	   been	   linked	   to	   hypertensive	  
diseases	  of	  pregnancy,	  such	  as	  preeclampsia	  (PE)	  259.	  	  
	  
PE	   is	  a	  multifactorial	  disorder	   that	  can	  manifest	  during	  pregnancy	  posing	  a	  major	   risk	   to	  both	  
the	   mother	   and	   fetus.	   It	   is	   typically	   diagnosed	   after	   20	   weeks	   of	   gestation	   as	   a	   maternal	  
syndrome	   defined	   by	   the	   sudden	   onset	   of	   hypertension	   (≥140/90	   mmHg)	   and	   proteinuria	  
(≥300mg	   in	   24h)	   318.	   Prior	   to	   the	   onset	   of	   the	   clinical	   condition,	   characterizations	   of	   poor	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trophoblast	  migration	  and	  invasion	  into	  the	  decidua,	  along	  with	  inadequate	  placental	  perfusion	  
due	   to	   shallow	   invasion	   of	   spiral	   arteries	   are	   reported	   319.	   These	   histological	   findings	   are	  
accompanied	   by	   elevated	   anti-­‐angiogenic	   factors,	   namely	   soluble	   fms-­‐like	   tyrosine	   kinase	   1	  
receptor	  (sFlt-­‐1)	  and	  soluble	  Endoglin	  (sEng),	  and	  the	  downregulation	  of	  pro-­‐angiogenic	  factors	  
such	   as	   placenta	   growth	   factor,	   PGF	   320,321.	   These	   intricate	   events	   involved	   in	   placental	  
development	   are	   tightly	   regulated	   by	   a	   large	   group	   of	  molecules,	   including	   the	   transforming	  
growth	  factor	  (TGF)-­‐β	  pathway	  322.	  	  
	  
The	   TGF-­‐β	   superfamily	   is	   a	   large	   group	   of	   growth	   factors	   implicated	   in	   a	   number	   of	   cellular	  
processes	  during	  vertebrate	  development	  including	  stem	  cell	  renewal	  and	  commitment,	  tissue	  
homeostasis,	  proliferation,	  and	  regulation	  of	  invasion.	  The	  signaling	  molecules	  include	  the	  TGF-­‐
βs,	  Activins,	  Nodal,	   and	  bone	  morphogenetic	   proteins	   (BMPs).	  Acting	   through	   the	   Type	   I	   and	  
Type	  II	  serine/threonine	  receptor	  complexes	  they	  activate	  the	  downstream	  receptor	  Smads	  (R-­‐
Smads).	   In	   general,	   R-­‐Smads,	   Smad2	   and	   Smad3,	   are	   activated	   by	   TGFβ,	   Activin,	   and	   Nodal	  
signals.	   Subsequently,	   they	   complex	  with	   the	   common	  Smad4	  and	   translocate	   to	   the	  nucleus	  
where	   they	   act	   to	   promote	   or	   repress	   gene	   transcription.	   While	   sharing	   96%	   of	   sequence	  
identity	  in	  their	  MH2	  domain,	  Smad2	  differs	  from	  Smad3	  mainly	  in	  the	  N-­‐terminal	  MH1	  domain	  
where	  an	  additional	  sequence	  insertion	  perturbs	  its	  ability	  for	  direct	  DNA	  binding	  189,323.	  	  Studies	  
on	  knockout	  mice	  have	  shown	  that	  while	  Smad2	  knockout	  mice	  are	  embryonically	  lethal,	  while	  
Smad3	   deficient	   mice	   are	   viable.	   A	   great	   deal	   of	   investigation	   into	   the	   exact	   phenotypes	   of	  
these	  mouse	  models	  has	  revealed	  both	  distinct	  and	  overlapping	  roles	  of	  Smad2	  and	  Smad3	  324-­‐
329.	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The	   TGF-­‐β	   pathway	   is	   involved	   in	   many	   aspects	   of	   placental	   development.	   While	   Activin	   A	  
promotes	   trophoblast	   differentiation	   down	   the	   invasive	   pathway,	   TGFβ-­‐1	   and	   -­‐3	   inhibit	   this	  
pathway	   330.	   Many	   studies	   have	   confirmed	   the	   inhibiting	   role	   of	   all	   three	   TGFβ	   isoforms	   in	  
trophoblast	   cell	   invasion	   and	   EVT	   outgrowth	   233,311,331.	   However,	   the	   pro-­‐migratory	   and	   pro-­‐
invasive	   effects	   of	   TGFβ	   have	   also	   been	   recently	   reported	   313,332.	   Likewise,	   Nodal	   has	   been	  
shown	   to	   both	   inhibit	   223,277,278	   and	   promote	   236	   trophoblast	   cell	   invasion.	   The	   mechanisms	  
responsible	   for	   different	   TGF-­‐β	   signaling	   responses,	   as	   well	   as	   the	   exact	   signals	   that	   are	  
regulated	  by	  Smad2	  versus	  Smad3	  are	  still	  unclear	  333.	  	  	  
	  
In	   our	   previous	   work	   (Chapter	   2)	   we	   show	   that	   a	   miRNA	   downregulated	   in	   PE,	   miR-­‐218-­‐5p,	  
promotes	   trophoblast	   invasion	   and	   differentiation	   into	   enEVT	   through	   the	   suppression	   of	  
TGFβ2.	   Furthermore,	   our	   data	   suggest	   that	   Smad2	   also	   plays	   a	   role	   in	  miR-­‐218-­‐5p-­‐regulated	  
enEVT	  differentiation.	   	   In	   the	  current	  study,	  we	   investigate	   the	  differential	   function	  of	  Smad2	  
and	   Smad3	   in	   first	   trimester	   trophoblasts	   and	   discuss	   their	   potential	   role	   in	   regulating	   EVT	  
differentiation.	  Furthermore,	  we	  characterize	  the	  expression	  and	  activity	  of	  Smad2	  and	  Smad3	  
across	  gestation	   in	  healthy	  placenta	  tissues	  as	  well	  as	  placentas	   from	  patients	  diagnosed	  with	  
PE.	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MATERIALS	  AND	  METHODS	  
	  
Patients	  and	  Placental	  Tissue	  Collection	  
All	   fresh	  and	  frozen	  human	  placenta	  tissues	  used	   in	  this	  study	  are	  described	   in	  Chapter	  2.	  For	  
the	   evaluation	   of	   Smad2	   and	   Smad3	   expression	   across	   gestation,	   20	   placentas	   were	   used.	  
Specifically,	  10	  from	  6-­‐20	  weeks	  and	  10	  from	  25-­‐40	  weeks	  were	  analyzed.	  To	  assess	  if	  there	  is	  
dysregulation	  of	  Smad2/3	  in	  PE,	  we	  used	  6	  placentas	  from	  PE	  patients	  delivered	  between	  28-­‐39	  
weeks.	   
Protein	  Extraction	  and	  Immunoblot	  Analysis	  
Snap	   frozen	   tissues	  were	   lysed	   in	   five	   volumes	   of	   HEPES	   lysis	   buffer	   (10	  mM	  HEPES,	   10	  mM	  
NaCl,	  0.1	  mM	  EDTA,	  0.1	  mM	  EGTA,	  1.0	  mM	  DTT,	  0.1%	  NP-­‐40,	  pH	  7.9)	  with	  a	  Pierce	  Protease	  and	  
Phosphatase	   inhibitor	   (Thermo	   Scientific)	   and	   homogenized	   for	   30	   s	   twice	  while	   kept	   on	   ice.	  
Protein	  was	  quantified	  using	  the	  Pierce	  BCA	  Protein	  Assay	  Kit	  (Thermo	  Fisher).	  Equal	  amounts	  of	  
protein	   were	   separated	   by	   SDS-­‐polyacrylamide	   gel	   electrophoresis	   and	   transferred	   to	   a	  
polyvinylidene	  difluoride	  membrane	  (Immobilon-­‐P,	  Millipore	  Corp.).	  Membranes	  were	  blocked	  
in	   5%	   blocking	   buffer	   (5%	   skim	   milk	   in	   Tris-­‐buffered	   Saline	   and	   Tween-­‐20)	   for	   1h	   at	   room	  
temperature,	  then	  incubated	  overnight	  in	  primary	  antibody	  at	  4°C	  (Table	  3.1).	  Membranes	  were	  
subsequently	  probed	  using	  horseradish	  peroxidase–conjugated	  secondary	  antibody	  (1:5000)	  at	  
room	  temperature	  for	  2h.	  Signals	  were	  detected	  using	  the	  ECL	  Plus	  Kit	  (Amersham	  Biosciences).	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Table	  3.1	  Primary	  Antibodies	  and	  Staining	  Reagents	  
	  
Antibody	   Company	   Cat	  No.	   Species	   Dilution	   Diluent	  
pSmad2	   Cell	  Signaling	   3101S	   Rabbit	   1:500	   5%	  Milk-­‐TBST	  
pSmad3	   Cell	  Signaling	   9520S	   Rabbit	   1:500	   5%	  BSA-­‐TBST	  
Smad3	   Invitrogen	   511500	   Rabbit	   1:150	   5%	  Milk-­‐TBST	  
Smad2/3	   Cell	  Signaling	   3102S	   Rabbit	   1:1000	   5%	  BSA-­‐TBST	  
Smad4	   Santa	  Cruz	   sc-­‐7966	   Mouse	   1:100	   5%	  Milk-­‐TBST	  
GAPDH	   Santa	  Cruz	   sc-­‐47724	   Mouse	   1:5000	   5%	  Milk-­‐TBST	  
Calcein	  AM	   Corning	   354217	   N/A	   1μM	   Serum-­‐free	  media	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Cell	  Culture	  	  
An	   immortalized	   human	   first	   trimester	   trophoblast	   cell	   line,	   HTR8/SVneo,	  was	   obtained	   from	  
Charles	   Graham	   (Queen’s	   University,	   Kingston,	   ON,	   Canada),	   and	   was	   cultured	   as	   previously	  
described	   279.	   Briefly,	   cells	   were	   maintained	   in	   HyClone™	   Classical	   Liquid	   Media	   RPMI	   1640	  
(Fisher	  Scientific)	  supplemented	  with	  10%	  Fetal	  Bovine	  Serum	  (FBS)	  (GIBCO),	  Streptomycin	  (100	  
μg/ml),	  and	  Penicillin	  (100	  IU/ml),	  in	  an	  atmosphere	  of	  5%	  CO2	  at	  37°C.	  Cells	  were	  periodically	  
checked	  for	  mycoplasma	  contamination	  using	  a	  Mycoplasma	  Detection	  Kit-­‐QuickTest	  (BioTools),	  
and	  when	  needed,	   treated	  with	  MycoSmash	  Mycoplasm	  Removal	  Kit	   (BioTools),	   following	   the	  
manufacturer’s	   directions.	   All	   experiments	  were	   carried	   out	   on	   cells	   in	   between	   passages	   73	  
and	  85.	  	  
Transfections	  and	  Recombinant	  Protein	  Treatment	  
Transient	   transfection	   of	   siRNA	   oligomers	   (100	   nM)	   was	   carried	   out	   using	   Lipofectamine	  
RNAiMax	   (Invitrogen).	   All	   plasmid	   transfections	   (1	   ug)	   were	   carried	   out	   using	   Lipofectamine	  
2000	  (Invitrogen).	  A	  modified	  protocol	  was	  used	  to	  optimize	  for	  transfection	  efficiency	  and	  cell	  
survival.	   Transfections	  were	   carried	   out	   in	   6-­‐well	   plates	   on	   70%	   confluent	   cultures.	   For	   each	  
transfection	  reaction,	  2	  µl	  of	  Lipofectamine	  reagent	  was	  used	  and	   incubated	  with	  nucleotides	  
for	  15min	  at	  room	  temperature	  in	  Opti-­‐MEM	  media	  (GIBCO).	  Transfections	  were	  carried	  out	  for	  
5h,	  then	  recovered	  with	  10%	  FBS	  containing	  media	  for	  16hr.	  Cells	  used	  for	  marker	  analysis	  were	  
recovered	   for	   an	   additional	   24h	   in	   serum-­‐free	   media.	   SiSmad2,	   siSmad3	   and	   non-­‐targeting	  
controls	  were	  purchased	   from	  GenePharma	  Co.	   (Shanghai,	  China)	   (Table	  3.2).	  The	  Smad2	  and	  
Smad3	  wild	   type	   constructs	  were	   a	   kind	   gift	   from	  Dr.	   Yan	  Chen	   (Indiana	  University	   School	   of	  
Medicine,	  Department	  of	  Medical	  and	  Molecular	  Genetics).	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Table	  3.2	  Primers	  and	  Oligomers	  
	  
Name	   Sequence:	  5’	  à	  3’	   NCBI	  BLAST	  	  
Cyc1	   F:	  CAGATAGCCAAGGATGTGTG	  R:	  CATCATCAACATCTTGAGCC	   Cytochrome	  c1	  
VE-­‐cad	   F:	  GCCAGTTCTTCCGAGTCACA	  R:	  TTTCCTGTGGGGGTTCCAGT	   Cadherin	  5	  
MMP1	   F:	  GTCTCACAGCTTCCCAGCGA	  R:	  ATGGCATGGTCCACATCTGC	   Matrix	  Metallopeptidase	  1	  
IL1b	   F:	  AATCTGTACCTGTCCTGCGTGTT	  R:	  TGGGTAATTTTTGGGATCTACACTCT	   Interleukin	  1	  beta	  
IL8	   F:	  CAGAGACAGCAGAGCACACA	  R:	  GGCAAAACTGCACCTTCACA	   C-­‐X-­‐C	  motif	  chemokine	  ligand	  8	  
ECSCR	   F:	  ACAACTCCCAGCCCACAATG	  R:	  GTGGTCAGACTTAGACCGCC	  
Endothelial	  Cell-­‐Specific	  Chemotaxis	  
Regulator	  
siSmad2	   Sense:	  GUCCCAUGAAAAGACUUAAtt	  Anti-­‐sense:	  UUAAGUCUUUUCAUGGGACtt	  	   SMAD	  family	  member	  2	  
siSmad3	   Sense:	  CUGUGUGAGUUCGCCUUCAtt	  Anti-­‐sense:	  UGAAGGCGAACUCACACAGtt	   SMAD	  family	  member	  3	  
siSmad4	   Sense:	  GGUCUUUGAUUUGCGUCAGtt	  Anti-­‐sense:	  CUGACGCAAAUCAAAGACCtt	   SMAD	  family	  member	  4	  
NC	   UUCUCCGAACGUGUCACGUtt	  ACGUGACACGUUCGGAGAAtt	   No	  match	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RNA	  Extraction,	  Reverse	  Transcription	  and	  qRT-­‐PCR	  
Total	   RNA	   from	   cells	   was	   extracted	   using	   TRIzol	   reagent	   (Invitrogen)	   as	   per	   manufacturer’s	  
protocol.	   Reverse	   transcription	   was	   performed	   on	   1.5	   μg	   total	   RNA	   with	   M-­‐MuLV	   Reverse	  
Transcriptase	  (New	  England	  Biolabs).	  Quantitative	  Real	  Time	  PCR	  was	  carried	  out	  with	  EvaGreen	  
qPCR	   Master	   Mix	   (ABM),	   following	   the	   manufacturer’s	   directions,	   on	   a	   RotorGene	   Q	  
thermocycler	  (QIAGEN).	  All	  target	  genes	  were	  normalized	  to	  cytochrome	  c1	  (Cyc1).	  The	  relative	  
mRNA	   level	  was	   calculated	   using	   the	   2-­‐ΔΔct	  method.	  All	   primers	   (Table	   3.2)	   used	   in	   this	   study	  
were	  validated	  for	  specificity	  with	  primer-­‐BLAST	  (NCBI),	  and	  amplified	  products	  were	  run	  on	  an	  
agarose	  gel	  to	  ensure	  a	  single	  band	  product.	  
Transwell	  Invasion	  Assay	  
Transwell	   inserts	   with	   8	   µm	   pores	   (Costar,	   Corning	   Inc.)	   were	   coated	   with	   Celtrex	   Reduced	  
Growth	   Factor	   BM	   extract-­‐PathClear	   (1:100	   in	   Serum	   Free	   media,	   Trevigen)	   and	   allowed	   to	  
polymerize	   overnight	   at	   37°C.	   Cells	   were	   gently	   removed	   from	   culture	   plates	   using	   Accutase	  
(Innovative	  Cell	   Technologies),	   and	   seeded	  at	   a	  density	  of	  20,000	   cells	  per	  well	   in	   serum-­‐free	  
RMPI1640	  media.	  As	  a	  chemotactic	  agent,	  10%	  serum	  containing	  medium	  was	  seeded	  on	   the	  
outside	   of	   the	   transwell.	   After	   24h,	   membranes	   were	   fixed	   for	   2min	   in	   100%	  methanol	   and	  
stained	  using	  Harleco	  Hemacolor	  Staining	  Kit	  (EMD	  Chemicals).	  Invaded	  cells	  were	  counted	  with	  
ImageJ	  280	  and	  the	  invasion	  index	  was	  calculated	  as	  a	  fold	  of	  invaded	  cells	  in	  the	  treated	  groups	  
compared	  to	  the	  control	  group.	  	  
First-­‐Trimester	  Human	  Placental	  Explant	  Culture	  
Explant	   cultures	   were	   performed	   as	   previously	   described	   21,235.	  Briefly,	   villous	   explants	   with	  
potential	  EVT	  columns	  were	  carefully	  dissected	  and	  positioned	  on	  Transwell	   inserts	  (Millipore,	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Billerica,	  MA)	   pre-­‐coated	  with	   200	   μL	   of	   undiluted	   phenol	   red-­‐free	  Matrigel	   (BD	   Biosciences,	  
Bedford,	  MA).	  Explants	  were	  left	  overnight	  to	  attach	  to	  the	  matrigel,	  at	  37°C	  with	  3%	  O2	  and	  5%	  
CO2,	  before	  adding	  serum-­‐free	  DMEM-­‐F12	  medium	  supplemented	  with	  100	  U/mL	  of	  penicillin,	  
100	  U/mL	  of	  streptomycin,	  100	  μg/mL	  Normacin™.	  After	  two	  days	  of	  culture,	  villous	  tips	  were	  
examined	   under	   the	   dissecting	   microscope	   for	   successful	   EVT	   outgrowths.	   All	   successful	  
explants	   were	   selected	   for	   treatment	   with	   200	   nM	   oligomers	   (Table	   3.2).	   Explants	   were	  
photographed	   immediately	   after	   adding	   treatment,	   and	   subsequently	   at	   48hr,	   using	   a	   Leica	  
DFC400	  camera	  attached	  to	  a	  dissecting	  microscope.	   ImageJ	  was	  used	  to	  measure	  the	  area	  of	  
EVT	  outgrowth.	  	  Specifically,	  total	  outgrowth	  area	  was	  calculated	  by	  subtracting	  the	  area	  at	  the	  
end	  point	  with	  the	  initial	  area	  upon	  treatment.	  Each	  experiment	  was	  designed	  with	  a	  minimum	  
of	   four	   replicates,	   and	   was	   repeated	   on	   three	   individual	   placental	   samples.	  	  
Endothelial-­‐like	  Network	  Formation	  Assay	  	  
On	   ice,	   96-­‐well	   plates	  were	   quickly	   coated	  with	   50	   μl	   of	   Celtrex	   Reduced	  Growth	   Factor	   BM	  
extract-­‐PathClear	   (Trevigen),	   and	   allowed	   to	   polymerize	   at	   37°C	   for	   30min.	   HTR8/SVneo	  cells	  
were	  seeded	  at	  25,000	  cells	  per	  well	  in	  100	  µl	  of	  10%	  FBS	  containing	  RPMI1640.	  After	  16-­‐20h	  of	  
culture,	  cells	  were	  stained	  with	  1	  μM	  Calcein	  AM	  (Corning)	  for	  15min,	  and	  pictures	  were	  taken	  
at	   20X	   magnification	   on	   a	   fluorescence	   microscope.	   Total	   network	   length	   was	   quantified	   in	  
ImageJ	  using	  the	  NeuronJ	  plugin	  285.	  
Statistical	  Analysis	  
Statistical	   analysis	   was	   performed	   using	   Graphpad	   Prism	   7	   (p<0.05,	   95%	   CI).	   Unpaired,	   two-­‐
tailed,	  Student	  t	  test	  was	  used	  for	  comparison	  between	  two	  groups.	  One-­‐way	  ANOVA	  followed	  
by	  a	  Dunnett's	  multiple	  comparisons	  test	  determined	  differences	  among	  several	  groups.	  	   	  
	   116	  
RESULTS	  
	  
Smad2	  and	  Smad3	  have	  opposing	  patterns	  of	  activity	  in	  placenta	  across	  gestation	  
To	   explore	   the	   roles	   of	   Smad2	   and	   Smad3	   in	   placenta	   development	   we	   first	   assessed	   their	  
expression	   pattern	   across	   gestation.	   Healthy	   placentas	   from	  patients	   at	  Mount	   Sinai	   Hospital	  
undergoing	   elective	   termination	   or	   Caesarean	   section	  were	   chosen	   at	   random	   from	  available	  
Biobank	   samples.	   Total	   Smad2	   and	   total	   Smad3	   levels	   were	   normalized	   to	   their	   respective	  
loading	   control,	   GAPDH.	   We	   found	   no	   significant	   difference	   in	   total	   Smad2	   (Figure	   3.1A)	   or	  
Smad3	  (Figure	  3.1B)	  protein	  expression	  across	  gestation.	  To	  assess	  if	  the	  active	  forms	  of	  Smad2	  
or	   Smad3	   differed	   between	   the	   two	   halves	   of	   pregnancy	   we	   used	   anti-­‐phospho	   antibodies.	  
Quantification	   of	   p-­‐Smad2	   and	   p-­‐Smad3	   levels	  was	   normalized	   to	   the	   total	   Smad2	   or	   Smad3	  
protein	   levels,	  respectively.	  A	  significant	   increase	  (p<0.01)	   in	  phosphorylated	  Smad2	  (pSmad2)	  
was	  observed	  between	  25-­‐40	  weeks	  of	  gestation	  compared	  to	  6-­‐20	  weeks	  of	  gestation	  (Figure	  
3.1A).	   Conversely,	   a	   significant	   decrease	   (p<0.01)	   in	   phosphorylated	   Smad3	   (pSmad3)	   was	  
observed	  in	  6-­‐20	  weeks	  of	  gestation	  compared	  to	  25-­‐40	  weeks	  of	  gestation	  (Figure	  3.1B).	  
	   	  











































Figure	  3.1	  Legend	  found	  on	  next	  page	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Figure	  3.1	  Smad2	  and	  Smad3	  activity	  has	  opposing	  patterns	  in	  placenta	  across	  gestation.	  
Healthy	   placentas	   from	   patients	   at	   Mount	   Sinai	   Hospital	   undergoing	   elective	   termination	   or	  
Caesarean	  section	  were	  assessed	  for	  (A)	  pSmad2/Total	  Smad2	  or	  (B)	  pSmad3/Total	  Smad3	  with	  
Western	  Blotting.	  Band	  density	  was	  quantified	  using	  ImageJ	  from	  two	  separate	  blots.	  A	  total	  of	  
ten	   placentas	  were	   used	   for	   each	   gestation	   period	   and	   a	   representative	   blot	   is	   shown.	   Total	  
Smad2	   and	   Smad3	   levels	   were	   normalized	   to	   corresponding	   GAPDH	   signal	   and	   no	   significant	  
difference	  was	  found.	  P-­‐Smad2	  and	  p-­‐Smad3	  were	  normalized	  to	  Total	  Smad2	  or	  Smad3	  protein,	  
respectively.	   (A)	   A	   significant	   increase	   (p<0.01)	   in	   pSmad2	   was	   observed	   in	   the	   25-­‐40	   week	  
group	  compared	  to	  the	  6-­‐20	  weeks	  of	  gestation.	  (B)	  A	  significant	  decrease	  (p<0.01)	  in	  pSmad3	  
was	   observed	   in	   the	   25-­‐40	   week	   group	   relative	   to	   the	   6-­‐20	   weeks	   of	   gestation.	   Statistical	  
analysis	  was	  performed	  on	  GraphPad	  Prism	  using	  an	  unpaired	  t-­‐test	  (p<0.05,	  95%	  CI).	  Error	  bars	  
represent	  SEM.	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Smad2	  and	  Smad3	  have	  differential	  roles	  in	  EVT	  differentiation	  
To	  investigate	  the	  functional	  roles	  of	  Smad2	  and	  Smad3	  we	  used	  a	  siRNA	  knockdown	  approach.	  
We	   used	   an	   established	   first	   trimester	   trophoblast	   cell	   line,	   HTR8/SVneo,	   with	   a	   confirmed	  
functioning	   TGFβ	   signaling	   pathway.	   First	   we	   validated	   the	   siRNA	   used	   in	   our	   study.	  
Quantitative-­‐Real	   Time	   PCR	   showed	   a	   significant	   downregulation	   (p<0.005)	   of	   Smad2	   mRNA	  
with	  siSmad2	  transfection,	  and	  Smad3	  mRNA	  with	  siSmad3	  transfection	  (Figure	  3.2A	  and	  3.2B,	  
respectively).	  Furthermore,	  Western	  blotting	  with	  the	  Total	  Smad2/3	  antibody	  showed	  a	  clear	  
downregulation	  of	  total	  Smad2	  protein	  by	  siSmad2	  and	  total	  Smad3	  protein	  by	  siSmad3	  (Figure	  
3.2C).	   	   HTR8/SVneo	   transfected	   with	   siSmad2	   showed	   a	   significant	   upregulation	   of	   major	  
markers	  of	  EVT	  differentiation	  previously	  shown	  to	  be	  upregulated	  by	  miR-­‐218-­‐5p	  (Chapter	  2).	  
Specifically,	  siSmad2	  transfected	  cells	  significantly	  upregulated	  VE-­‐cadherin	  by	  4	   fold	   (p<0.01),	  
MMP1	  by	  14	  fold	  (p<0.01),	  ECSCR	  by	  2.5	  fold	  (p<0.01),	  IL1b	  by	  5	  fold	  (p<0.05),	  and	  IL8	  by	  5	  fold	  
(p<0.001)	   (Figure	   3.3A).	   In	   contrast,	   siSmad3	   transfected	   cells	   showed	   a	   significant	  
downregulation	  of	  all	  of	  these	  markers.	  Specifically,	  a	  significant	  downregulation	  of	  VE-­‐cadherin	  
by	   4	   fold	   (p<0.0001),	  MMP1	  by	   2	   fold	   (p<0.005),	   ECSCR	   by	   1.5	   fold	   (p<0.001),	   IL1b	   by	   6	   fold	  
(p<0.0001),	  and	  IL8	  by	  23	  fold	  (p<0.01)	  was	  observed	  in	  siSmad3	  transfected	  cells	  compared	  to	  
the	  control	  (Figure	  3.3B).	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Figure	  3.2	  Validation	  of	  Smad	  siRNAs.	  
To	  investigate	  the	  functional	  roles	  of	  Smad2	  and	  Smad3	  we	  used	  a	  siRNA	  knockdown	  approach.	  
(A)	   Using	   q-­‐RT-­‐PCR	   we	   validated	   that	   siSmad2	   significantly	   downregulated	   (p<0.01)	   Smad2	  
mRNA,	   without	   reducing	   Smad3	   levels.	   (B)	   siSmad3	   significantly	   reduced	   (p<0.001)	   Smad3	  
mRNA	   without	   reducing	   Smad2	   levels.	   (C)	  Western	   blotting	   with	   a	   Total	   Smad2/3	   antibody	  
further	   validated	   the	   downregulation	   of	   Smad2	   with	   siSmad2	   and	   Smad3	   with	   siSmad3.	   (D)	  
Western	  blotting	  with	  Total	  Smad4	  antibody	  confirmed	  the	  knockdown	  of	  Smad4	  by	  siSmad4.	  


















































Figure	  3.3	  Smad2	  and	  Smad3	  have	  differential	  roles	  in	  EVT	  differentiation. 
(A)	  First	   trimester	  cell	   line,	  HTR8/SVneo,	  was	   transfected	  with	  100nM	  siSmad2	  and	   total	  RNA	  
was	   extracted	   and	   used	   for	   qRT-­‐PCR.	   A	   significant	   upregulation	   of	   major	   markers	   of	   EVT	  
differentiation	  were	   observed.	   (B)	  HTR8/SVneo	  was	   transfected	  with	   siSmad3	   and	   total	   RNA	  
was	   used	   for	   qRT-­‐PCR.	   A	   significant	   downregulation	   of	   key	   markers	   involved	   in	   EVT	  
differentiation	  were	  observed.	  Statistical	  analysis	  was	  performed	  on	  GraphPad	  Prism	  using	  an	  
unpaired	   t-­‐test	   (p<0.05,	   95%	   CI).	   Error	   bars	   represent	   SEM.	   	   *p<0.05,	   **p<0.01,	   ***p<0.001,	  
****p<0.0001	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Next,	  we	  investigated	  the	  effect	  of	  Smad2	  or	  Smad3	  knockdown	  on	  trophoblast	  cell	  invasion.	  In	  
our	   first	  model	  we	   used	  HTR8/SVneo	   transfected	   cells	   seeded	   on	  matrigel-­‐coated	   transwells.	  
Cells	   transfected	  with	   siSmad2	   invaded	   significantly	   higher	   (p<0.01)	   than	   control	   cells	   (Figure	  
3.4A).	   HTR8/SVneo	   cells	   transfected	  with	   siSmad3	   showed	   a	   significant	   reduction	   (p<0.01)	   in	  
invasion	  compared	   to	   control	   cells	   (Figure	  3.4B).	   In	  our	   second	  model	  we	  used	   first	   trimester	  
placental	   explants	   attached	   to	   a	   matrigel	   substrate.	   Tissues	   treated	   with	   siSmad2	   showed	   a	  
significantly	  higher	  (p<0.05)	  48h	  EVT	  outgrowth	  area	  compared	  to	  control	  tissues	  (Figure	  3.4C).	  
Whereas,	  first	  trimester	  placental	  explants	  treated	  with	  siSmad3	  showed	  a	  significant	  reduction	  
(p<0.05)	  in	  EVT	  outgrowth	  at	  48h	  compared	  to	  control	  treated	  tissues	  (Figure	  3.4D).	  	  	  
	  
Since	   many	   of	   the	   upregulated	   gene	   markers	   suggest	   a	   switch	   from	   the	   epithelial	   to	  
endovascular	  phenotype,	  we	  assessed	   the	   role	  of	  Smad2	  and	  Smad3	  using	  an	  endothelial-­‐like	  
network	  formation	  assay.	  HTR8/SVneo	  cells	  were	  transfected,	  seeded	  on	  matrigel-­‐coated	  wells,	  
and	  after	  16h	  were	  stained	  with	  Calcein	  AM.	  Total	  network	  length	  was	  measured	  with	  ImageJ.	  
Cells	  transfected	  with	  siSmad2	  had	  a	  significantly	  larger	  (p<0.0001)	  network	  formed	  compared	  
to	  the	  scramble	  control.	  Interestingly,	  siSmad2	  co-­‐transfected	  with	  siSmad4	  increased	  the	  total	  
network	  length	  even	  further	  (Figure	  3.5A).	  	  Conversely,	  siSmad3	  transfected	  cells	  formed	  overall	  
a	   significantly	   smaller	   (p<0.0001)	   network	   structure	   compared	   to	   scramble	   control	   cells.	  
Similarly,	  co-­‐transfection	  of	  siSmad3	  and	  siSmad4	  enhanced	  the	  effect	   further,	  with	  nearly	  no	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Figure	  3.4	  Smad2	  represses	  and	  Smad3	  promotes	  invasion	  and	  EVT	  outgrowth.	  
	  (A)	   HTR8/SVneo	   cells	   transfected	   with	   siSmad2	   and	   seeded	   on	   matrigel-­‐coated	   transwells	  
invaded	   significantly	  higher	   (p<0.01)	   than	   control	   cells.	   (B)	  HTR8/SVneo	  cells	   transfected	  with	  
siSmad3	   showed	   a	   significant	   reduction	   (p<0.01)	   in	   invasion	   compared	   to	   control	   cells.	   (C)	  
SiSmad2	   treated	   first	   trimester	   placenta	   explants	   showed	   a	   significantly	   higher	   (p<0.05)	   48h	  
outgrowth	  area	  compared	  to	  control	  tissues.	  (D)	  First	  trimester	  placental	  explants	  treated	  with	  
siSmad3	  showed	  a	  significant	  reduction	  (p<0.05)	  in	  EVT	  outgrowth	  at	  48h	  compared	  to	  control	  
treated	   tissues.	   Image	   quantifications	   were	   performed	   using	   ImageJ	   software.	   Statistical	  
analysis	  was	  performed	  on	  GraphPad	  Prism	  using	  an	  unpaired	  t-­‐test	  (p<0.05,	  95%	  CI).	  	  
Scale	  bar:	  500	  μm.	  Error	  bars	  represent	  SEM.	  	  	  
	  	   	  











































Figure	  3.5	  Legend	  found	  on	  next	  page	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Figure	  3.5	  Smad2	  represses,	  while	  Smad3	  promotes	  trophoblast	  network	  formation.	  
HTR8/SVneo	  cells	   transfected	  with	  100	  nM	  oligomers	   (A)	  or	  1	  µg	  plasmid	   (B)	  were	  seeded	  on	  
matrigel-­‐coated	  wells.	  After	  16h	  cells	  were	   stained	  with	  Calcein	  AM	  and	   total	  network	   length	  
was	  measured	  with	  ImageJ.	  (A)	  siSmad2	  and	  siSmad2/4	  transfected	  cells	  formed	  more	  intricate	  
network	   structures	   with	   significantly	   larger	   (p<0.0001)	   total	   length	   compared	   to	   scramble	  
control.	   Conversely,	   siSmad3	   and	   siSmad3/4	   transfected	   cells	   formed	   significantly	   smaller	  
(p<0.0001)	   network	   structures	   compared	   to	   scramble	   control	   cells.	   SiSmad4	   transfected	   cells	  
formed	   structures	   similar	   to	   scramble	   control	   cells.	   (B)	  Overexpression	  of	   Smad2	   significantly	  
suppressed	   (p<0.05)	   the	   network	   size,	   while	   Smad3	   significantly	   increased	   (p<0.001)	   total	  
network	  length	  compared	  to	  the	  empty	  vector	  control.	  Western	  Blot	  indicates	  levels	  of	  Smad2	  
or	  Smad3	  after	  indicated	  construct	  transfection.	  Statistical	  analysis	  was	  performed	  on	  GraphPad	  
Prism	  using	  an	  unpaired	  t-­‐test	  (p<0.05,	  95%	  CI).	  Scale	  bar:	  500	  μm.	  Error	  bars	  represent	  SEM.	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On	  the	  other	  hand,	  cells	  transfected	  with	  only	  siSmad4	  formed	  networks	  similar	  to	  the	  	  control	  
cells	   (Figure	   3.5A).	   To	   support	   these	   findings	   further,	   we	   overexpressed	   wild	   type	   Smad2	   or	  
Smad3	  into	  HTR8/SVneo	  cells.	  Overexpression	  of	  Smad2	  significantly	  suppressed	  (p<0.05),	  while	  
Smad3	  significantly	  increased	  (p<0.001)	  the	  total	  network	  length	  compared	  to	  the	  empty	  vector	  
control	  (Figure	  3.5B).	  
 
Smad2	  and	  Smad3	  activity	  in	  PE	  placenta	  
Healthy	  placentas	  and	  placentas	  from	  PE	  diagnosed	  patients	  at	  Mount	  Sinai	  Hospital	  undergoing	  
Caesarean	  section	  were	  processed.	  Total	  Smad2	  and	  Smad3	  protein	  levels	  were	  normalized	  to	  
their	  GAPDH	  loading	  control.	  No	  significant	  difference	  in	  total	  levels	  of	  Smad2	  and	  Smad3	  were	  
found	   in	  either	  healthy	  or	  PE	   tissues	   (Figure	  3.6A	  and	  B,	   respectively).	  P-­‐Smad2	  and	  p-­‐Smad3	  
were	  normalized	  to	  Total	  Smad2	  or	  Smad3	  protein,	  respectively.	  The	  expression	  of	  pSmad2	  was	  
slightly	   elevated	   in	   PE	   samples	   compared	   to	   gestation	   age-­‐matched	   controls	   (Figure	   3.6A).	  
Whereas	  the	  level	  of	  p-­‐Smad3	  was	  significantly	  decreased	  (p<0.0001)	  in	  PE	  placentas	  relative	  to	  
healthy	  gestation	  age-­‐matched	  controls	  (Figure	  3.6B).	  Interestingly,	  the	  expression	  of	  p-­‐Smad3	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Figure	  3.6	  Legend	  found	  on	  next	  page 	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Figure	  3.6	  p-­‐Smad3	  is	  downregulated	  in	  PE	  tissues.	  
Healthy	  placentas	  and	  placentas	  from	  PE	  diagnosed	  patients	  at	  Mount	  Sinai	  Hospital	  undergoing	  
Caesarean	  section	  were	  assessed	  for	  (A)	  pSmad2/Total	  Smad2	  or	  (B)	  p-­‐Smad3/Total	  Smad3	  with	  
Western	  Blotting.	  Band	  density	  was	  quantified	  using	  ImageJ.	  Each	  group	  consisted	  of	  six	  unique	  
patient	   placenta	   samples.	   Total	   Smad2	   and	   Smad3	   levels	   were	   normalized	   to	   corresponding	  
GAPDH	  signal	  and	  no	  significant	  difference	  was	  found.	  P-­‐Smad2	  and	  p-­‐Smad3	  were	  normalized	  
to	  Total	  Smad2	  or	  Smad3	  protein,	  respectively.	  (A)	  p-­‐Smad2	  was	  slightly	  elevated	  in	  PE	  samples	  
compared	  to	  gestation	  age-­‐matched	  controls	  (B)	  A	  significant	  decrease	  (p<0.0001)	   in	  p-­‐Smad3	  
was	   observed	   in	   PE	   placenta	   relative	   to	   healthy	   gestation	   age-­‐matched	   controls.	   Statistical	  
analysis	  was	  performed	  on	  GraphPad	  Prism	  using	  an	  unpaired	  t-­‐test	  (p<0.05,	  95%	  CI).	  Error	  bars	  
represent	  SEM.	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DISCUSSION	  
 
In	   this	   study,	  we	  provide	   the	   first	  evidence	   that	  Smad2	  and	  Smad3	  may	  have	  distinct	   roles	   in	  
EVT	  invasion	  and	  endovascular	  differentiation.	  Specifically,	  we	  show	  that	  Smad2	  inhibits,	  while	  
Smad3	   promotes	   trophoblast	   invasion	   and	   differentiation	   into	   enEVTs.	   Our	   expression	   data	  
indicate	   that	  while	   total	   Smad2/3	   levels	  are	  consistent	  across	  gestation,	   their	  phosphorylated	  
(p-­‐Smad)	  levels	  have	  differential	  expression.	  P-­‐Smad3	  was	  relatively	  higher	  in	  the	  first	  20	  weeks	  
of	  gestation	  compared	  to	   later	   in	  gestation.	  Where	  as	  p-­‐Smad2	   levels	  were	  relatively	   lower	   in	  
the	  first	  20	  weeks	  of	  gestation	  compare	  to	  later	  in	  gestation.	  Furthermore,	  we	  are	  first	  to	  show	  
that	  pSmad3	  levels	  are	  significantly	  downregulated	  in	  placenta	  from	  PE	  patients.	  	  
	  
Knockdown	  of	  Smad2	  promoted,	  while	  knockdown	  of	  Smad3	  inhibited,	  several	  important	  genes	  
that	   promote	   the	   invasive	   capacity	   of	   trophoblasts.	   Matrix	   metallopeptidase	   1	   (MMP1)	   is	   a	  
collagenase	   important	   for	   deep	   placental	   invasion	   and	   is	   downregulated	   in	   EVTs	   from	   PE	  
placentas	  334.	   Interleukin-­‐1b	  (IL1b)	  upregulates	  trophoblast	  proteases	  essential	   in	  EVT	  invasion	  
230.	   Likewise,	   Interleukin-­‐8	   (IL8)	   promotes	   trophoblast	   migration	   and	   invasion	   through	   the	  
upregulation	   of	   MMP2/9	   335.	   Additionally,	   we	   report	   that	   Smad2	   suppressed,	   while	   Smad3	  
promoted,	  the	  epithelial	  to	  endovascular	  marker	  switch	  involved	  in	  enEVT	  differentiation,	  such	  
as	   the	   VE-­‐cadherin	   and	   Endothelial	   Cell-­‐Specific	   Chemotaxis	   Regulator	   (ECSCR).	   VE-­‐cadherin	  
upregulation	   is	   essential	   in	   the	   trophoblast-­‐mediated	   endothelial	   replacement	   during	   spiral	  
artery	  remodeling	  336.	  Although	  no	  known	  function	  of	  ECSCR	  has	  been	  reported	  in	  placenta,	  the	  
enEVT	   of	   decidua	   basalis	   have	   shown	   strong	   immunostaining	   337.	   Despite	   their	   sequence	  
similarity,	  Smad2	  and	  Smad3	  have	  shown	  distinct	  transcriptional	  activities	  338,339.	  Furthermore,	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their	   distinct	   roles	   in	   regulating	   cell	   differentiation	  have	  been	   reported	   in	   other	   systems.	   For	  
example,	  Smad3	  has	  been	  identified	  as	  a	  key	  promoter	  of	  neuronal	  differentiation	  and	  cell	  fate	  
specification,	   independent	   of	   Smad2	   340.	   While	   Smad2	   signaling,	   and	   not	   Smad3,	   was	  
indispensible	  for	  normal	  epiblast	  development	  339.	  	  
	  
As	  suggested	  by	  the	  gene	  expression	  data,	  Smad2-­‐depletion	  promoted	  trophoblast	  cell	  invasion	  
through	  matrigel-­‐coated	  transwells	  and	  EVT	  outgrowth	  of	  first	  trimester	  placenta	  tissues.	  These	  
data	   are	   in	   line	  with	   previous	   findings	   that	   Smad2	   inhibits	   trophoblast	   invasion	   160.	   Previous	  
studies	  also	   identified	  p-­‐Smad2	  positive	  EVTs	  to	  be	   located	   in	  the	  proximal	  anchoring	  column,	  
which	   is	   composed	   of	   proliferating,	   non-­‐invasive	   trophoblasts	   332.	   P-­‐Smad2	   expression	   also	  
decreased	  along	  the	  distal	  ends	  of	  the	  column	  as	  the	  cells	  entered	  the	  invasive	  pathway	  332.	  In	  
contrast,	   our	   findings	   from	   Smad3	   knockdown	   experiments	   suggest	   that	   Smad3	   promotes	  
trophoblast	   invasion.	  The	  role	  of	  Smad3	  in	  trophoblast	  function	  has	  not	  been	  directly	  studied.	  
However,	   previous	   studies	   have	   suggested	   the	   involvement	   of	   both	   Smad2	   and	   Smad3	   as	  
mediators	   of	   invasive	   and	   pro-­‐angiogenic	   signals	   from	   TGF-­‐β	   family	   proteins.	   Pro-­‐invasive	  
effects	   of	   Activins,	   by	   the	   upregulation	   of	   N-­‐Cadherin,	   were	   mediated	   by	   both	   Smad2	   and	  
Smad3	   238.	   Similarly,	   pro-­‐invasive	   effects	   of	   Activin	   by	   MMP2	   upregulation	   were	   mediated	  
through	  an	  ALK4/Smad2/3/Snail	  mechanism	  237.	  Conversely,	   the	  anti-­‐invasive	  effect	  of	  TGF-­‐β1	  
through	  VE-­‐cadherin	  downregulation	  was	  also	  mediated	   through	  Smad2/3	   312.	   The	   reason	   for	  
these	  discrepancies	  is	  not	  clear;	  however,	  the	  siRNAs	  used	  between	  these	  studies	  and	  ours	  may	  
target	   different	   regions	   of	   Smad2	   or	   Smad3.	   	   Alternatively,	   the	   relative	   expression	   level	   of	  
Smad2	   and	   Smad3	   may	   determine	   their	   functions	   in	   trophoblasts.	   Additional	   siRNAs	   will	   be	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used	   in	   the	   future	   to	   rule	  out	  potential	  off-­‐target	  effects	  of	   the	   siRNAs.	   In	  addition,	  different	  
doses	   of	   siSmad2	   and	   Smad3,	   either	   alone	   or	   in	   combination,	   will	   also	   be	   used	   to	   further	  
characterize	   the	   functions	   of	   Smad2	   and	   Smad3	   in	   trophoblast	   invasion	   and	   enEVT	  
differentiation.	  	  
	  
Consistent	  with	  the	  increased	  endovascular	  gene	  expression,	  we	  observed	  that	  the	  knockdown	  
of	  Smad2	  promoted	  the	  endothelial	  network-­‐forming	  ability	  of	  trophoblasts,	  while	  depletion	  of	  
Smad3	   significantly	   reduced	   the	   total	   network	   length.	   Previously,	   Activin	   A	   was	   shown	   to	  
promote	  trophoblast	  endothelial-­‐like	  network	  formation	  through	  Smad2/3/4	  mediated	  VEGF-­‐A	  
upregulation	   240.	   Lastly,	   our	   data	   show	   that	   additional	   knockdown	   of	   Smad4	   in	   the	   network	  
formation	   assay	   further	   enhanced	   the	   differential	   phenotypes	   of	   Smad2	   and	   Smad3.	   This	  
suggests	  that	  Smad4	   is	   involved	   in	  both	  the	  Smad2	  suppression	  and	  Smad3	  promotion	  of	  EVT	  
differentiation.	  	  
	  
In	  this	  study,	  we	  show	  that	  the	  total	   levels	  of	  Smad2	  and	  Smad3	  proteins	  across	  gestation	  do	  
not	  change	  significantly.	  However,	  their	  activities,	  reflected	  by	  the	  levels	  of	  the	  phosphorylated	  
forms	  (Ser465/467	  and	  Ser423/425,	  respectively),	  varied	  during	  different	  stages	  of	  pregnancy.	  
Specifically,	  we	  found	  that	  the	  relative	  activity	  of	  Smad3	  is	  higher	  in	  the	  period	  between	  6	  and	  
20	  weeks	   compared	   to	   late	   gestation,	  while	   the	   opposite	   is	   true	   for	   p-­‐Smad2	   protein	   levels.	  
Placental	   expression	   of	   active	   Smad2	   and	   Smad3	   has	   not	   been	   closely	   examined.	   The	  
cytoplasmic	  expression	  of	  total	  Smad2/3	  has	  been	  reported	  in	  both	  STBs	  and	  CTBs,	  decreasing	  
in	  expression	  with	  gestational	  age	   341.	  However,	   the	  antibody	  used	  detected	   the	   total	  protein	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level	   of	   both	   Smads	   concurrently.	   A	   recent	   study	   has	   reported	   that	   active	   Smad2	   has	   been	  
detected	   in	   both	   STBs	   and	   proliferating	   EVTs	   of	   first	   trimester	   placentas.	   Furthermore,	   they	  
show	  that	   the	  p-­‐Smad2	  protein	   levels	  decrease	  with	  advancing	  gestational	  age	  332.	   In	  general,	  
Smad2	  and	  Smad3	  are	  activated	  by	  signals	  from	  TGFβs,	  Nodal,	  and	  Activins	  342.	  The	  expression	  
pattern	  of	   TGF-­‐β/Nodal/Activin	   signaling	   components	   suggests	  a	   complex	  autocrine/paracrine	  
role	   in	  both	   the	   fusion	  and	   invasive	   trophoblast	  pathway	   343.	  All	   three	   isoforms	  of	  TGF-­‐β	  and	  
their	   receptors,	   ALK-­‐5	   and	   TGFβ-­‐RII,	   have	  been	   localized	   to	   the	   STBs	   and	   EVTs,	   decreasing	   in	  
intensity	  with	  gestational	  age	  341,344.	  Similarly,	  Nodal	  and	  its	  Type	  I	  receptor,	  ALK-­‐7,	  have	  been	  
localized	  to	  the	  STBs,	  CTBs	  and	  EVTs,	  staining	  highest	  in	  the	  first	  trimester	  and	  disappearing	  by	  
term	  277.	  Activin	  A	  was	  detected	  in	  the	  STBs	  and	  EVTs	  of	  term	  placentas	  345.	  Expression	  patterns	  
of	  ALK-­‐4	  have	  not	  been	  reported	  in	  humans.	  Although	  Activin	  signaling	  through	  ALK-­‐4	  promotes	  
trophoblast	   invasion,	   suggesting	   it	   is	   expressed	   in	   invasive	   trophoblasts	   237.	   Furthermore,	  
conditional	   knockout	   of	   ALK-­‐4	   in	   mice	   causes	   subfertility	   in	   females	   due	   to	   inadequate	  
trophoblast	   action	   in	   establishing	   the	   maternal-­‐fetal	   interface	   346.	   	   Together,	   these	   studies	  
suggest	   that	   the	   TGF-­‐β/Nodal/Activin-­‐Smad2/3	   pathway	   plays	   important	   roles	   in	   placental	  
development.	  	  
	  
The	   differential	   activity	   of	   Smads	   depends	   on	   many	   factors;	   all	   centered	   around	   the	  
phosphorylation	  of	  Smad2	  or	  Smad3	  C-­‐terminal	  Serines	  by	  their	  cognate	  Type	  I	  receptors.	  Upon	  
ligand	  binding,	  the	  differential	  recruitment	  of	  Smad2	  versus	  Smad3	  to	  the	  receptor	  is	  complex	  
333,347.	   Several	   accessory	  proteins	  have	  high	   affinity	   for	   non-­‐phosphorylated	   Smad2/3	  and	  are	  
responsible	  for	  recruiting	  them	  to	  the	  Type	  I	  receptor	  for	  activation.	  For	  example,	  Smad	  Anchor	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for	   Receptor	   Activation	   (SARA)	   is	   able	   to	   bind	   to	   both	   Smad2	   and	   Smad3	   213.	   Interestingly,	  
preferential	   selection	   by	   SARA	   has	   been	   reported	   348,349.	   Furthermore,	   cytoplasmic	   pro-­‐
myelocytic	  leukemia	  (cPML)	  and	  disabled-­‐2	  (DAB-­‐2)	  adaptor	  proteins	  are	  also	  important	  for	  the	  
specific	   recruitment	   of	   Smad2	   and	   Smad3	   for	   activation	   350,351.	   Expression	   of	   these	   adaptor	  
proteins	  has	  been	  reported	  in	  the	  placenta,	  although	  their	  exact	  cellular	  localization	  remains	  to	  
be	   fully	   characterized	   352-­‐354.	   Conversely,	   availability	   of	   inhibitory	   Smads,	   Smad6	   and	   Smad7,	  
influences	   the	   accessibility	   of	   the	   Type	   I	   receptor	   activation	   site	   to	   Smad2	   or	   Smad3.	   For	  
example,	   Smad7	   was	   shown	   to	   block	   only	   Smad3	   signaling	   in	   mesangial	   cells,	   while	   Smad6	  
enhanced	   Smad3	   signaling	   355.	   Both	   Smad6	   and	   Smad7	   expression	   have	   been	   reported	   in	  
trophoblasts	   356.	   Furthermore,	   Smad7	   expression	   was	   shown	   to	   increase	   with	   gestation	   and	  
shift	  to	  the	  STB	  layer	  towards	  term	  332.	  Crosstalk	  of	  Smad2/3	  with	  other	  signaling	  pathways	  also	  
influences	   their	   relative	   activity.	   For	   example,	   ERK	   (Extracellular	   signal–regulated	   kinases)	  
phosphorylation	   of	   the	   Smad	   linker	   region	   positively	   regulates	   the	   Smad2	   pathway	   357	   while	  
negatively	   regulating	   Smad3	   signaling	   358.	   Furthermore,	   Akt	   (RAC-­‐alpha	   serine/threonine-­‐
protein	  kinase;	  PKB)	  was	  shown	  to	  sequester	  Smad3,	  making	  it	  unavailable	  for	  Type	  I	  receptor	  
phosphorylation	   359.	  While	   we	   show	   that	   the	   relative	   phosphorylation	   levels	   of	   Smad2	   and	  
Smad3	  differ	  across	  gestation,	  it	  is	  important	  to	  note	  that	  both	  signaling	  mediators	  are	  active	  at	  
the	   same	   time.	   The	   formation	   of	   Smad2	   or	   Smad3	   homodimers,	   as	  well	   as	   the	   formation	   of	  
Smad2/3	   heterodimers	   has	   been	   reported	   195.	   The	   possibility	   that	   a	   specific	   ratio	   of	   active	  
Smad2	  and	  Smad3	  proteins	  available	  for	  transcription	  complex	  formation	  could	  be	  responsible	  
to	   mediate	   genes	   required	   in	   first	   and	   second	   trimester	   tissues	   versus	   later	   in	   gestation.	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Additionally,	   Smad2	   and	   Smad3	   cooperation	   and	   antagonism	   have	   been	   reported	   to	   occur	  
simultaneously	  in	  the	  same	  cellular	  context	  360.	  	  
	  
Furthermore,	  we	  show	  that	  the	  total	  protein	  levels	  of	  Smad2	  and	  Smad3	  are	  not	  dysregulated	  in	  
PE.	  Although	  in	  our	  PE	  tissues	  the	  increase	  in	  the	  level	  of	  p-­‐Smad2	  is	  minor,	  the	  upregulation	  of	  
p-­‐Smad2	   in	  PE	  has	  been	  previously	   reported	   332.	   Likewise,	   the	  upregulation	  of	   total	   Smad2	   in	  
severe	   PE	   has	   been	   reported	   160.	   On	   the	   other	   hand,	  we	   are	   the	   first	   to	   show	   that	   p-­‐Smad3	  
levels	   were	   significantly	   downregulated	   in	   PE.	   We	   can	   only	   speculate	   as	   to	   whether	   the	  
dysregulation	  of	  Smad2/3	  observed	  in	  PE	  is	  a	  picture	  of	  an	  early	  event	  that	  contributes	  to	  the	  
etiology	  of	  the	  disease,	  or	  if	  this	  is	  a	  result	  of	  this	  gestational	  complication.	  It	  is	  possible	  that	  the	  
prolonged	  hypoxic	  status	  of	  PE	  can	  selectively	  inactivate	  Smad3	  without	  altering	  p-­‐Smad2	  levels	  
as	   reported	   in	   some	   cancers	   361.	   Alternatively,	   it	   is	   possible	   that	   the	   elevated	  p-­‐Smad2	   levels	  
contribute	  to	  the	  maternal	  dysfunction	  of	  PE	  by	  the	  Smad2-­‐dependent	  upregulation	  of	  sFlt-­‐1	  362.	  	  
	  
In	   conclusion,	   our	   study	   provides	   evidence	   for	   specific	   roles	   of	   Smad2	   and	   Smad3	   in	   TGF-­‐β	  
signaling	   in	  placenta.	   It	  demonstrates	   the	   importance	  of	   investigating	   the	   roles	  of	  Smad2	  and	  
Smad3	   independently,	   as	  well	   as	   together.	   Since	   siRNA	   are	   known	   to	   have	   off-­‐target	   effects,	  
validation	  of	  these	  findings	  with	  additional	  siRNA	  sequences	  would	  strengthen	  our	  conclusion.	  
From	  our	  findings	  and	  those	  reported	  by	  others,	  we	  postulate	  that	  a	  delicate	  balance	  of	  Smad2	  
versus	  Smad3	  expression	  exists	  at	  the	  anchoring	  column	  that	  drives	  the	  proliferative	  phenotype	  
at	   the	   proximal	   end,	   while	   promoting	   the	   pro-­‐invasive	   and	   pro-­‐angiogenic	   phenotype	   at	   the	  
distal	  end.	  However,	   the	  exact	  expression	  of	  both	  p-­‐Smad2	  and	  p-­‐Smad3	  across	  EVT	  columns	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needs	   to	   be	   validated.	   The	   mechanisms	   of	   Smad2	   and	   Smad3	   differential	   activation	   remain	  
unclear.	   It	   is	   most	   likely	   a	   spatially	   and	   temporally	   regulated	   mechanism	   dependent	   on	  
availability	  of	  ligands,	  receptors,	  and	  accessory	  proteins	  333.	  Our	  study	  is	  the	  first	  to	  explore	  the	  
differential	   role	  of	  Smad2	  and	  Smad3	   in	   the	   Invasive	  EVT	  pathway.	  Furthermore,	  our	   findings	  
highlight	   the	   importance	   of	   further	   characterizing	   key	   proteins	   involved	   in	   the	   regulation	   of	  
Smad2/3	   phosphorylation	   states	   across	   the	   feto-­‐placental	   interface	   in	   order	   to	   better	  
understand	  these	  intricate	  processes	  essential	  to	  healthy	  pregnancy	  outcomes.	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In	   this	   dissertation,	   I	   have	   investigated	   the	   function	   and	  mechanism	  of	  miR-­‐218-­‐5p	   in	  human	  
placenta	   development.	   Specifically,	   the	   overall	   objectives	   of	   this	   study	  were	   to	   1)	   determine	  
miR-­‐218-­‐5p	  function	  in	  EVT	  differentiation;	  2)	  investigate	  how	  the	  TGFβ	  pathway	  is	  involved	  in	  
miR-­‐218-­‐5p-­‐induced	   EVT	   differentiation;	   and	   3)	   further	   characterize	   the	   role	   of	   the	   TGFβ	  
pathway	  in	  EVT	  differentiation.	  	  
	  	  
I.	  miR-­‐218-­‐5p	  promotes	  trophoblast	  invasion	  and	  enEVT	  differentiation.	  
	  
The	   function	   of	   miR-­‐218-­‐5p	   in	   placenta	   development	   was	   investigating	   using	   both	   an	  
immortalized	   first	   trimester	   trophoblast	   cell	   line	  and	  human	  placenta	   tissues	   (Chapter	  2).	  We	  
confirm	   earlier	   reports	   of	  miR-­‐218-­‐5p	   downregulation	   in	   PE	   160.	   Furthermore,	  we	   report	   that	  
miR-­‐218-­‐5p	   is	   upregulated	   during	   second	   trimester	   and	   promotes	   trophoblast	   cell	  migration,	  
invasion,	  and	  differentiation	  into	  enEVTs.	  In	  addition,	  we	  show	  that	  miR-­‐218-­‐5p	  accelerated	  the	  
process	   of	   spiral	   artery	   remodelling.	   Together,	   our	   findings	   suggest	   that	   miR-­‐218-­‐5p	   is	   an	  
important	   regulator	   of	   placental	   development	   where	   it	   promotes	   the	   processes	   of	   EVT	  
differentiation,	   invasion	   and	   spiral	   artery	   remodelling.	   Dysregulation	   of	   miR-­‐218-­‐5p,	   and	  
consequently	  these	  key	  developmental	  processes,	  may	  contribute	  to	  the	  etiology	  of	  PE.	  	  	  
	  
Overexpression	  of	  miR-­‐218-­‐5p	  upregulated	  genes	  known	  to	  promote	  trophoblast	   invasion	  and	  
that	   are	   involved	   in	   enEVT	   differentiation,	   such	   as:	  MMP1,	   VE-­‐cad,	   PECAM1,	   IL-­‐1b,	   and	   IL8.	  
These	  data	  were	  confirmed	  with	   first	   trimester	  EVT	   treated	  with	  miR-­‐218-­‐5p	  or	  anti-­‐miR-­‐218-­‐
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5p.	  Migration	  and	  invasion	  assays	  revealed	  that	  cells	  overexpressing	  miR-­‐218-­‐5p	  migrated	  and	  
invaded	   in	   greater	   number	   across	   the	   transwells	   compared	   to	   controls.	   The	   opposite	   was	  
observed	   with	   anti-­‐miR-­‐218-­‐5p	   transfection.	   These	   data	   were	   validated	   in	   a	   first	   trimester	  
explant	  model.	  Overexpression	   of	  miR-­‐218-­‐5p	   promoted	   trophoblast	   endothelial-­‐like	   network	  
formation	   on	   matrigel,	   while	   anti-­‐miR-­‐218-­‐5p	   inhibited	   this	   process.	   Similarly,	   miR-­‐218-­‐5p	  
overexpressing	  cells	  promoted	  network	  formation	   in	  co-­‐culture	  with	  HUVEC	  and	  exhibited	  the	  
ability	   to	   replace	   endothelial	   cells.	   These	   data	   were	   confirmed	   in	   an	   in	   vitro	   model	   of	  
trophoblast-­‐mediate	  decidua	  vessel	  remodelling	  where	  miR-­‐218-­‐5p	  accelerated	  the	  remodelling	  
process.	  	  
	  
Starting	  from	  late	  first	  trimester	  the	  remodelling	  of	  spiral	  arteries	  is	  actively	  occurring	  until	  ~20	  
weeks	  of	  gestation	  54.	  As	  such,	  a	  spike	  in	  miR-­‐218-­‐5p	  during	  this	  stage	  of	  development	  is	  inline	  
with	  our	  observations	  that	  miR-­‐218-­‐5p	  promotes	  EVT	  differentiation,	  invasion	  and	  spiral	  artery	  
remodeling.	   Furthermore,	   we	   hypothesize	   that	   the	   upregulation	   of	   miR-­‐218-­‐5p	   in	   second	  
trimester	  is	  specific	  to	  the	  trophoblasts	  at	  the	  anchoring	  column	  that	  are	  entering	  the	  invasive	  
pathway.	   However,	   since	   these	   data	   were	   obtained	   from	   placental	   tissues	   that	   consist	   of	  
multiple	   cell	   types,	   future	   studies	   are	   required	   to	   identify	   which	   cell	   type(s)	   in	   the	   placenta	  
expresses	  miR-­‐218-­‐5p.	   Specifically	   in	   situ	   hybridization	   using	   first	   trimester	   EVT	   columns	   and	  
decidua	  basalis	  can	  be	  conducted	  to	  determine	  if	  miR-­‐218-­‐5p	  is	  expressed	  in	  the	  EVT	  population	  
that	  is	  actively	  invading	  and	  remodelling	  spiral	  arteries.	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In	  the	  future	  we	  are	   interested	   in	   investigating	  the	  possible	  use	  of	  miR-­‐218-­‐5p	  as	  a	  predictive	  
biomarker	  of	  PE.	  As	  previously	  discussed,	  miRNA	  show	  great	  potential	   as	   stable,	  non-­‐invasive	  
biomarkers	   262.	   Furthermore,	   miR-­‐218-­‐5p	   has	   already	   shown	   great	   promise	   as	   a	   predictive	  
biomarker	   in	  certain	  types	  of	  cancers	  272,273.	  Currently,	   in	  collaboration	  with	  Dr.	  Lye’s	  group	  at	  
Mount	   Sinai	   Hospital,	   we	   have	   obtained	   approval	   from	   the	   research	   ethics	   board	   to	   begin	  
processing	  plasma	  samples	  collected	  from	  asymptomatic	  women	  at	  10-­‐14	  weeks	  of	  gestation,	  
that	   later	   developed	   PE.	   In	   order	   to	   compare	   miR-­‐218-­‐5p	   levels	   from	   patients	   destined	   to	  
develop	  PE,	  we	  have	  a	   control	   group	   that	   is	  matched	   for	   race,	   gestational	   age,	   and	  maternal	  
age.	   I	   have	   conducted	   a	   pilot	   experiment	   with	   a	   small	   group	   of	   these	   samples	   to	   verify	   the	  
successful	  isolation	  and	  amplification	  of	  miR-­‐218-­‐5p.	  	  
	  
II.	  miR-­‐218-­‐5p	  exerts	  its	  effect	  through	  suppression	  of	  TGF-­‐β2.	  
The	   mechanism	   of	   miR-­‐218-­‐5p	   action	   was	   examined	   in	   the	   miR-­‐218-­‐5p	   overexpressing	   first	  
trimester	   trophoblast	   cell	   line	   (Chapter	   2).	   We	   found	   that	   miR-­‐218-­‐5p	   suppressed	   TGF-­‐β2	  
expression.	  TGF-­‐β2	   is	  a	  predicted	  target	  of	  miR-­‐218-­‐5p	  and	  a	   luciferase	  reporter	  assay	  using	  a	  
construct	  that	  contains	  a	  portion	  of	  the	  wild	  type	  TGF-­‐β2	  3’UTR	  confirms	  that	  TGF-­‐β2	  is	  a	  direct	  
target	  of	  miR-­‐218-­‐5p.	  To	  further	  validate	  this	  interaction	  we	  will	  repeat	  the	  luciferase	  reporter	  
assay	  using	  a	  construct	  containing	  point	  mutations	  in	  the	  miR-­‐218-­‐5p	  predicted	  binding	  region.	  	  
Treatment	  with	  recombinant	  TGF-­‐β2	  protein	  was	  able	  to	  rescue	  the	  pro-­‐invasive,	  and	  pro-­‐enEVT	  
differentiation	   effects	   observed	   with	  miR-­‐218-­‐5p	   overexpression.	   	   These	   results	   suggest	   that	  
miR-­‐218-­‐5p	  exerts	  its	  effects	  on	  placenta	  in	  part	  via	  the	  suppression	  of	  TGF-­‐β2	  expression.	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Furthermore,	   we	   showed	   miR-­‐218-­‐5p	   suppressed	   TGF-­‐β	   signaling	   using	   pAR3-­‐Lux	   reporter	  
assay.	  Interestingly,	  treatment	  with	  TGF-­‐β2	  was	  not	  able	  to	  rescue	  the	  reporter	  activity	  in	  miR-­‐
218-­‐5p	  overexpressing	  cells.	  These	  data	  suggest	  that	  TGF-­‐β2	  downstream	  signaling	  components	  
were	  also	  downregulated	  in	  our	  system.	  Since	  pAR3-­‐Lux	  is	  mainly	  Smad2	  responsive,	  and	  Smad2	  
had	   a	   potential	  miR-­‐218-­‐5p	  binding	   site,	  we	   checked	   for	   Smad2	   involvement	   in	   the	  miR-­‐218-­‐
5p/TGF-­‐β2	  mechanism.	  As	  suspected,	  Smad2	  was	  downregulated	  in	  miR-­‐218-­‐5p	  overexpressing	  
cells.	   Furthermore,	   the	   knockdown	   of	   Smad2	   mimicked	   the	   miR-­‐218-­‐5p	   phenotype.	  
Interestingly,	   the	   overexpression	   of	   Smad2	   did	   not	   suppress	   enEVT	  markers,	   suggesting	   that	  
TGF-­‐β2	  was	  needed	  for	  the	  activation	  of	  specific	  Smad2	  co-­‐repressors	  (data	  not	  shown).	  	  
	  
In	   addition	   to	   TGF-­‐β2,	  miR-­‐218-­‐5p	  has	   two	  predicted	   targets	   in	   the	   3’UTR	  of	  Nodal.	   Previous	  
studies	   from	   our	   lab	   reported	   the	   Nodal	   was	   upregulated	   in	   PE	   and	   inhibited	   trophoblast	  
proliferation,	  migration,	   and	   invasion	   221,235.	  We	   confirmed	   that	   Nodal	  was	   downregulated	   in	  
miR-­‐218-­‐5p	  overexpressing	  cells	   (Figure	  4.1A	  and	  4.1B).	  Furthermore,	  we	  confirmed	  that	  miR-­‐
218-­‐5p	   suppressed	  Nodal	   expression	   through	   binding	   to	   both	   its	   targets	   in	   the	   3’UTR	   (Figure	  
4.1C).	   Future	   studies	  are	  needed	   to	  determine	   if	  Nodal	  mediates	   some	  of	   the	  effects	  of	  miR-­‐
218-­‐5p	  on	  enEVT	  differentiation	  and	  spiral	  artery	  remodelling.	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Figure	  4.1	  miR-­‐218-­‐5p	  downregulates	  Nodal	  through	  its	  3'UTR.	  
(A)	   Nodal	   mRNA	   expression	   was	   significantly	   (p<0.001)	   reduced	   in	   mir-­‐218-­‐1	   overexpressing	  
cells	   compared	   to	   control	   cells.	   (B)	   Mir-­‐218-­‐1	   suppressed	   levels	   of	   mature	   nodal	   protein	  
compared	  to	  control.	  (C)	  A	  fragment	  of	  the	  Nodal	  3’UTR	  containing	  the	  two	  predicted	  miR-­‐218-­‐
5p	   target	   sites	   was	   cloned	   upstream	   of	   a	   luciferase	   gene.	   Transfection	   with	   miR-­‐218-­‐5p	  
significantly	  (p<0.05)	  suppressed	  luciferase	  activity	  of	  the	  wild	  type	  (WT)	  3’UTR.	  Mutation	  of	  the	  
first	  or	  second	  binding	  site	  partially	  reversed	  the	  miR-­‐218-­‐5p	  effect.	  Mutation	  of	  both	  binding	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III.	  Smad2	  and	  Smad3	  have	  distinct	  roles	  in	  enEVT	  differentiation.	  	  
	  
In	   Chapter	   2	   of	   this	   dissertation	   I	   report	   that	   the	   miR-­‐218-­‐5p/TGF-­‐β2	   mechanism	   is	   in	   part	  
mediated	  through	  Smad2,	  and	  not	  Smad3.	  The	  distinct	  roles	  of	  Smad2	  and	  Smad3	  prompted	  us	  
to	   further	   characterize	   these	   R-­‐Smads	   in	   placenta	   development	   (Chapter	   3).	   Specifically,	   we	  
show	  that	  Smad2	  acts	  as	  a	  suppressor,	  while	  Smad3	  acts	  as	  a	  promoter,	  of	  trophoblast	  invasion	  
and	  differentiation	  into	  invasive,	  endovascular	  EVTs.	  Furthermore,	  we	  report	  that	  the	  total	  level	  
of	  Smad2	  and	  Smad3	  protein	  does	  not	  change	  across	  gestation,	  but	  the	  phosphorylated	  states	  
of	  these	  proteins	  show	  opposite	  patterns.	  P-­‐Smad2	  was	  higher	  in	  later	  gestation,	  while	  p-­‐Smad3	  
was	  higher	   in	  the	  first	  twenty	  weeks	  when	  the	   invasive	  pathway	   is	  most	  active.	  Lastly,	   for	  the	  
first	  time	  we	  report	  a	  complete	  loss	  of	  p-­‐Smad3	  in	  PE	  placenta	  tissues.	  	  
	  
Our	  findings,	  that	  Smad2	  and	  Smad3	  have	  differential	  roles	  in	  EVT	  differentiation,	  can	  be	  further	  
strengthened	   through	   several	   methods.	   First,	   we	   can	   repeat	   our	   key	   findings	   with	   two	  
additional	  siRNAs	  targeting	  different	  regions	  of	  Smad2	  or	  Smad3	  to	  ensure	  the	  observed	  effects	  
are	  not	  a	   result	  of	  off-­‐target	   genes.	  However,	  our	   Smad2	  or	   Smad3	  overexpression	  data	   is	   in	  
support	   of	   our	   endothelial-­‐like	   network	   formation	   in	   the	   siRNA	   knockdown	   approach.	   I	   have	  
already	   confirmed	   the	   suppression	   of	   endothelial-­‐like	   network	   formation	   for	   two	   additional	  
siSmad3	  siRNAs.	  Second,	  our	  phosphorylation	  Smad	  data	  is	  based	  on	  protein	  lysates	  from	  pieces	  
of	  whole	  placenta.	  As	  such,	  the	  relative	  Smad2	  or	  Smad3	  expression	  may	  be	  confounded	  by	  the	  
presence	   of	   cell	   types	   other	   than	   trophoblasts.	   I	   have	   performed	   preliminary	  
immunohistochemistry	   experiments	   on	   first	   trimester	   placenta,	   and	   observed	   strong	   staining	  
for	  both	  Smad2	  and	  Smad3	  in	  EVT	  columns.	  	  We	  have	  obtained	  histological	  sections	  of	  healthy	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placenta	  across	  gestation,	  and	  PE	   tissues.	  These	   sections	  can	  be	  used	   to	  validate	  our	   findings	  
with	  p-­‐Smad2	  or	  p-­‐Smad3	  specific	  antibodies.	  	  
	  
Furthermore,	   our	   Smad2	   and	   Smad3	   functional	   findings	   focus	   on	   the	   invasive	   trophoblast	  
pathway.	   As	   previously	   mentioned,	   the	   expression	   of	   TGF-­‐β/Nodal/Activin	   pathway	   signaling	  
components	   in	  STBs	  have	  been	  reported	  235,363,364.	  TGF-­‐β1	  was	  shown	  to	  promote	  trophoblast	  
fusion	  into	  STBs	  and	  hCG	  production	  in	  part	  through	  a	  Smad-­‐dependent	  mechanism	  228,365.	  On	  
the	  other	  hand,	  TGF-­‐β1	  inhibition	  of	  hCG	  production	  was	  also	  reported	  224.	  TGF-­‐β1	  inhibition	  on	  
progesterone	   and	   estradiol	   production	   by	   trophoblast	   has	   also	   been	   reported	   226,366,	   while	  
Activin	  signals	  have	  shown	  to	  have	  a	  promoting	  effect	  on	  progesterone	  and	  estradiol	  225.	  	  In	  the	  
future,	  we	   can	   investigate	   the	   role	   of	   Smad2	   versus	   Smad3,	   or	   their	   combined	   action,	   in	   the	  
trophoblast	  fusion	  and	  hormone	  production	  pathway.	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FUTURE	  DIRECTIONS	  
	  
In	  Chapter	  2	  of	  this	  dissertation,	  we	  report	  that	  miR-­‐218-­‐5p	  promotes	  trophoblast	  invasion	  and	  
enEVT	   differentiation	   in	   part	   through	   the	   suppression	   of	   TGF-­‐β2/Smad2	   signaling.	   The	   Gene	  
Ontology	  enrichment	  analysis	  from	  our	  mir-­‐218-­‐1	  overexpressing	  cell	   line	  showed	  a	  significant	  
enrichment	  of	  genes	  belonging	  to	  the	  nuclear	  factor	  kappa-­‐light-­‐chain-­‐enhancer	  of	  activated	  B	  
cells	   (NF-­‐κB)	   pathway.	   The	   NF-­‐κB	   pathway	   is	   important	   in	   the	   expression	   of	   many	  
proinflammatory	   cytokines	   and	   adhesion	   molecules	   367.	   The	   upregulation	   of	   NF-­‐κB	   in	   first	  
trimester	   trophoblasts	   resulted	   in	   increased	   migration	   368.	   Furthermore,	   IL1b	   expression	   is	  
upregulated	   by	   the	   NF-­‐κB	   transcription	   heterodimer,	   p50/p65	   369.	   I	   performed	   several	  
preliminary	  experiments	  to	  elucidate	  the	  possible	  role	  of	  NFκB	  in	  the	  miR-­‐218-­‐5p	  upregulation	  
of	  invasion	  and	  enEVT	  differentiation.	  	  
	  
	  To	   confirm	   the	  upregulation	  of	  NF-­‐κB	   signaling	   in	  our	  mir-­‐218	   stable	   cell	   lines	   I	   performed	  a	  
nuclear	  fractionation	  in	  order	  to	  check	  for	  p50	  and	  p65	  nuclear	  accumulation.	   In	   line	  with	  our	  
microarray	   findings,	  we	   observed	   the	   nuclear	   accumulation	   of	   both	   p50	   and	   p65,	  which	  was	  
reversed	  upon	   treatment	  with	  a	  NF-­‐κB	   inhibitor,	  ACHP	   (2-­‐Amino-­‐6-­‐[2-­‐(cyclopropylmethoxy)-­‐6-­‐
hydroxyphenyl]-­‐4-­‐(4-­‐piperidinyl)-­‐3-­‐pyridinecarbonitrile)	  (Figure	  4.2A).	  Next	  we	  wanted	  to	  test	  if	  
the	   miR-­‐218-­‐5p	   upregulation	   of	   IL1b	   was	   positively	   regulated	   through	   the	   NF-­‐κB	   pathway.	  
Transfection	  of	  primary	  EVT	  with	  miR-­‐218-­‐5p	  upregulated	  IL1b	  as	  reported	  in	  Chapter2,	  and	  this	  
effect	  was	  inhibited	  with	  ACHP	  treatment	  (Figure	  4.2B).	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Figure	  4.2	  Mir-­‐218-­‐1	  promotes	  invasion	  and	  enEVT	  differentiation	  through	  IL1b/NFkB.	  
(A)	  Mir-­‐218	   overexpressing	   cells	   had	   an	   increase	   of	   p50	   and	   p65	   nuclear	   accumulation	   than	  
control	   cells.	   The	   nuclear	   accumulation	   was	   reversed	   with	   a	   NF-­‐κB	   pathway	   inhibitor,	   ACHP	  
(10μM).	   The	   “+”	   indicated	   a	   longer	   exposure	   time	   during	   development.	  NB:	  GAPDH	  blot	  was	  
stripped	   and	   re-­‐blotted	  with	   Lamin	   B	   (nuclear	  marker)	   (B)	  Mir-­‐218	   upregulation	   of	   IL1b	  was	  
inhibited	   with	   the	   NF-­‐κB	   pathway	   inhibitor	   (C)	   The	  mir-­‐218	   pro-­‐invasive	   effect	   was	   reversed	  
with	   inhibition	   of	   the	   NF-­‐κB	   pathway.	   (D)	   Treatment	   with	   recombinant	   IL1b	   (10ng/mL)	  
upregulated	  genes	  involved	  in	  trophoblast	  invasion	  and	  enEVT	  differentiation.	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The	  pro-­‐invasive	   role	  of	   IL1b	   in	  primary	   first	   trimester	   trophoblasts	  has	  been	   reported	   370.	   To	  
investigate	  if	  the	  NF-­‐κB	  pathway	  mediated	  the	  pro-­‐invasive	  effect	  of	  miR-­‐218-­‐5p	  we	  treated	  our	  
stable	  cells	  with	  and	  without	  the	  NF-­‐κB	  inhibitor.	  Our	  data	  report	  that	  miR-­‐218-­‐5p	  upregulated	  
invasion	  through	  the	  upregulation	  of	  NFkB	  signaling	  (Figure	  4.2C).	  Next,	  we	  wanted	  to	  test	  the	  
possible	   role	  of	  NF-­‐κB/IL1b	   signaling	   in	   enEVT	  differentiation.	   Treatment	  of	  HTR8/SVneo	   cells	  
with	  recombinant	   IL1b	  resulted	   in	  the	  upregulation	  of	  the	  same	  genes	   involved	   in	  trophoblast	  
invasion	   and	   enEVT	   differentiation	   that	   we	   observed	   with	   miR-­‐218-­‐5p	   overexpression.	  
Specifically,	   IL1b	  upregulated	  VE-­‐cadherin,	  PECAM1,	  MMP1,	   IL8,	  and	  had	  positive	  feedback	  on	  
its	   own	   expression	   (Figure	   4.2D).	   	   To	   our	   knowledge,	   the	   role	   of	   IL1b	   or	   NFkB	   on	   enEVT	  
differentiation	  has	  not	  been	  reported.	  However,	  IL1b	  has	  been	  reported	  to	  upregulate	  MMP1,	  
IL8,	   and	   to	   form	   a	   positive	   feedback	   with	   NF-­‐κB	   in	   other	   systems	   371-­‐373.	   These	   preliminary	  
findings	  suggest	  that	  miR-­‐218-­‐5p	  exerts	  its	  effect	  through	  the	  upregulation	  of	  NF-­‐κB	  in	  addition	  
to	  its	  suppression	  of	  TGF-­‐β2.	  	  	  
	  
In	  the	  future,	  we	  can	   investigate	  the	  potential	  mechanisms	  by	  which	  miR-­‐218-­‐5p	   	  upregulates	  
NFkB	   signaling.	   Since	   the	   TGF-­‐β-­‐Smad	   pathway	   has	   been	   reported	   to	   inhibit	   NFkB	   signaling	  
374,375,	  one	  possible	  mechanism	  to	  explore	  is	  to	  determine	  if	  miR-­‐218-­‐5p	  activates	  NFkB	  signaling	  
via	  the	  inhibition	  of	  TGF-­‐β/Smad.	  Furthermore,	  we	  can	  further	  characterize	  the	  role	  of	  NF-­‐κB	  in	  
the	  invasive	  and	  enEVT	  pathway	  by	  investigating	  another	  NF-­‐κB	  regulated	  cytokine,	  IL8.	  IL8	  has	  
been	  reported	  to	  promote	  trophoblast	  invasion,	  but	  its	  direct	  role	  in	  enEVT	  differentiation	  has	  
not	  been	  well	  characterized.	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Despite	   the	   downregulation	   of	   miR-­‐218-­‐5p	   in	   PE,	   its	   role	   in	   placenta	   has	   never	   been	  
investigated.	   The	   present	   study	   provides	   the	   first	   evidence	   that	   miR-­‐218-­‐5p	   promotes	  
trophoblast	   migration,	   invasion,	   differentiation	   into	   enEVT,	   and	   spiral	   artery	   remodelling.	  
Identifying	  the	  mechanisms	  involved	  in	  establishing	  the	  feto-­‐maternal	  perfusion	  are	  important	  
to	  our	  understanding	  of	  the	  critical	  processes	  that	  are	  dysregulated	  in	  gestational	  hypertensive	  
disorders	   like	   PE.	   To	   our	   knowledge,	   this	   is	   the	   first	   study	   to	   implicate	   the	   involvement	   of	  
miRNAs	   in	   these	   vital	   processes.	   Specifically,	   this	   study	   has	   highlighted	   the	   importance	   of	  
investigating	   the	   role	   of	   miRNAs	   further	   than	   their	   implication	   on	   trophoblast	   invasion	   and	  
migration,	  which	  is	  the	  predeominant	  focus	  of	  research	  currently	  published.	  In	  addition,	  this	  is	  
the	   first	   study	   to	   implement	   the	   in	   vitro	   model	   of	   trophoblast-­‐mediated	   decidua	   vessel	  
remodelling	  and	  will	  hopefully	  contribute	  to	  future	  utilization	  of	  this	  novel	  and	  useful	  tool.	  	  
	  
Furthermore,	  this	  study	  identifies	  TGF-­‐β2-­‐Smad2	  as	  a	  key	  pathway	  that	  mediates	  the	  action	  of	  
miR-­‐218-­‐5p.	   In	   addition,	   we	   report	   a	   differential	   role	   of	   Smad2	   and	   Smad3	   in	   placenta	  
development.	   Our	   data	   suggest	   that	   Smad2	   acts	   to	   suppress,	   while	   Smad3	   acts	   to	   promote,	  
trophoblast	  invasion	  and	  enEVT	  differentiation.	  These	  data	  highlight	  the	  role	  of	  miR-­‐218-­‐5p	  and	  
TGF-­‐β	  signaling	   in	  key	  events	  that	  are	  dysregulated	  in	  PE.	  While	  the	  involvement	  of	  the	  TGF-­‐β	  
pathway	   in	   PE	   is	   not	   novel,	   we	   have	   added	   to	   the	   current	   understanding	   of	   this	  mechanism	  
through	  the	  involvement	  of	  miRNA	  regulation.	  In	  addition,	  our	  preliminary	  findings	  that	  Smad2	  
and	   Smad3	  have	  distinct	   function	   in	   trophoblast	   development	   introduce	   a	   new	  aspect	   of	   the	  
TGF-­‐β	  signaling	  pathway	  that	  may	  elucidate	  some	  conflicting	  reports	  in	  literature.	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Taken	   together,	   our	   study	   suggests	   the	   dysregulation	   of	   the	   miR-­‐218-­‐5p/TGF-­‐β	   mechanism	  
contributes	   to	   the	   etiology	   of	   PE	   (Figure	   4.3).	   The	   use	   of	   microRNAs	   as	   potential	   plasma	  
biomarkers	   has	   been	   investigated	   223,316,	   and	   a	   significant	   increase	   in	   serum	   TGFβ-­‐2	   was	  
reported	   in	   cases	   of	   severe	   PE	   and	   eclampsia	   compared	   to	   control	   254.	   These	   data,	   taken	  
together	  with	  our	  findings,	  suggest	  great	  potential	  of	  investigating	  the	  utilization	  of	  miR-­‐218-­‐5p	  
as	  part	  of	  a	  predictive	  biomarker	  panel	  of	  PE.	  The	  effectiveness	  of	  managing	  clinical	  symptoms	  
greatly	  depends	  on	  implementing	  therapeutic	  intervation	  early.	  Having	  a	  collection	  of	  predictive	  
and	  accurate	  biomarkers	  can	  ultimately	  help	   in	   reducing	  severity	  of	   symptons	  and	  subseqntly	  
the	   frequency	   of	   premature	   deliveries	   and	   other	   complications	   thereby	   improving	   the	   health	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Figure	  4.3	  Proposed	  mechanism	  of	  miR-­‐218-­‐5p	  in	  healthy	  and	  PE	  placentas.	  
Mir-­‐218-­‐5p	  promotes	  trophoblast	  invasion,	  enEVT	  differentiation,	  and	  spiral	  artery	  remodeling	  
partially	  by	  the	  suppression	  of	  TGFβ2/Smad2	  signaling.	  We	  postulate	  that	  the	  downregulation	  
of	   miR-­‐218-­‐5p,	   and	   the	   subsequent	   upregulation	   of	   TGFβ	   signaling,	   contribute	   to	   poor	  
trophoblast	   invasion,	   reduced	   enEVT	   pool,	   and	   shallow	   spiral	   artery	   remodelling	   resulting	   in	  
variable	   blood	   flow	   with	   high	   velocity	   to	   the	   intervillous	   space	   that	   are	   observed	   in	  
preeclampsia.	  iEVT-­‐	  interstitial	  extravillous	  trophoblast,	  enEVT-­‐	  endovascular	  EVT.	  Bottom	  panel	  
used	  with	  permission	  from	  Chaiworapongsa	  T.,	  et	  al.	  (2014)	  60.	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APPENDIX	  A:	  EXTENDED	  PROTOCOLS	  
	  
Isolation	  of	  Primary	  Human	  Umbilical	  Vein	  Endothelial	  Cells	  (HUVEC)	  
	  
Protocol	  modified	  from	  Davis,	  J.,	  Crampton,	  S.	  P.,	  Hughes,	  C.	  C.	  Isolation	  of	  Human	  Umbilical	  Vein	  Endothelial	  Cells	  




1. After	  cesarean	  delivery,	  if	  the	  placenta	  is	  not	  needed,	  sever	  the	  umbilical	  cord	  from	  the	  
placenta	  with	  a	  fresh	  razor	  blade.	  	  
N.B:	  If	  cord	  blood	  was	  banked	  ensure	  to	  ask	  the	  nurse	  to	  retrieve	  the	  umbilical	  cord	  that	  
was	  removed	  during	  this	  procedure.	  Otherwise	  the	  cord	  remaining	  attached	  to	  the	  
placenta	  may	  not	  be	  sufficient	  for	  the	  isolation	  procedure.	  	  
	  
2. Transport	  the	  umbilical	  cord	  in	  a	  clean	  container	  or	  ziplock	  bag	  on	  ice	  and	  transfer	  to	  4°C	  
refrigerator	  for	  a	  minimum	  of	  2	  and	  a	  maximum	  of	  4	  days.	  	  
N.B:	  For	  successful	  isolation	  the	  cord	  needs	  to	  be	  aged	  in	  order	  for	  the	  coagulation	  





3. Take	  the	  umbilical	  cord	  out	  of	  the	  refrigerator	  and	  lay	  it	  down	  onto	  a	  clean	  diaper	  pad	  
inside	  the	  cell	  culture	  hood.	  	  
	  
4. With	  gauze	  dab	  off	  excess	  blood	  and	  make	  fresh	  cuts	  on	  both	  ends	  of	  the	  cord	  with	  
sterile	  scissors	  or	  razor	  blade.	  You	  should	  see	  two	  arteries	  (protruding	  out)	  and	  one	  vein	  
(largest	  opening).	  	  
	  
5. Gently	  insert	  the	  21g	  butterfly	  needle	  with	  sheath	  on	  (BD	  Vacutainer	  No.	  367296)	  into	  
the	  vein.	  If	  you	  feel	  any	  resistance,	  just	  twist	  the	  cord	  as	  you	  gently	  push	  the	  needle	  
(with	  sheath	  on)	  until	  the	  wings	  of	  the	  butterfly	  needle	  are	  flush	  with	  the	  cord.	  At	  this	  
point	  clasp	  the	  needle	  in	  place	  with	  a	  sterile	  hemostat.	  
	  
6. Fill	  a	  20mL	  syringe	  with	  Hank’s	  Buffered	  Salt	  Solution	  (1X	  -­‐Mg2+,	  -­‐Ca2+,	  and	  10,000	  
I.U./mL	  Penicillin,	  10,000	  (μg/mL)	  Streptomycin)	  and	  attach	  to	  the	  butterfly	  
needle	  tubing.	  Gently	  push	  the	  fluid	  through	  the	  cord	  allowing	  it	  to	  pass	  out	  the	  open-­‐
end	  one	  drip	  at	  a	  time	  into	  a	  waste	  container	  filled	  with	  bleach.	  	  
	  
7. Repeat	  the	  wash	  with	  an	  additional	  20mL	  of	  HBSS.	  Before	  the	  last	  5mL	  are	  pushed	  
through,	  lay	  the	  cord	  down	  and	  clasp	  the	  open	  end	  of	  the	  cord	  closed	  with	  a	  second	  
haemostat.	  Slowly	  fill	  the	  vein	  with	  the	  remaining	  HBSS	  to	  check	  for	  any	  leaks.	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N.B:	  This	  is	  especially	  important	  if	  cord	  blood	  was	  banked.	  In	  the	  case	  of	  holes	  you	  need	  
to	  locate	  them	  and	  see	  if	  they	  can	  be	  closed	  off	  with	  a	  third	  haemostat	  during	  the	  
enzymatic	  step.	  If	  not,	  the	  cord	  will	  not	  be	  usable	  for	  the	  remainder	  of	  the	  protocol	  and	  
can	  be	  discarded.	  	  	  
	  
8. Remove	  the	  haemostat	  from	  the	  open	  end	  and	  slowly	  push	  the	  remaining	  HBSS	  into	  the	  
waste	  collection	  container.	  	  
	  
9. 	  Place	  10mL	  of	  sterile	  Dulbecco's	  Phosphate-­‐Buffered	  Saline	  (1X	  +D-­‐Glucose,	  +	  Sodium	  
Pyruvate;	  GIBCO	  14287)	  into	  a	  sterile	  15mL	  falcon	  tube.	  Weigh	  out	  10mg	  of	  Collagenase	  
Type	  I	  (Worthington),	  then	  add	  it	  to	  the	  DPSB	  and	  invert	  until	  dissolved.	  
	  
10. 	  Once	  the	  0.1%	  collagenase	  solution	  is	  fully	  dissolved,	  filter	  it	  with	  a	  syringe	  filter	  (0.22	  
micron)	  and	  warm	  in	  37°C	  in	  water	  bath	  for	  15min.	  	  
	  
11. In	  a	  1L	  glass	  beaker	  place	  ~500mL	  of	  DPBS,	  cover	  with	  aluminum	  foil,	  and	  place	  into	  37°C	  
water	  bath.	  
	  
12. 	  Take	  out	  a	  new	  25mL	  syringe	  and	  remove	  the	  plunger.	  	  Attach	  25mL	  syringe	  to	  the	  
needle	  tubing	  and	  pour	  in	  the	  10ml	  of	  collagenase	  and	  replace	  the	  plunger.	  
	  
13. Slowly	  push	  the	  collagenase	  into	  the	  vein	  until	  you	  see	  the	  first	  amount	  exit	  the	  open	  
end.	  This	  is	  to	  wash	  out	  the	  residual	  HBSS.	  Then	  quickly	  re-­‐clamp	  the	  open	  end	  and	  fill	  
with	  collagenase	  until	  there	  is	  moderate	  distention	  of	  vein.	  	  
	  
14. Once	  the	  cord	  is	  filled	  with	  collagenase	  you	  want	  to	  gently	  massage	  it	  starting	  from	  left	  
to	  right.	  Using	  the	  pads	  of	  three	  fingers	  apply	  moderate	  pressure	  to	  the	  cord.	  The	  
pressure	  and	  motion	  is	  similar	  to	  that	  of	  rolling	  bread	  dough.	  Spend	  about	  5-­‐6	  seconds	  
on	  each	  portion	  of	  the	  cord.	  The	  pressure	  and	  length	  need	  to	  be	  strong/long	  enough	  to	  
dislodge	  the	  HUVECs	  but	  not	  to	  get	  smooth	  muscle	  contamination.	  	  
	  
15. After	  massaging	  incubate	  the	  cord	  (with	  hemostats,	  needle	  and	  syringe	  attached)	  in	  
DPBS	  at	  37°C	  for	  15	  min.	  	  
N.B:	  Collagenase	  activity	  varies,	  therefore	  will	  need	  to	  optimize	  the	  incubation	  time	  
(10min-­‐20min)	  for	  each	  lot.	  Keep	  in	  mind	  the	  HUVEC	  readily	  proliferate	  so	  it	  is	  safer	  to	  
incubate	  for	  shorter	  time	  than	  risk	  contamination	  of	  smooth	  muscle	  cells	  or	  fibroblasts.	  	  
	  
16. After	  incubation,	  remove	  cord	  from	  DPBS.	  Place	  a	  50mL	  falcon	  tube	  filled	  with	  5mL	  of	  
plating	  media	  in	  a	  rack.	  While	  holding	  the	  cord	  over	  the	  50mL	  tube	  cut	  the	  end	  above	  
the	  line	  of	  the	  bottom	  clamp	  creating	  a	  fresh	  cut.	  Push	  the	  remaining	  collagenase	  
through	  the	  cord	  slowly,	  same	  as	  before	  with	  the	  HBSS.	  	  
17. Remove	  the	  syringe	  from	  the	  tubing.	  Place	  a	  fresh	  25mL	  syringe	  filled	  with	  20mL	  of	  HBSS	  
and	  slowly	  push	  through	  the	  vein	  into	  the	  collection	  tube	  with	  the	  same	  pace	  as	  during	  
the	  washing	  step.	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N.B:	  In	  this	  step	  you	  are	  dislodging	  any	  HUVEC	  that	  didn’t	  come	  out	  during	  the	  previous	  
step.	  	  
	  
18. Spin	  the	  collection	  tube	  at	  1200	  rpm	  for	  5min	  (as	  with	  other	  cells).	  	  
N.B:	  There	  will	  be	  a	  big	  pellet	  that	  appears	  to	  be	  made	  of	  red	  blood	  cells,	  debris,	  etc.	  
After	  the	  HUVEC	  attach	  overnight	  all	  of	  these	  components	  will	  be	  washed	  off.	  
	  
19. Aspirate	  the	  supernatant	  and	  resuspend	  in	  10%	  FBS	  containing	  M199	  media	  
supplemented	  with	  10,000	  I.U./mL	  Penicillin,	  10,000	  (μg/mL)	  Streptomycin,	  and	  50	  
μg/mL	  of	  Endothelial	  Cell	  Growth	  Supplement	  (ECGS;	  Corning	  356006)	  on	  a	  10cm	  cell	  
culture	  dish.	  Incubate	  overnight	  at	  37°C	  with	  5%	  CO2.	  
N.B:	  Cells	  can	  be	  grown	  in	  20%	  FBS	  containing	  media	  to	  speed	  up	  their	  initial	  recovery	  
after	  isolation.	  Alternatively,	  the	  cells	  can	  be	  grown	  in	  Lonza	  Endothelial	  Cell	  Basal	  Media	  
-­‐2	  +	  Bullet	  Kit	  (No.CC-­‐3156)	  media.	  However,	  if	  you	  are	  testing	  the	  effect	  of	  certain	  
molecules	  on	  their	  pro-­‐	  or	  anti-­‐angiogenic	  capacity,	  using	  a	  very	  rich	  media	  may	  
confound	  your	  findings.	  In	  this	  case	  using	  the	  M199	  media	  supplemented	  with	  ECGS	  is	  




20. Aspirate	  the	  media	  from	  the	  attached	  cells,	  and	  wash	  several	  times	  with	  warmed	  1x	  PBS.	  
Replenish	  with	  fresh	  growth	  media	  and	  allow	  cells	  to	  proliferate	  until	  80%	  confluent	  
refreshing	  the	  media	  every	  2	  days.	  	  
N.B:	  HUVEC	  will	  begin	  to	  senes	  after	  10-­‐15	  passages.	  It	  is	  best	  to	  allow	  freshly	  isolated	  
cells	  to	  grow	  in	  10cm	  dish	  then	  split	  the	  one	  plate	  onto	  four	  additional	  10cm	  plates	  (if	  
cells	  are	  fast	  growing	  can	  split	  1:6)	  and	  freeze	  them	  down	  for	  future	  use	  at	  the	  early	  
passage.	  Cells	  can	  be	  frozen	  down	  as	  usual	  in	  10%	  DMSO	  containing	  full	  growth	  media	  
(ECGS	  not	  needed).	  	  
	  
	  
Preparation	  of	  ECGS	  (Corning	  356006)	  
	  
100mg	  ECGS	  	  
100mg	  Heparan	  Sulfate	  Salt	  
	  
1.	  Dissolve	  in	  20mL	  of	  serum	  free	  M199	  media	  
2.	  Filter	  with	  0.22	  micron	  syringe	  filter	  
3.	  Store	  in	  200ul	  aliquots	  in	  -­‐80°C	  
4.	  Use	  100ul	  of	  the	  5mg/mL	  solution	  per	  10mL	  of	  media.	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1. Thaw	  phenol	  red-­‐free	  growth	  factor	  containing	  matrigel	  (BD	  Biosciences	  354262)	  on	  ice.	  	  
N.B:	  Matrigel	  will	  polymerize	  at	  room	  temperature,	  ensure	  it	  is	  kept	  on	  ice	  at	  all	  times	  
until	  needed.	  	  
	  
2. Place	  all	  placenta	  tissues	  for	  processing	  on	  ice.	  Each	  patient’s	  placenta	  will	  be	  contained	  
in	  a	  numbered	  50mL	  falcon	  tube	  in	  PBS	  (without	  Ca++	  and	  Mg++).	  One	  placenta	  at	  a	  time,	  
empty	  contents	  of	  falcon	  tube	  into	  a	  clean	  10cm	  petri	  dish.	  	  Keep	  sample	  ID	  and	  
gestation	  age	  in	  notes	  for	  future	  reference.	  	  
	  
3. Clean	  fine	  tweezers	  and	  dissecting	  scissors	  with	  70%	  Ethanol.	  	  
	  
4. Under	  sterile	  conditions	  place	  the	  Millicell™	  Culture	  Plate	  Inserts	  (Millipore;	  PICM01250)	  
into	  a	  24-­‐well	  cell	  culture	  plate.	  One	  insert	  per	  villi	  tree	  will	  be	  needed.	  Pipette	  200	  μl	  of	  
ice-­‐cold	  matrigel	  into	  each	  insert	  ensuring	  to	  cover	  the	  whole	  bottom	  and	  not	  create	  any	  
bubbles.	  	  Pipette	  600	  μl	  of	  DMEM/F12	  Phenol-­‐red	  free	  media	  around	  each	  insert.	  Let	  the	  
matrigel	  polymerize	  at	  37°C	  for	  20	  minutes.	  
	  
5. Examine	  the	  tissue	  under	  a	  dissecting	  microscope	  (preferably	  in	  a	  sterile	  environment	  
eg.	  Class	  II	  fume	  hood).	  Depending	  on	  gestation	  age,	  a	  healthy	  placenta	  will	  have	  these	  
key	  features:	  
i. Intact	  villi	  with	  little/no	  shredding	  and	  debris	  
ii. 5-­‐6	  week	  placentas	  have	  shorter	  villi	  that	  lack	  elaborate	  vascularization.	  Many	  
villi	  contain	  EVT	  columns,	  however	  overall	  tissue	  size	  is	  small.	  
iii. 7-­‐9	  week	  placentas	  have	  longer	  villi	  that	  are	  progressively	  more	  vascularized.	  
With	  advancing	  gestation	  EVT	  containing	  villi	  decrease	  and	  are	  often	  found	  in	  
clusters	  of	  very	  bright	  and	  vascularized	  villi.	  The	  placenta	  will	  contain	  more	  
floating	  villi	  than	  in	  younger	  tissues.	  
iv. EVT	  containing	  villi	  will	  often	  have	  white	  fuzzy	  caps	  that	  consist	  of	  the	  
trophoblast-­‐derived	  matrix.	  	  
	  
6. Once	  an	  EVT	  column	  containing	  villi	  is	  identified,	  carefully	  cut	  the	  villi	  tree	  at	  its	  base	  
where	  it	  connects	  to	  the	  chorionic	  plate.	  Place	  the	  cut	  villi	  in	  fresh	  PBS	  on	  ice.	  	  
N.B:	  To	  ensure	  enough	  tissue	  will	  be	  successfully	  attached	  for	  experimental	  set	  up	  always	  
process	  more	  tissue	  than	  needed.	  	  
	  
7. Process	  one	  villi	  at	  a	  time	  to	  ensure	  tissue	  does	  not	  dry	  out.	  Hold	  the	  base	  of	  the	  villi	  
with	  tweezers	  while	  gently	  separating	  the	  villi	  tips	  from	  one	  another	  with	  a	  sterile	  
needle.	  Very	  carefully	  loosen	  the	  matrix	  on	  the	  tip	  of	  the	  EVT	  columns.	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N.B:	  Gently	  scratching	  the	  matrix	  will	  allow	  the	  EVT	  located	  beneath	  to	  grow	  out	  on	  to	  
the	  matrigel.	  Completely	  removing	  the	  matrix	  can	  risk	  removing	  all	  EVT	  cells	  in	  the	  tip	  
with	  them.	  	  
	  
8. Transfer	  the	  prepared	  villi	  tri	  onto	  the	  polymerized	  matrigel.	  Pull	  the	  base	  of	  the	  villi	  tri	  
(where	  it	  was	  cut)	  to	  one	  side	  and	  with	  a	  needle,	  ensuring	  not	  to	  damage	  the	  matrigel,	  
spread	  out	  the	  remaining	  villi	  branches	  giving	  them	  each	  room	  to	  grow	  out	  on	  to	  the	  
matrigel.	  	  
	  
9. Once	  all	  villi	  are	  spaced	  out	  onto	  the	  matrigel-­‐coated	  inserts,	  place	  the	  plate	  into	  a	  37°C	  




10. Cover	  each	  tissue	  gently	  with	  200	  μl	  pre-­‐warmed,	  serum-­‐free,	  phenol-­‐red	  free	  
DMEM/F12	  media	  supplemented	  with	  Normacin	  (1:100).	  	  
	  
11. Place	  the	  plate	  back	  into	  the	  37°C	  incubator	  at	  3%	  O2	  and	  5%	  CO2	  to	  allow	  for	  the	  EVT	  




12. Under	  a	  bright	  field	  microscope	  check	  each	  villi	  tip	  for	  EVT	  sprouts.	  Transfer	  all	  inserts	  
with	  villi	  that	  have	  successfully	  attached	  to	  the	  matrigel	  into	  a	  new	  24-­‐well	  plate.	  Place	  
fresh	  media	  around	  each	  insert	  like	  before.	  	  
N.B:	  if	  a	  villus	  tree	  has	  no	  successful	  sprouts	  formed	  it	  need	  to	  be	  excluded	  from	  
experiment	  and	  discarded.	  	  
	  
13. Depending	  on	  the	  speed	  of	  growth	  the	  tissues	  can	  be	  allowed	  to	  incubate	  another	  day	  
prior	  to	  treatment.	  	  
N.B:	  if	  we	  anticipate	  a	  promoting	  effect	  starting	  treatment	  with	  small	  outgrowths	  will	  
allow	  for	  the	  induction	  of	  outgrowth	  in	  treatment	  group	  to	  be	  easily	  visualized.	  
Alternatively,	  allowing	  EVT	  to	  grow	  up	  abundantly	  will	  make	  observing	  an	  inhibition	  of	  




14. With	  a	  200	  μl	  pipette	  carefully	  remove	  the	  media	  and	  replace	  with	  fresh	  media	  
containing	  desired	  treatment	  (oligomers	  were	  used	  at	  200	  nM).	  	  
	  
15. Using	  a	  camera	  attached	  to	  a	  dissecting	  microscope,	  take	  a	  0h	  picture	  of	  each	  villi	  tree.	  	  
	  
16. Place	  the	  plate	  back	  into	  the	  37°C	  incubator	  at	  3%	  O2	  and	  5%	  CO2	  to	  allow	  for	  the	  EVT	  
columns	  to	  grow	  out	  for	  24h.	  




17. Using	  the	  same	  microscope	  settings	  take	  a	  24h	  picture	  of	  each	  villi	  tree.	  	  
	  
18. If	  48h	  time	  point	  id	  desired	  place	  the	  plate	  back	  into	  the	  37°C	  incubator	  at	  3%	  O2	  and	  5%	  




19. Using	  the	  same	  microscope	  settings	  take	  a	  48h	  picture	  of	  each	  villi	  tree.	  
	  
20. Dispose	  of	  tissues	  in	  proper	  biohazard.	  Alternatively	  tissues	  can	  be	  fixed	  in	  4%	  PFA	  for	  1h	  
and	  embedded	  for	  downstream	  histology	  procedure.	  
N.B:	  Ensure	  to	  submerge	  the	  whole	  insert	  with	  the	  tissue	  into	  a	  well	  filled	  with	  fixative	  
and	  not	  only	  fill	  the	  middle.	  This	  will	  ensure	  the	  matrigel	  doesn’t	  curl	  during	  the	  
dehydration	  process.	  	  
	  
21. Area	  of	  EVT	  outgrowth	  is	  quantified	  using	  ImageJ	  by	  drawing	  around	  the	  EVT	  outgrowth	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N.B:	  Early	  tissues	  (5-­‐6	  week)	  are	  primarily	  proliferative.	  For	  differentiation	  markers,	  ie.	  enEVT,	  
later	  tissues	  respond	  better	  to	  treatment	  (7.5-­‐9	  weeks).	  	  
	  
1. Empty	  the	  first	  trimester	  tissue	  into	  a	  10cm	  petri	  dish	  containing	  PBS	  (without	  Ca++	  and	  
Mg++).	  
	  
2. Under	  the	  dissecting	  microscope	  locate	  and	  remove	  all	  villi	  trees	  that	  contain	  potential	  
EVT	  columns	  (see	  First	  Trimester	  Human	  Placental	  Explant	  Culture	  protocol	  for	  more	  
details)	  and	  place	  in	  new	  falcon	  tube	  with	  PBS.	  	  
	  
3. One	  at	  a	  time,	  remove	  the	  tissue	  from	  PBS	  and	  hold	  the	  villus	  base	  with	  tweezers	  and	  
touch	  the	  tips	  of	  the	  villi	  to	  the	  dry,	  inside	  lid	  of	  a	  10cm	  dish.	  Essentially	  you	  want	  to	  let	  
the	  tips	  of	  the	  villi	  stick	  to	  the	  surface	  of	  the	  dish	  and	  carefully	  with	  fine	  dissecting	  
scissors	  trim	  those	  tips	  off.	  You	  should	  be	  left	  with	  very	  fine	  tissues	  on	  the	  lid	  and	  the	  
majority	  of	  the	  villi	  tissue	  left	  over	  held	  by	  the	  tweezers.	  You	  can	  discard	  the	  large	  villi	  
tree	  tissue	  and	  gently	  gather	  the	  fine	  tissues	  containing	  EVT	  columns	  into	  a	  pile	  on	  the	  
dish	  cover.	  If	  you	  feel	  the	  trimmed	  tissue	  is	  drying	  up	  you	  can	  add	  a	  tiny	  drop	  (<10	  μl)	  of	  
PBS.	  	  
N.B:	  This	  is	  one	  method	  of	  trimming	  the	  tissues.	  The	  goal	  is	  to	  enrich	  the	  tissues	  
containing	  EVT	  cells,	  reducing	  the	  remaining	  tissue	  that	  is	  not	  of	  interest.	  
	  
4. Once	  all	  of	  the	  villi	  have	  been	  trimmed	  (at	  least	  25	  villi	  per	  treatment	  group)	  you	  want	  to	  
divide	  the	  trimmed	  tissues	  into	  equal	  groups	  depending	  on	  the	  number	  of	  treatments.	  	  
	  
5. Place	  500	  μl	  pre-­‐warmed	  serum-­‐free	  DMEM/F12	  media	  supplemented	  with	  ITS	  Liquid	  
Media	  Supplement	  (1:100,	  I3146	  SIGMA)	  and	  your	  treatment	  (oligomers	  were	  used	  at	  
200	  nM)	  in	  a	  24	  well	  plate.	  
	  
6. Transfer	  approximately	  equal	  amount	  of	  cut	  tissue	  into	  each	  treatment.	  Place	  the	  plate	  
to	  incubate	  at	  37°C,	  3%	  O2	  and	  5%	  CO2	  for	  48h.	  	  
	  
7. After	  48h,	  carefully	  remove	  the	  conditioned	  media	  and	  place	  in	  freezing	  vials	  labeled	  
with	  Tissue	  ID,	  gestation	  age,	  and	  treatment.	  Subsequently,	  collect	  the	  tissue	  into	  a	  
separate	  labeled	  freezing	  vial.	  	  
	  
8. Drop	  all	  vials	  into	  a	  thermos	  with	  liquid	  nitrogen	  to	  snap	  freeze	  and	  transfer	  tubes	  to	  dry	  
ice	  for	  transportation	  or	  place	  in	  -­‐80°C	  for	  future	  processing.	  	  
	  
N.B:	  Tissues	  can	  be	  homogenized	  in	  either	  1mL	  Trizol	  for	  RNA	  processing,	  or	  in	  300-­‐500	  μl	  lysis	  
buffer	  +	  protease	  and	  phosphatase	  inhibitors	  for	  protein	  work.	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Protocol	  modified	  from	  Dunk	  C,	  Petkovic	  L,	  Baczyk	  D,	  Rossant	  J,	  Winterhager	  E,	  Lye	  S.	  A	  novel	  in	  vitro	  model	  of	  
trophoblast-­‐mediated	  decidual	  blood	  vessel	  remodeling.	  Lab	  Invest.	  2003	  Dec;83(12):1821–8.	  	  
	  




1. Thaw	  phenol	  red-­‐free	  growth	  factor	  containing	  matrigel	  (BD	  Biosciences	  354262)	  on	  ice.	  	  
N.B:	  Matrigel	  will	  polymerize	  at	  room	  temperature,	  ensure	  it	  is	  kept	  on	  ice	  at	  all	  times	  
until	  needed.	  	  
	  
2. Clean	  fine	  tweezers	  and	  dissecting	  scissors	  with	  70%	  Ethanol.	  	  
	  
3. Place	  all	  placenta	  and	  decidua	  tissues	  for	  processing	  on	  ice.	  Each	  patient’s	  tissue	  will	  be	  
contained	  in	  a	  numbered	  50mL	  falcon	  tube	  in	  PBS	  (without	  Ca++	  and	  Mg++).	  One	  patient	  
ID	  at	  a	  time,	  empty	  the	  decidua	  tissue	  into	  a	  clean	  10cm	  petri	  dish.	  	  Keep	  sample	  ID	  and	  
gestation	  age	  in	  notes	  for	  future	  reference.	  Examine	  the	  decidua	  to	  assess	  if	  usable,	  
keeping	  in	  mind	  the	  following	  points:	  
i. The	  tissue	  should	  feel	  thick,	  you	  can	  check	  by	  pressing	  gently	  down	  on	  the	  tissue	  
with	  tweezers	  and	  checking	  if	  you	  can	  tap	  on	  the	  dish	  through	  it.	  Tissue	  should	  
not	  be	  scrappy	  and	  be	  a	  minimum	  of	  5mm	  thickness.	  	  
ii. Ensure	  the	  tissue	  is	  intact	  by	  checking	  for	  the	  epithelial	  layer	  (will	  be	  smooth	  and	  
shiny	  under	  the	  dissecting	  microscope).	  
iii. Any	  large	  bloody	  vessels/clots	  may	  indicate	  this	  is	  decidua	  basalis	  (we	  want	  
decidua	  parietalis)	  and	  should	  be	  avoided	  if	  possible.	  However,	  nice	  blood	  vessels	  
along	  the	  surface	  are	  desired.	  	   	  
	  
4. With	  dissecting	  scissors	  cut	  a	  minimum	  of	  3	  squares/rectangles	  of	  decidua	  tissue	  per	  
treatment	  group.	  The	  tissue	  should	  be	  approximately	  4-­‐6	  mm3	  with	  the	  epithelial	  layer	  
on	  one	  side	  and	  a	  thick	  spongy	  decidua	  mesenchyme	  on	  the	  other.	  	  
N.B:	  Keep	  in	  mind	  that	  an	  additional	  3	  squares	  of	  decidua	  are	  needed	  for	  the	  decidua-­‐
only	  control.	  	  
	  
5. If	  the	  patient’s	  decidua	  is	  usable	  next	  you	  need	  to	  examine	  the	  matched	  placental	  tissue.	  
Empty	  the	  contents	  of	  the	  falcon	  tube	  on	  a	  clean	  10cm	  dish.	  As	  for	  other	  EVT	  protocols,	  
identify	  villi	  with	  intact	  EVT	  columns.	  A	  villus	  tree	  with	  several	  anchoring	  villi	  is	  
preferred.	  Once	  identified,	  cut	  the	  villus	  tree	  off	  the	  chorionic	  plate	  and	  transfer	  it	  to	  a	  
fresh	  falcon	  tube	  with	  PBS.	  	  
	  
6. Under	  sterile	  conditions	  place	  the	  Millicell™	  Culture	  Plate	  Inserts	  (Millipore;	  PICM01250)	  
into	  a	  24-­‐well	  cell	  culture	  plate.	  One	  insert	  per	  decidua	  square-­‐villi	  tree	  will	  be	  needed.	  
Pipette	  150	  μl	  of	  ice-­‐cold	  matrigel	  into	  each	  insert	  ensuring	  to	  cover	  the	  whole	  bottom	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and	  not	  create	  any	  bubbles.	  	  	  
	  
7. Before	  the	  matrigel	  can	  polymerize,	  transfer	  one	  cut	  decidua	  at	  a	  time	  into	  the	  matrigel.	  
Ensure	  to	  place	  the	  tissue	  with	  the	  luminal	  epithelial	  side	  facing	  up	  at	  a	  45°	  angle	  by	  
resting	  it	  on	  one	  side	  of	  the	  insert.	  Pipette	  600	  μl	  of	  DMEM/F12	  Phenol-­‐red	  free	  media	  
around	  each	  insert.	  Let	  the	  matrigel	  polymerize	  at	  37°C	  for	  20	  minutes.	  
	  
8. While	  waiting	  for	  the	  matrigel	  to	  set,	  prepare	  the	  treatments	  for	  the	  placental	  explants.	  
Place	  500	  μl	  phenol-­‐red	  free,	  serum-­‐free	  DMEM/F12	  media	  into	  a	  24-­‐well	  plate	  and	  add	  
treatment	  (eg.	  200	  nM	  oligomers).	  To	  each	  treatment	  add	  three-­‐four	  dissected	  placental	  
explants	  with	  intact	  EVT	  columns.	  Place	  the	  plate	  in	  37°C,	  3%	  O2	  and	  5%	  CO2	  for	  24h.	  	  
	  
9. After	  the	  matrigel	  has	  set,	  add	  200	  μl	  of	  phenol-­‐red	  free,	  serum-­‐free,	  DMEM/F12	  media	  
supplemented	  with	  Normacin	  (1:100),	  Estrodiol	  (0.3	  ng/mL)	  and	  Progesterone	  (20ng/mL)	  
on	  top	  of	  each	  decidua	  square.	  Return	  to	  37°C,	  3%	  O2	  and	  5%	  CO2	  for	  24h.	  
	  





11. Remove	  placental	  explants	  from	  treatments	  and	  wash	  three	  times	  in	  PBS	  or	  HBSS	  
(without	  Ca++	  and	  Mg++)	  using	  fresh	  wash	  buffer	  for	  each	  wash.	  	  
	  
12. Place	  on	  villus	  tree	  at	  a	  time	  onto	  a	  dish	  and	  gently	  separate	  the	  villi	  and	  scrape	  the	  fuzzy	  
caps	  on	  the	  villi	  tips.	  	  
N.B:	  A	  good	  way	  to	  check	  for	  EVT	  is	  if	  the	  villi	  sticks	  to	  the	  bottom	  of	  the	  10cm	  dish	  when	  
you	  gently	  shake	  the	  PBS	  around.	  This	  is	  due	  to	  EVT	  columns	  being	  very	  sticky.	  	  
	  
13. Take	  the	  decidua	  tissues	  out	  of	  the	  incubator	  and	  carefully	  remove	  the	  media	  with	  a	  
pipette.	  	  
	  
14. Gently	  place	  one	  villi	  tree	  per	  decidua	  ensuring	  the	  villi	  tips	  are	  laying	  flat	  against	  the	  
epithelial	  surface	  of	  the	  decidua.	  Adjust	  the	  tissue	  carefully	  with	  a	  needle	  tip	  if	  
necessary.	  	  
	  




16. Place	  the	  small	  aliquot	  of	  matrigel	  on	  ice	  to	  thaw.	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17. Remove	  the	  tissues	  from	  the	  incubator	  and	  at	  the	  base	  of	  each	  placental	  villus	  gently	  
add	  50-­‐100	  μl	  of	  matrigel.	  Return	  the	  tissues	  to	  37°C	  for	  10min.	  	  
N.B:	  This	  step	  will	  secure	  the	  placenta	  to	  the	  decidua	  further,	  which	  is	  essential	  during	  
the	  fixation	  and	  dehydration	  step	  as	  to	  not	  lose	  the	  tissue	  for	  downstream	  histology	  
work.	  	  
	  
18. Once	  matrigel	  is	  polymerized,	  to	  each	  insert	  add	  200	  μl	  of	  media	  as	  before	  
(supplemented	  with	  Normacin,	  P4	  and	  E2).	  	  
	  
19. Return	  the	  plates	  to	  incubate	  at	  37°C,	  3%	  O2	  and	  5%	  CO2	  for	  3-­‐6	  days.	  	  
N.B:	  This	  is	  Day	  1	  of	  spiral	  arteriole	  remodelling.	  	  
	  
20. Once	  the	  incubation	  is	  done	  continue	  to	  Fixation,	  Dehydration,	  and	  Embedding	  of	  
Tissues	  followed	  by	  H&E	  staining	  and	  IHC.	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Fixation,	  Dehydration,	  Embedding,	  and	  Sectioning	  of	  Tissues	  
	  
1. Gently	  remove	  the	  media	  from	  the	  well	  and	  insert	  using	  a	  low	  suction	  or	  pipette	  taking	  
care	  not	  to	  disturb	  the	  tissues.	  	  
	  
2. To	  each	  well	  add	  1mL	  of	  freshly	  prepared	  4%	  Paraformaldehyde	  (PFA)	  in	  PBS.	  Holding	  
the	  plate	  on	  an	  angle,	  tip	  each	  insert	  using	  tweezers	  to	  allow	  for	  the	  PFA	  to	  flood	  the	  
inside	  of	  the	  insert.	  	  
	  
3. Fix	  the	  tissues	  for	  1h	  at	  room	  temperature.	  	  
	  
4. Remove	  the	  PFA	  slowly	  and	  replace	  with	  PBS.	  Repeat	  the	  wash	  three	  times	  to	  ensure	  all	  
PFA	  residue	  is	  removed	  before	  continuing.	  	  
N.B:	  If	  not	  able	  to	  continue	  to	  the	  embedding	  procedure,	  leave	  the	  tissue	  in	  the	  last	  PBS	  
wash	  and	  keep	  in	  4°C	  fridge	  for	  up	  to	  3	  days.	  	  
	  
5. Prepare	  ethanol	  solutions	  diluting	  with	  distilled	  water:	  100%,	  95%,	  90%,	  80%,	  and	  70%.	  	  
	  
6. Remove	  the	  PBS	  from	  each	  well	  and	  replace	  with	  1mL	  of	  stock	  ethanol	  submerging	  the	  
insert	  to	  fill	  the	  inside	  as	  before.	  Start	  with	  70%	  ethanol	  for	  15min	  (increase	  to	  20min	  if	  
tissue	  is	  bigger	  >5mm3).	  	  
	  
7. Repeat	  the	  dehydration	  with	  80%,	  90%,	  95%,	  and	  3x	  100%.	  	  
	  
8. During	  the	  dehydration	  process	  label	  the	  embedding	  cassettes	  with	  pencil.	  Each	  
treatment	  n=3	  or	  4	  will	  be	  embedded	  in	  one	  block	  ie.	  one	  cassette	  per	  treatment.	  Label	  
the	  tissue	  ID	  and	  treatment	  on	  the	  bottom	  of	  each	  cassette	  (yellow	  cassettes	  are	  a	  good	  
size	  for	  co-­‐culture,	  Fisher	  Tissue	  Path	  Cassettes	  IV).	  
	  
9. Prepare	  a	  500mL-­‐1L	  beaker	  with	  Xylene	  (cover	  with	  aluminum	  foil	  if	  not	  working	  in	  fume	  
hood)	  filled	  enough	  to	  accommodate	  all	  of	  the	  cassettes	  that	  will	  be	  cleared.	  	  
	  
10. One	  treatment	  at	  a	  time,	  take	  all	  the	  inserts	  and	  place	  them	  into	  a	  10cm	  dish	  filled	  with	  
100%	  ethanol.	  Holding	  the	  insert	  with	  one	  hand	  score	  the	  backside	  of	  the	  insert	  with	  a	  
razor	  without	  cutting	  the	  matrigel.	  With	  fine	  tip	  tweezers	  remove	  the	  insert	  membrane	  
from	  the	  underside	  of	  the	  matrigel.	  Next,	  gently	  push	  the	  edges	  of	  the	  matrigel	  from	  the	  
underside	  and	  guide	  the	  matrigel	  disk	  (wish	  tissue)	  to	  the	  top	  of	  the	  insert	  and	  remove	  it	  
from	  the	  insert.	  Place	  the	  matrigel/tissue	  disk	  into	  the	  ethanol-­‐containing	  dish	  until	  the	  
remaining	  inserts	  are	  processed	  for	  that	  treatment.	  	  
	  
11. Transfer	  all	  the	  matrigel/tissues	  removed	  from	  the	  inserts	  into	  the	  appropriately	  labeled	  
cassette	  (one	  cassette	  per	  treatment	  group).	  Leave	  the	  cassette	  laying	  in	  the	  ethanol	  
dish	  while	  you	  process	  the	  remaining	  treatment	  groups	  in	  the	  same	  fashion.	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12. Once	  all	  groups	  have	  been	  processed,	  transfer	  all	  of	  the	  cassettes	  containing	  tissues	  into	  
the	  xylene	  at	  the	  same	  time.	  Clear	  the	  tissues	  for	  20min.	  	  	  
	  
13. Drain	  the	  cassettes	  from	  xylene	  and	  transfer	  to	  the	  first	  paraffin	  wax	  beaker	  in	  a	  60°C	  
oven	  for	  30	  min.	  	  
	  
14. Transfer	  the	  cassettes	  from	  the	  first	  wax	  beaker	  to	  the	  second	  for	  another	  20	  min.	  	  
	  
15. Again,	  transfer	  the	  cassettes	  from	  the	  second	  wax	  beaker	  to	  the	  third	  for	  another	  20	  
min.	  	  
	  
16. Submerge	  the	  metal	  trays	  for	  embedding	  into	  the	  wax	  reservoir	  of	  the	  embedding	  
machine.	  	  
	  
17. Transfer	  all	  of	  the	  cassettes	  from	  the	  third	  beaker	  to	  the	  embedding	  station	  wax	  
reservoir	  once	  ready	  for	  embedding.	  
	  
18. Embed	  one	  cassette	  at	  a	  time.	  Take	  one	  metal	  embedding	  tray	  from	  the	  wax	  reservoir	  
and	  place	  on	  the	  hot	  plate	  of	  embedding	  station	  and	  pour	  in	  some	  wax	  from	  the	  spout.	  
Remove	  one	  cassette	  from	  the	  wax	  reservoir	  and	  open	  it.	  Evenly	  space	  out	  all	  of	  the	  
tissues	  in	  the	  wax-­‐filled	  metal	  tray	  with	  the	  tissue	  facing	  up	  and	  matrigel	  touching	  the	  
bottom	  of	  the	  metal	  tray.	  Quickly	  transfer	  the	  metal	  tray	  to	  a	  cool	  portion	  of	  the	  
embedding	  station	  and	  with	  tweezers	  press	  down	  the	  tissues	  while	  the	  wax	  starts	  to	  
cool.	  Then	  quickly	  return	  the	  metal	  tray	  under	  the	  wax	  spout	  and	  place	  the	  bottom	  part	  
of	  the	  cassette	  (with	  the	  label)	  on	  top	  of	  the	  wax	  tray	  and	  pour	  more	  wax	  on	  top.	  
Transfer	  everything	  to	  the	  cooling	  table	  of	  the	  embedding	  station.	  
	  
19. Once	  the	  wax	  has	  fully	  cooled,	  remove	  the	  wax	  block	  from	  the	  metal	  embedding	  tray.	  
Store	  the	  blocks	  at	  room	  temperature	  until	  ready	  for	  sectioning.	  	  
	  
20. To	  section	  tissue	  place	  the	  block	  into	  the	  microtome	  and	  align	  the	  blade.	  	  
	  
21. Label	  positively	  charged	  slides	  with	  tissue	  ID,	  treatment,	  and	  slide	  number.	  Depending	  
on	  depth	  of	  tissue	  you	  will	  need	  roughly	  40-­‐60	  slides	  per	  block.	  
	  
22. Trim	  the	  block	  until	  you	  begin	  to	  cut	  into	  tissue	  and	  then	  reduce	  the	  thickness	  to	  5	  μm.	  	  
23. Cut	  strips	  of	  tissue	  and	  check	  every	  10th	  section	  under	  the	  light	  microscope	  to	  catch	  
when	  you	  have	  started	  cutting	  across	  the	  placenta.	  
N.B:	  The	  decidua	  portion	  will	  be	  visible	  much	  sooner	  than	  the	  placenta	  since	  it	  was	  
embedded	  into	  the	  matrigel	  while	  the	  placenta	  lays	  on	  top	  of	  the	  matrigel.	  	  	  
	  
24. Once	  you	  have	  reached	  a	  portion	  of	  the	  tissue	  where	  both	  the	  decidua	  and	  placenta	  are	  
visible	  begin	  to	  collect	  the	  tissues.	  Cut	  tissue	  into	  strips	  long	  enough	  for	  you	  to	  handle.	  	  
N.B:	  It	  is	  important	  that	  serial	  sections	  be	  preserved	  so	  do	  not	  handle	  long	  strips	  that	  can	  
	   182	  
result	  in	  losing	  large	  portions	  of	  the	  tissue.	  	  
	  
25. Transfer	  the	  strip	  carefully	  to	  a	  warm	  water	  bath	  ensuring	  you	  don’t	  form	  any	  bubbles	  or	  
folds	  in	  the	  tissue.	  
	  
26. Using	  flat	  tipped	  tweezers	  separate	  the	  tissue	  sections	  into	  two-­‐three	  section	  pieces	  
(depending	  on	  how	  many	  can	  fit	  on	  a	  slide).	  	  
	  
27. Dip	  the	  labelled	  slide	  into	  the	  water	  bath	  and	  place	  under	  the	  floating	  section.	  Align	  the	  
first	  section	  with	  the	  top	  of	  the	  slide,	  allow	  it	  to	  come	  into	  contact	  with	  the	  wax	  section,	  
and	  slowly	  pull	  the	  slide	  out	  of	  the	  water	  bath	  at	  a	  45°	  angle	  as	  the	  section	  lays	  across	  
the	  slide.	  	  
	  
28. Place	  the	  slide	  upright	  to	  allow	  to	  dry	  and	  repeat	  this	  process	  with	  all	  of	  the	  remaining	  
tissue.	  You	  want	  to	  stop	  cutting	  when	  you	  feel	  that	  the	  region	  where	  the	  placenta	  is	  in	  
contact	  with	  the	  decidua	  (where	  we	  would	  observe	  remodelling	  of	  vessels)	  is	  out	  of	  
view.	  	  
N.B:	  Ensure	  to	  not	  mess	  up	  the	  order	  of	  the	  sections.	  Serial	  sections	  are	  vital	  to	  
successfully	  investigating	  a	  region	  of	  the	  remodelling	  process	  after	  a	  part	  is	  selected	  for	  
Immunohistochemistry.	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Haematoxylin	  and	  Eosin	  Staining	  of	  Paraffin	  Embedded	  Tissue	  
	  
Protocol	  adapted	  from	  Dr.	  Lye	  Lab	  at	  Lunenfeld-­‐TaneN.Baum	  Research	  Institute	  
	  
1. After	  sectioned	  tissues	  have	  fully	  dried	  select	  several	  slides	  for	  H&E	  staining	  to	  decide	  on	  
which	  slides	  should	  be	  used	  for	  IHC	  (1st,	  10th	  etc,	  last).	  
	  
2. Dewax	  in	  consecutive	  Xylene	  (Leica	  Surgipath	  3803665)	  solutions	  for	  5min/each	  
• 1st	  xylene	  =	  most	  wax	  
• 3rd	  xylene	  =	  least	  wax	  
	  
3. Clear	  the	  Xylene	  in	  three	  solutions	  of	  100%	  Ethanol	  1min/each	  
• 1st	  EtOH=	  most	  Xylene	  
• 3rd	  EtOH=least	  Xylene	  
	  
4. Rehydrate	  the	  tissue	  by	  submerging	  the	  slides	  in	  a	  series	  of	  EtOH	  solutions	  for	  30s/each	  
starting	  with	  
• 95%,	  90%,	  80%,	  70%,	  50%	  (diluted	  in	  tap	  water)	  
	  
5. Wash	  sections	  in	  tap	  water	  for	  2min	  
	  
6. Stain	  in	  Harris	  Haematoxylin	  (Sigma	  HH532)	  for	  2min	  (return	  to	  bottle,	  can	  reuse	  stain)	  
	  
7. Dip	  5	  times	  in	  Acid	  Alcohol	  (recipe	  below)	  à	  dispose	  in	  Ethanol	  waste	  
	  
8. Wash	  slides	  in	  tap	  water	  until	  they	  run	  clear	  (at	  least	  3min)	  
	  
9. Stain	  slides	  in	  Eosin	  (Sigma	  HT110316)	  for	  1min	  20sec	  (return	  to	  bottle,	  can	  reuse	  stain)	  
	  
10. Wash	  in	  tap	  water	  until	  runs	  clear	  (at	  least	  3min)	  
	  
11. Dehydrate	  slides	  for	  5s/each	  in	  ethanol	  
• 90%,	  95%,	  100%	  Ethanol	  2,	  100%	  Ethanol	  1	  (1min)	  
	  
12. Clear	  in	  Xylene	  for	  1min/each	  
• Xylene	  2nd	  
• Xylene	  3rd	  	  
	  
13. Mount	  slides	  with	  coverslip	  straight	  from	  Xylene	  (don’t	  let	  them	  dry	  out).	  Place	  two	  
small	  dabs	  of	  Paramount	  onto	  cover	  slip	  and	  place	  slide	  with	  tissue	  down	  on	  top.	  Let	  dry	  
overnight	  before	  handling.	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Immunohistochemistry	  of	  Paraffin	  Embedded	  Tissues	  
	  




1. After	  looking	  at	  the	  H&E	  stained	  slides	  the	  corresponding	  tissue	  of	  interest	  in	  the	  
surrounding	  area	  is	  placed	  in	  a	  rack	  and	  baked	  overnight	  at	  60°C.	  
	  
2. Deparaffinization	  in	  Xylene	  for	  5min/each	  
• Xylene	  1	  =	  most	  wax	  
• Xylene	  3	  =	  least	  wax	  
	  
3. Rehydration	  for	  2min/each	  ethanol	  
• 100%	  EtOH	  1,	  100%	  EtOH	  2,	  100%	  EtOH	  3,	  95%	  	  
	  
4. Quench	  endogenous	  peroxidase	  activity	  in	  3%	  Hydorgen	  Peroxide	  solution	  in	  Methanol	  
(30%	  solution	  diluted	  1:10	  in	  methanol.	  25ml	  H2O2	  +	  225	  MeOH).	  Normally	  for	  30min	  
*modified	  to	  50	  min	  with	  decidua.	  	  
N.B.	  H2O2	  should	  be	  stored	  at	  -­‐20°C,	  it	  goes	  off	  at	  room	  temp	  or	  4°C.	  If	  slides	  (including	  
negative	  control)	  turn	  brown,	  buy	  a	  new	  bottle.	  	  
	  
5. Continue	  Rehydration	  for	  2min/each	  ethanol	  
• 90%,	  80%,	  70%	  
	  
6. Wash	  in	  1X	  PBS	  two	  times,	  5min/each	  
	  
7. Fix	  slides	  in	  4%	  PFA	  (in	  PBS)	  for	  15min	  
	  
8. Wash	  in	  1X	  PBS	  two	  times,	  5min/each	  
	  
9. Antigen	  retrieval	  will	  depend	  on	  antibody	  –	  for	  these	  antibodies	  use	  Sodium	  citrate	  
boiling	  
	  
i. Triton	  0.01-­‐0.02%	  in	  PBS	  10min	  at	  room	  temperature.	  This	  will	  
permeabilise	  the	  cell	  membrane	  to	  allow	  the	  Ab	  to	  go	  in.	  	  
ii. Trypsin	  (50ul	  of	  5%Trypsin	  in	  1.9ml	  PBS	  pH7.4)	  at	  37°C	  for	  10min	  
iii. Proteinase	  K	  (5-­‐40ug/ml	  in	  PBS	  at	  37°C	  for	  10min)	  
iv. Microwave	  pretreatment,	  10mM	  sodium	  citrate:	  bring	  to	  a	  boil	  (5	  min,	  
power	  6,	  lid	  on)	  cool	  for	  20min,	  boil	  again	  (3	  min,	  power	  6,	  lid	  off),	  cool	  
for	  15min.	  Solutions	  A	  and	  B	  in	  4°C	  
• Solution	  A:	  Citric	  Acid	  4.5ml	  in	  250ml	  of	  water	  
• Solution	  B:	  Sodium	  Citrate	  20.5ml	  in	  250ml	  of	  water	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10. Wash	  in	  1X	  PBS	  two	  times,	  5min/each	  
	  
11. One	  by	  one,	  take	  slide	  out	  of	  PBS,	  make	  circle	  around	  each	  tissue	  with	  IHC	  pen	  	  
and	  add	  one	  drop	  of	  blocking	  buffer-­‐	  10%	  Goat	  Serum	  2%	  Rabbit	  serum	  (Dako	  X0909)	  for	  
1h	  at	  RT	  in	  a	  covered	  humidified	  tray.	  	  
	  
12. Place	  1°Ab	  (50ul	  in	  PBS)	  at	  a	  time	  by	  vacuum	  suctioning	  off	  the	  blocking	  buffer	  and	  
replacing	  as	  follows:	  
• CK7	  (Dako	  M7018)	  1:100	  
• CD31	  (Dako	  M0823)	  1:50	  
• SMA	  (Dako	  M0851)	  1:100	  
• CD45	  (Dako	  M0701)	  1:100	  
• HLAG	  (ExBio	  11-­‐499)	  1:500	  *modified	  to	  1:300	  
• Ki67	  1:100	  
• Cleaved	  Caspase	  3	  1:300	  
• Mouse	  IGG	  (X0931)	  1:100	  
	  




14. 	  Wash	  in	  1X	  PBS	  two	  times,	  5min/each	  
	  
15. 	  Add	  Secondary	  Antibody	  (1:300	  in	  PBS)	  for	  1hour	  at	  RT	  in	  a	  covered	  humidified	  tray.	  
• Polyclonal	  Rabbit	  anti	  Mouse	  Biotinylated	  Ref:E0464	  
	  
16. 	  Wash	  in	  1X	  PBS	  two	  times,	  5min/each	  
	  
17. 	  Add	  tertiary	  reagent	  Invitrogen	  Streptavidin	  HRPO	  Conjugated	  (SA1007)	  1:2000	  PBS	  for	  
1h	  at	  room	  temperature.	  	  
	  
18. Wash	  in	  1X	  PBS	  two	  times,	  5min/each	  
	  
19. Add	  DAB	  (DiAminoBenzidene)	  and	  observe	  for	  precipitate	  formation	  on	  a	  white	  piece	  of	  
paper.	  Double	  check	  under	  the	  light	  microscope	  for	  appropriate	  signal	  intensity	  and	  
once	  reached	  place	  slides	  in	  new	  rack	  in	  distilled	  water.	  	  
• DAB	  +	  Substrate	  Ref	  K3468	  
• 2ml	  Buffer	  +	  1	  drop	  substrate	  *	  modified	  to	  3ml	  Buffer	  +	  1	  drop	  substrate	  to	  try	  
and	  remove	  the	  unspecific	  glandular	  stain	  
• Use	  only	  for	  specific	  antibodies	  
	  
20. 	  Counter	  stain	  with	  Haematoxylin	  diluted	  Harris	  1:2	  with	  tap	  water	  for	  15s	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21. 	  Rinse	  slides	  in	  tap	  water	  until	  runs	  clear.	  	  
	  
22. 	  Dehydrate	  the	  tissue	  for	  2min	  each	  in	  Ethanol	  
• 70%,	  80%,	  90%,	  95%,	  100%	  –	  Ethanol	  2,	  100%	  -­‐	  Ethanol	  3	  
	  
23. Clear	  in	  xylene	  for	  2	  min	  each	  
• Xylene	  2	  
• Xylene	  3	  
N.B.	  If	  there	  is	  a	  lot	  of	  wax	  pen	  left,	  prolong	  the	  xylene.	  	  
	  
24. Mount	  slides	  with	  coverslips	  using	  Peramount,	  let	  dry	  in	  hood	  overnight.	  	  
	  
25. Image	  slides	  on	  a	  bright	  field	  microscope.	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APPENDIX	  B:	  ADDITIONAL	  PUBLICATIONS	  
	  
1.	  Cytoplasmic	  mislocalization	  of	  p27	  and	  CDK2	  mediates	  the	  anti-­‐migratory	  and	  anti-­‐
proliferative	  effects	  of	  Nodal	  in	  human	  trophoblast	  cells.	  
	  
Nadeem	  L,	  Brkic	  J,	  Chen	  YF,	  Bui	  T,	  Munir	  S,	  Peng	  C.	  
	  
Journal	  of	  Cell	  Science	  2013	  Jan	  15;126(Pt	  2):445-­‐53.	  	  
	  
	  
I	   contributed	   to	   this	   paper	   during	   the	   revision	   processes.	   I	   performed	   experiments	   that	  
addressed	   several	   reviewer	   questions.	   First,	   I	   performed	   the	   qRT-­‐PCR	   to	  measure	   p27	  mRNA	  
levels	  after	  Nodal	  treatment	  (Figure	  1A).	  Additionally,	  I	  addressed	  the	  concerns	  of	  establishing	  a	  
causal	   link	  between	  Nodal,	  stathmin	   inactivation,	  and	   inhibition	  of	  cell	  migration.	   I	  performed	  
many	   experiments	   to	   characterize	   the	   effects	   of	   Stathmin	   siRNA,	   HDAC6,	   and	   Nocadazol	   on	  
microtubule	  acetylation	  and	   trophoblast	  migration.	  These	   findings	  were	  not	   included	   into	   the	  
final	  manuscript,	  and	  instead	  I	  used	  them	  in	  writing	  a	  response	  to	  the	  reviewers	  concerns.	  
	  
2. MicroRNAs in Human Placental Development and Pregnancy Complications.	  
 
Fu G, Brkić J, Hayder H, Peng C. 
International Journal of Molecular Sciences 2013 Mar 8;14(3):5519-44.  
 
I contributed to this review by writing section 2 (Key Processes in Human Placenta 
Development) and section 4.3 (MicroRNAs and Placental Angiogenesis). I also created Figure 1 
used, and in the editing the final draft for submission.  
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3.	  Placental	  trophoblast	  cell	  differentiation:	  physiological	  regulation	  and	  pathological	  
relevance	  to	  preeclampsia.	  
	  
Ji	  L*,	  Brkić	  J*,	  Liu	  M*,	  Fu	  G,	  Peng	  C,	  Wang	  YL.	  
 
* Contributed equally 
	  
Molecular	  Aspects	  of	  Medicine	  2013	  Oct;34(5):981-­‐1023.	  
	  
I	   contributed	   to	   this	   special	   edition	   review	   by	   writing	   section	   1	   (Introduction)	   and	   Section	   2	  
(Pathways	  of	  Human	  Placental	  Trophoblast	  Cell	  Differentiation).	   I	  also	  contributed	  information	  
used	  in	  generating	  Figure	  1.	  I	  was	  closely	  involved	  in	  editing	  the	  review	  to	  the	  final	  version.	  In	  
addition,	  I	  addressed	  the	  requested	  revisions	  and	  drafted	  the	  response	  to	  reviewers.	  	  
	  
4.	   Activated	   NK	   cells	   cause	   placental	   dysfunction	   and	   miscarriages	   in	   fetal	   alloimmune	  
thrombocytopenia	  	  
	  
Issaka	  Yougbaré,	  Wei-­‐She	  Tai,	  Darko	  Zdravic,	  Brigitta	  Elaine	  Oswald,	  Sean	  Lang,	  Guangheng	  Zhu,	  
Howard	  Leong-­‐Poi,	  Qu	  Dawei,	  Yu	  Lisa,	  Caroline	  Dunk,	  Jianhong	  Zhang,	  John	  G.	  Sled,	  Stephen	  J.	  
Lye,	  Jelena	  Brkić,	  Chun	  Peng,	  Petter	  Höglund,	  Anne	  Croy,	  S.	  Lee	  Adamson,	  Duncan	  J.	  Stewart,	  
John	  Freedman,	  and	  Heyu	  Ni	  
	  
Currently	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  to	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  review	  
	  
I	  contributed	  to	  this	  manuscript	  by	  validating	  the	  effect	  of	  Integrin	  β3	  antibodies	  on	  trophoblast	  
migration	  and	   invasion.	   I	   used	   sera	   from	   immunized	  mice	  provided	  by	  Yougbaré	  on	   transwell	  
migration	   and	   invasion	   assays	   with	   human	   first	   trimester	   trophoblast	   cell	   line,	   HTR8/SVneo.	  
Additionally,	  I	  used	  these	  sera	  in	  the	  human	  first	  trimester	  EVT	  outgrowth	  model.	  Furthermore,	  
I	  processed	  these	  EVT	  outgrowths	  for	  sectioning	  and	  provided	  first	  trimester	  tissues	  processed	  
for	  protein	  and	  RNA	  work.	  	  
